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SUMMARY
This thesis describes an investigation into the aetiopathogenesis of equine chronic obstructive
pulmonary disease (COPD).
To investigate the aetiology of equine COPD, control and asymptomatic COPD affected
horses were given nebulised inhalation challenges with extracts of Micropolyspora faeni
(MF), Aspergillus fumigatus (AF) and Thermoactinomyces vulgaris (TV). MF and AF
challenges induced pulmonary disease, similar to naturally occurring COPD, only in the
COPD affected horses, implicating MF and AF in the aetiology of equine COPD. The role of
TV in the aetiology of equine COPD could, however, not be assessed as the TV challenges
induced pulmonary inflammation in 2 control horses, which had been unaffected by hay and
straw challenges i.e. 'natural challenges' (NC), indicating that the experimental TV challenge
differed from the TV challenge which occurs during NC. The absence of pulmonary disease in
control horses following MF, AF challenges and after NC suggests that equine COPD is a
pulmonary hypersensitivity, rather than a non specific toxic response.
In this study, bronchoalveolar lavage fluid (BALF) cytology examinations proved to be more
useful for detecting pulmonary disease than clinical, pulmonary mechanics, arterial blood gas
tensions and arterial pH examinations.
The role of oil seed rape (OSR) (Brassica spp.) in the aetiology of equine pulmonary disease
was investigated by exposing horses to a field of flowering B.campestrus and by experimental
B.napus inhalation challenges. OSR had no detectable effect on control and asymptomatic
COPD affected horses, suggesting that OSR is not a major cause of equine respiratory disease.
However, the experimental B.napus inhalation challenges exacerbated pulmonary disease in
some symptomatic COPD affected horses, presumably via non specific bronchial
hyperresponsiveness/toxicity. Intradermal testing using a commercial B.napus pollen extract
suggested that none of the horses investigated was hypersensitive to B.napus pollen antigens.
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As BALF is comprised of lavage fluid and pulmonary epithelial lining fluid (PELF) in
variable proportions, quantitative comparisons of the cellular and molecular components in
different BALF samples are valid only if the proportions of PELF in the BALF samples are
standardised. Two BALF standardisation techniques, namely the urea and albumen dilution
techniques, were evaluated in the horse. While both techniques were found to be satisfactory,
the urea dilution technique was considered to be the more accurate.
Comparison of the cellular and molecular components of BALF collected from 4 different
lung segments of control and symptomatic COPD affected horses indicated that, in these
horses, BALF components showed regional homogeneity. This suggests that the composition
of PELF is uniform throughout the lungs of these horses and that a single BALF sample,
collected from any lung lobe, is representative of the entire lung.
The role of mast cells/basophils in the pathogenesis of equine COPD was investigated by
quantifying histamine, an indicator of mast cell/basophil degranulation, in plasma, BALF and
PELF of control and COPD affected horses, before and at 0.5 and 5h after NC. The PELF
histamine concentrations of COPD affected horses were significantly increased only at 5h
after NC. NC had no significant effect on the PELF histamine concentrations of control horses
nor on the plasma and BALF histamine concentrations of either group. As the histamine
concentrations of whole BALF lysates were significantly correlated with the numbers of
metachromatically staining BALF cells, presumed to be mast cells and/or basophils, these
findings support involvement of a late phase, mast cell/basophil mediated, hypersensitivity
reaction in the pathogenesis of equine COPD.
Quantification of tryptase, an inflammatory mediator which offers potential advantages over
histamine as an indicator of mast cell degranulation, in equine serum and BALF, using a
commercial radioimmunoassay kit for human tryptase, was unsuccessful.
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The role of lymphocytes in the pathogenesis of equine COPD was investigated by
determining the lymphocyte phenotype distributions of peripheral blood (PB) and BALF from
control and COPD affected horses, before and after NC. Prior to NC, asymptomatic COPD
affected horses had a significantly higher proportion of BALF B lymphocytes than control
horses, suggesting that these cells have a role in the pathogenesis of equine COPD. NC
significantly increased the ratios of CD4+, T helper/inducer lymphocytes and significantly
reduced the ratios of CD8+, T suppressor/cytotoxic lymphocytes in BALF from COPD
affected horses, suggesting that T lymphocytes have an important role in the pathogenesis of
equine COPD.
Intradermal mould antigen testing was evaluated as a diagnostic technique for equine COPD.
The intradermal endpoint litres of control horses for AF, MF and TV were not significantly
different from those of COPD affected horses, suggesting that this technique is of limited
value in the diagnosis of equine COPD. Furthermore, the lack of correlation between the
intradermal endpoint titres for each antigen and the changes in pulmonary mechanics, arterial
blood gas tensions and with BALF neutrophil ratios which had followed previous MF, AF and
TV inhalation challenges and NC suggests divergence of equine dermal and pulmonary
reactivities to these antigens.
Local transendoscopic endobronchial antigen challenge, which has proved to be a valuable
clinical and research technique in the study of human pulmonary hypersensitivity, was
evaluated in the horse. As local endobronchial challenges with phosphate buffered saline, MF
extract and mouldy hay extract induced a non specific pulmonary neutrophilia in both control
and asymptomatic COPD affected horses and elicited endoscopically visible responses in a
proportion of horses from both these groups, this technique was considered to be of limited




While the domestication of the horse has benefited man in numerous ways, it has
unfortunately resulted in the exposure of many horses to environments which are detrimental
to their health. Frequently horses are maintained in poorly designed and poorly ventilated
environments (Jones et al 1987), fed on poorly saved hay and bedded on poorly saved straw,
and as a result are exposed to high levels of airborne pollutants including inorganic dusts,
ammonia, endotoxins, bacteria, viruses, fungi, actinomycctes and mites. Consequently large
numbers of housed horses develop environmental pulmonary diseases, which adversely affect
both their welfare and athletic performance.
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Chronic obstructive pulmonary disease (COPD) is the most important environmental
pulmonary disease to affect the horse. Unfortunately the literature regarding COPD and other
equine environmental pulmonary diseases is contused by the plethora of terms used to name
and define these conditions, many of which were erroneously adopted from human medicine
e.g. heaves, chronic alveolar emphysema, chronic bronchiolitis and allergic small airway
disease.
To enable valid comparisons of findings from different laboratories, it is important to fully
define the disease under investigation. In this study COPD was defined as reversible
pulmonary inflammation and airway obstruction, characterised by excessive numbers of
tracheobronchial and bronchoalveolar neutrophils and by clinical and laboratory evidence of
pulmonary dysfunction, which was consistently induced in susceptible horses by exposing
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them to poorly saved hay and straw and fully reversed by transferring them to an environment
free from hay and straw.
In this study, COPD affected horses with clinical or laboratory evidence of pulmonary
disease i.e. those which were being maintained in an environment containing hay or straw or
those which had not achieved complete remission following subsequent transfer to a hay and
straw free environment were termed 'symptomatic'. Those horses which were in remission i.e.
those which had been maintained in a hay and straw free environment until they showed no
clinical or laboratory evidence of pulmonary inflammation were termed 'asymptomatic'. The
populations of control and COPD affected horses used in this study and the clinical and
laboratory techniques employed to detect pulmonary inflammation and dysfunction arc further
defined in Chapter 2.
COPD is the most commonly recognised equine environmental pulmonary disease and is
considered to be one of the most common causes of premature loss due to disease in the
United Kingdom and Western Europe (Gerber 1973; Cook 1976; McPhcrson and Thomson
1983).
COPD appears to occur world wide, although it is uncommon in Australia and New Zealand
(Goulden, B. pers comm 1990).
While estimations of incidence vary from 54% in Switzerland (Bracher et al 1991) to up to
70% in riding stables in Holland (Sasse quoted by Dixon 1986), the apparent incidence of
COPD in any population is likely to be influenced not only by the environments in which the
horses are maintained but also by the sensitivity of the techniques employed to detect the
disease. With the current expansion in the urban horse population in the United Kingdom,
much of which is maintained predominantly in stables, the number of horses affected by this
condition is likely to increase.
The incidence of COPD increases with age and there is no apparent sex or breed distribution
(Alexander 1959; Lowell 1964; McPherson and Thomson 1983).
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AETIOLOGY OF EQUINE COPD
COPD has long been recognised as a disease of domestication which is attributable to
housing in poor environments containing poorly saved hay and/or straw and consequently
does not affect horses maintained at pasture (Alexander 1959; Cook and Rossdale 1963;
Lowell 1964; Thurlbeck and Lowell 1964), although a less common condition which shows
many similarities to COPD, termed summer pasture associated obstructive pulmonary disease
(SPAOPD), which may be a pulmonary hypersensitivity to inhaled moulds or pollens, has
been recently reported in pastured horses (Beadle 1983; Dixon and McGorum 1990 A & B).
(1) INHALED THERMOPHILIC ACTINOMYCETES AND FUNGI
While the aetiology of equine COPD remains speculative, antigen inhalation challenges
(reviewed in Chapter 2), intradermal antigen testing (reviewed in Chapter 3) and the detection
of serum precipitins to putative allergens suggest that COPD is a pulmonary hypersensitivity
to inhaled allergens. The major inhalant allergens are considered to be Micropolyspora faeni,
a thermophilic actinomycctc which causes extrinsic allergic alveolitis in man (Wenzel et al
1965) and cattle (Pirie et al 1971) and A.fumigatus, a fungus which causes bronchial asthma,
allergic bronchopulmonary aspergillosis and allergic alveolitis in man (Vallery-Radot and
Giroud 1928; Crompton 1990) (Eyre 1972; Halliwcll et al 1979; McPhcrson et al 1979;
McPherson and Thomson 1983). It is however possible that the actiological agents may show
geographical variation.
M.faeni and A.fumigatus aeroallergcns originate from contaminated hay and straw. While hay
and straw, when cut, is virtually free form these moulds and contains only small numbers of
non pathogenic fungi, if it is baled with a moisture content above 20%, significant mould
contamination is likely to occur during storage (Clarke 1987).
Stables which contain poorly saved hay and straw may contain high levels of airborne
Mfaeni and Afumigatus antigens, exposing horses to large quantities of these aeroaliergens.
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Woods,P. et al (pers comm. 1991) recorded levels of 1500ng/m^ M.faeni and 1800ng/m^
A.fumigatus aeroallergens in such stables, while hay and straw free stables contained
approximately half of these levels. As thermophilic actinomycete and fungal spores are,
respectively, 0.7-1.3u and <5u in diameter, if inhaled, many will be deposited in the small
airways (Lacey and Lacey 1964) where they may induce local inflammation.
While the structural and chemical basis of the allergenicity of these agents is unknown, in
addition to inducing specific immunological reactions, M.faeni has additional properties
which may contribute to its pathogenic effects. It can activate complement by the alternative
pathway (Marx and Flaherty 1976), induce lymphocyte mitogenesis (Smith et al 1980), has
adjuvant activity (Bice et al 1977) and contains proteolytic enzymes (Roberts 1978).
A.fumigatus may also activate complement by the alternate pathway (Marx and Flaherty
1976).
(2) FORAGE MITES
Large numbers of forage mites, belonging to several species, have been identified in stored
hay (Halls and Gudmundsson 1985) and high concentrations of mite aeroallergens have been
demonstrated in stables containing hay and straw (Robinson,N.E. et al, pers comm 1991).
Forage mites depend on fungal spores for food and are thus always found in conjunction with
mould contamination (Clarke and Madelin 1987). Forage mites excrete faeces containing
semidigested mould spores and it is possible that this digestion may alter the antigenicity of
the spores.
In man, there is a high incidence (30% of farmers in Scotland) of immediate type bronchial
hypersensitivity to forage mites (Cuthbert et al 1984) and house dust mites are a major cause
of human extrinsic allergic asthma in many regions of the world (Platts-Mills and de Week
1989). However, the role of forage mites in the pathogenesis of equine COPD has received
surprisingly little attention, and there is currently no evidence to implicate forage mites as
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allergens in equine COPD. The findings of the limited number of studies which have
performed intradermal testing with mite antigens are reviewed in Chapter 3. There are no
reports of equine bronchial provocation challenges with mite antigens.
(3) BACTERIA AND ENDOTOXINS
Stables contain large numbers of airborne bacteria which may be inhaled and which are
considered to be the major source of the pulmonary bacterial flora of housed animals (Jones
1922). The presence of hay and straw in a stable was shown to increase the number of bacteria
within the lungs. There is however no good evidence that inhaled bacteria are causal agents of
equine COPD.
Significant numbers of bacteria, mainly Streptomyces and Bacillus species, which produced
elastases when cultured in vitro, were demonstrated in horse lungs (Grunig et al 1986). While
it is possible that bacterial elastases could result in pulmonary damage, if produced in vivo , as
elastase activity was not detected in equine tracheobronchial secretions (Grunig et al 1985)
and pulmonary histopathological findings were not correlated with the numbers of elastase
producing bacteria (Grunig et al 1986), the significance of this observation is not known. It
seems unlikely that bacterial elastases have an important role in equine COPD as, if present,
they would presumably induce emphysema (Janoff 1983), which is not major feature of
equine COPD (Nicholls 1978)
Stables also contain airborne endotoxins (Robinson,N.E. et al, pers comm 1991), which are
derived from bacterial cell walls. While endotoxins have been associated with occupational
lung disease in humans and experimental lung disease in rabbits (Pemis et al 1967; Cavagna
et al 1969), the role of endotoxins in equine COPD has not been investigated.
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(4) POLLENS
McPherson et al (1979) demonstrated positive clinical, pulmonary mechanic and arterial
blood gas responses to rye grass pollen dust inhalation challenges in 5 of 6 COPD affected
horses but not in 6 controls. While this suggested that pollens may have a role in the aetiology
of equine COPD, as some of the COPD affected horses used in their study were not fully
asymptomatic prior to the challenges, the observed positive responses may have been due to
non specific bronchial hyperresponsiveness (NSBHR) (Klein 1984; Dcrksen et al 1985A)
rather than to true hypersensitivity. NSBHR is manifested by horses with symptomatic COPD
as an exaggerated bronchospasm following inhalation with a wide range of inhaled agents
including dusts. Furthermore, the absence of COPD in horses maintained at pasture, which are
presumably exposed to large numbers of pollens, suggests that pollens arc unlikely to be
important in the aetiology of equine COPD.
(5) DIETARY TOXICITY
Breeze et al (1978) suggested that 3-mcthylindolc, a derivative of ingested L-tryptophan,
which is considered to be the cause of bovine fog fever (Carlson and Breeze 1983), could
cause equine COPD. Experimental administration of 3-mcthylindole to horses induced an
obstructive pulmonary toxicosis with necrotising bonchiolitis, small airway obstruction, acinar
overinflation and ultrastructural changes in Clara cells, which had some pathological
resemblance to COPD (Derksen et al 1982; Turk et al 1983; Breeze et al 1984). Recently,
Kaup et al (1990B) demonstrated ultrastructural changes in Clara cells from horses with
spontaneously occurring COPD which were similar to those reported in horses with
experimental 3-mcthylindolc toxicity (Turk et al 1983; Breeze et al 1984).
However, as COPD is not encountered in horses which are maintained at pasture, and as grass
is an important source of dietary L-tryptophan, the precursor of 3-methylindole, it seems
unlikely that 3-methylindole has a role in the pathogenesis of equine COPD.
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(6) OIL SEED RAPE
The possible role of oil seed rape (Brassica napus and B.campestrus), an alleged cause of
equine and human pulmonary disease, was investigated in this study and is reviewed in
Chapter 10.
(7) INORGANIC DUSTS
While there is no evidence to suggest that inhaled inorganic dusts have an important role in
the aetiology of equine COPD, they may exacerbate pulmonary dysfunction in horses with
symptomatic COPD via NSBHR.
Thus the success of environmental management of equine COPD may not only reflect a
reduction in exposure to the allergens which cause COPD but also the concomitant reduction
in non specific irritants e.g. irritant gases and dusts, which may exacerbate the clinical signs
via NSBHR.
(8) ANTIPROTEASE DEFICIENCY
The finding that one form of human emphysema is due to an inherited deficiency of alpha-1-
antitrypsin, an enzyme which inhibits proteases, including trypsin, plasm in, cathepsin,
collagenase, elastase, thrombin, kallikrein and chymotrypsin, which could otherwise induce
proteolytic degradation of the pulmonary connective tissue elements (Kueppers and Black
1974), prompted the investigation of protease inhibitor function in horses with COPD.
While Littlejohn (1978) found reduced serum alpha-1-globulin levels in 12 horses with
COPD and suggested that deficiency of antiproteases may be associated with equine COPD,
further, and more detailed, studies have found no difference in serum antiprotease activity of
controls and COPD affected horses (Gillespie and Tyler 1969; Breeze et al 1977; Matthews
1979).
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Matthews (1979) demonstrated that the clcctrophorctically slower alleles of the equine
homologue of human alpha-1-antitrypsin were present in increased frequency in horses with
COPD. However, as the horses investigated were of mixed breeds and there was no significant
correlation between these alleles and low serum trypsin inhibitory capacity, the significance of
this finding is unclear. Further studies employing larger numbers of genetically similar horses
may clarify this area.
Endogenous and exogenous, bacterially derived, proteases and protease inhibitors have been
demonstrated in tracheobronchial secretions of horses with COPD, although their significance
in the pathogenesis of equine COPD is unclear (Grunig 1985; Von Fcllenberg 1987).
(9) RESPIRATORY INFECTIONS PREDISPOSING TO COPD
An association between the onset of COPD and previous bacterial or viral respiratory
infections has long been recognised (Gcrber 1973; McPherson and Lawson 1974; Thorsen et
al 1983). Similarly, in man, severe respiratory infections often precede the onset of human
asthma (Busse et al 1989).
While the mechanism underlying this association is unknown, pulmonary inflammation
induced by the infectious agents may favour antigen contact with immunologically active
tissues (McPherson and Lawson 1974), while virus induced reductions in mucociliary
clearance may lead to the retention of antigens and thus result in prolonged and increased
exposure to antigens (Willoughby and Ecker 1990). In man, viral infections have also been
shown to induce NSBHR and increase the late phase airway obstruction which follows
antigen challenge (Busse et al 1989).
PATHOGENESIS OF EQUINE COPD
The pathogenesis of equine COPD remains speculative. The putative causal agents, namely
fungi and thermophilic actinomycetes, could potentially induce pulmonary inflammation
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either by non specific irritation, e.g. by the action of proteases and/or by complement
activation, or alternatively by hypersensitivity mechanisms (Pcpys 1978; Halliwcll et al
1979). Non specific irritation is, however, unlikely to be an important mechanism in the
pathogenesis of equine COPD as all individuals exposed to a non specific irritant would be
expected to develop pulmonary inflammation (Salvaggio and Hendrick 1989), in contrast to
COPD, which affects only a proportion of horses.
A considerable body of evidence, including antigen inhalation challenge studies, intradermal
antigen testing studies, serum precipitins studies (Eyre 1972; Lawson et al 1979; Mansmann
et al 1975; Madelin et al 1991) and the demonstration of positive in vitro Schultz-Dale
phenomena, active cutaneous anaphylaxis and Prausnitz-Kustncr passive cutaneous
anaphylaxis (Eyre 1972; Schatzmann et al 1973), suggests that COPD is a pulmonary
hypersensitivity.
While one or more of the four types of hypersensitivity, as classified by Coombs and Gc'il
(1968), could be involved in the pathogenesis of pulmonary hypersensitivity to moulds (Pcpys
1978), most current evidence favours involvement of types 1 and 111 hypersensitivity (Gcrbcr
1973; Schatzmann et al 1973; Halliwcll ct al 1979; McPherson and Thomson 1983).
TYPE I HYPERSENSITIVITY
Type I hypersensitivity is mediated by the interaction of allergen with allergen specific IgE
or, less commonly, IgG antibodies, which are present on mast cells and basophils. The
resultant degranulation of these cells releases numerous preformed and newly synthesised
mediators capable of inducing pulmonary inflammation.
The role for type I hypersensitivity in equine COPD, proposed by Cook and Rossdalc (1963),
Lowell (1964), Eyre (1972), Halliwcll et al (1979), McPhcrson et al (1979) and Thomson
(1989), was further investigated in this study and is reviewed in Chapter 5.
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TYPE II HYPERSENSITIVITY
Mould allergens may induce type II hypersensitivity, also termed antibody dependent
cytotoxic hypersensitivity, by interacting with molecules on the surface of cells within the
lungs, to produce haptens, against which IgG or IgM antibodies are produced (Pepys 1978).
Subsequent interaction of the hapten and antibody induces activation of the complement
cascade which results in lysis and/or phagocytosis of the cell.
There is currently no evidence to support involvement of this mechanism in the pathogenesis
of equine COPD.
TYPE III HYPERSENSITIVITY
Type III, or immune complex hypersensitivity is considered to be the most important
mechanism in the pathogenesis of hypersensitivity pneumonitis in man (Pcpys 1978) and is
thought to have a role in the pathogenesis of equine COPD (Schat/.mann et al 1973;
Mansmann et al 1975; Halliwell et al 1979; McPhcrson and Thomson 1983; Thomson 1989).
Immune complexes, formed by the interaction of specific antigen and IgG, or possibly IgM
precipitating antibodies, activate the complement, coagulation and kinin systems and induce
release of mediators from mast cells, platelets, neutrophils and eosinophils (Gorman and
Halliwell 1989; Pelikan 1990), resulting in a pulmonary inflammatory response. Alternatively
the precipitins may elicit a hypersensitivity response without fonning immune complexes by
directly interacting with IgG-Fc receptors on activated mast cells (Coble et al 1984),
neutrophils and platelets (Pelikan 1990).
It has been suggested by Cochrane (quoted by Pcpys 1978) that a preceding type I
hypersensitivity response is a prerequisite to the development of a type III response.
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The presence of complement fragment C3 and IgG deposits, within the alveolar septa of one
horse with COPD supports involvement of this mechanism in the pathogenesis of COPD in
that animal (Winder and Von Fellenberg 1986).
While serum precipitins to a wide range of environmental aeroallergens, including fungi,
actinomycetes and chicken sera have been identified in the scrum of horses with COPD
(Lawson et al 1979; Mansmann et al 1975; Madclin et al 1991), their significance in the
pathogenesis of COPD remains unclear. Their presence in horses which have no evidence of
pulmonary disease indicates that they may merely reflect previous exposure to these antigens
and need not be of pathogenic significance. Furthermore, some horses with COPD (Lawson et
al 1979; Zeitler 1984) and some humans with hypersensitivity pneumonitis have no detectable
precipitins (Edwards et al 1974), although this may reflect the limited number of antigens
utilised to detect the precipitins in these studies.
TYPE IV HYPERSENSITIVITY
Type IV or delayed type hypersensitivity is mediated by a population of activated T
lymphocytes, designated delayed type hypersensitivity cells (Tq^ cells). Upon subsequent
challenge with antigen, TqH cells initiate an inflammatory reaction characterised by
macrophage and lymphocyte infiltration and by granuloma formation (Gorman and Halliwcll
1989).
While this mechanism has been implicated in the pathogenesis of human allergic alveolitis
(Moore et al 1976; Pepys 1978), its proposed involvement in equine COPD (Gerber 1973;
Schatzmann et al 1973) seems unlikely, as the classical hallmark of this reaction, namely
granuloma formation, is not a histological feature of COPD (Nicholls 1978).
While Halliwell et al (1979) observed an occasional dermal type IV response in normal and
COPD affected horses, at 48h after intradermal challenge with Candida albicans, this
organism has not been associated with equine COPD.
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EARLY AND LATE PHASE RESPONSES TO ANTIGEN
Horses with COPD may show early (maximal at 90min) or late (maximal at 4-6h) onset
pulmonary or dermal inflammatory responses to experimental antigen inhalation challenges
(AICs), 'natural (hay and straw) challenges' (NC) or intradermal antigen challenges
(Mansmann et al 1975; Halliwell et al 1979; McPhcrson et al 1979; McPhcrson and Thomson
1983; Thomson 1989).
Similarly, natural and experimental allergen challenges of human allergic asthmatics may
induce isolated early bronchial responses (ER) (reported incidence 7-50%), which occur
within a few minutes of challenge and usually resolve by 30-60min, isolated late phase
responses (LPRs) (18-84%), which commence 3-4h post challenge and resolve by 24-48h, or
dual responses (9-53%) (reviewed by Lemanskc and Kalincr 1988).
ERs, LPRs and dual responses have also been reported following bronchial challenges in rats
(Lemanske and Kaliner 1981-1982), guinea pigs (Hutson et al 1990), rabbits (Mct/.gcr 1990),
sheep (Russi 1990) and dogs (Griffin et al 1986), and following cutaneous and nasal allergen
challenges in several species (Lemanskc and Kaliner 1988).
EARLY RESPONSE (ER)
Numerous studies have focused on the ERs to experimental and natural allergen challenges in
man and laboratory animals and have demonstrated that they are largely type 1
hypersensitivity responses (Kay 1988; Johnston and Holgalc 1990; Pcpys 1990).
In the horse, the early intradermal reactions to M.faeni and A fumigatus antigens were shown
histologically to be consistent with a type I hypersensitivity (Halliwcll et al 1979; Beech and
Gunson 1981) and it is possible that the early pulmonary response to these antigens and to NC
may also be mediated by this mechanism (McPhcrson and Thomson 1983).
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LATE PHASE RESPONSE (LPR)
It is apparent, however, that naturally occurring allergic disease does not result from a
continuous series of immediate hypersensitivity responses (Gleich 1982) and considerable
evidence now indicates that the LPR more closely resembles naturally occurring allergic
disease than does the ER (reviewed by Iliopoulos et al 1990). Accordingly the LPR is now
receiving greater attention.
While the pathogenesis of the LPR in man and animals is unclear, there is evidence to
implicate a number of inflammatory cells and mediators.
(1) THE ROLE OF TYPE III HYPERSENSITIVITY IN LPRs
Classically, the LPR was considered to result from a type III hypersensitivity response to
allergen (Pepys et al 1968). There is evidence to suggest that this mechanism is responsible, in
man, for inducing the cutaneous and bronchial LPRs to Aspergillus antigens in allergic
bronchopulmonary aspergillosis (Pepys et al 1968) and in subjects with non atopic extrinsic
allergic alveolitis, which have specific precipitins but no IgE (Warren et al 1977).
However, alternative mechanisms arc believed to induce LPRs to other antigens, and to cause
LPRs in subjects which have no detectable precipitins (Booij-Noord et al 1971; Taylor and
Shivalkar 1971; Robertson et al 1974). As a consequence, Pelikan (1990) emphasised that,
where possible, a distinction should be made between a LPR and a Type III hypersensitivity
response.
In horses the late phase dermal response to M.faeni and A.fumigatus antigens was shown
histologically to be consistent with type III hypersensitivity (Halliwcll et al 1979; McPhcrson
et al 1979; Beech and Gunson 1981) and it is possible that the late phase pulmonary response
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which follows antigen inhalation challenges and NC may also be mediated by this mechanism
(McPherson and Thomson 1983).
(2) THE ROLE OF IgE, MAST CELLS AND BASOPHILS IN THE PATHOGENESIS OF
LPRs
Considerable evidence indicates that IgE and mast cells and/or basophils arc important in the
pathogenesis of LPRs.
The release of mast cell and/or basophil mediators during the LPR to cutaneous (Shalit et al
1988), bronchial (Durham et al 1984) and nasal (Iliopolous et al 1990) allergen challenges
and the ability of these mediators to recruit, prime and activate neutrophils, macrophages and
eosinophils (reviewed by Johnston and Holgalc 1990) is evidence for mast cell and/or
basophil involvement in human LPRs.
Furthermore, LPRs may be induced solely by challenge with mast cell and basophil
secretagogues, including F(ab)2 anti-IgE and compound 48/80, or by isolated mast cell
granules or granule contents (Dolovich et al 1973; Solley et al 1976; Umcmoto et al 1976;
Lemanske et al 1981-1982). The LPR which follows acroallergen challenge in rabbits was
also shown to be IgE and mast cell dependent (Behrens et al 1984).
Human asthmatics which showed LPRs following allergen inhalation challenges had higher
levels of allergen specific IgE within their respiratory secretions than those which did not
show LPRs (Crimi et al 1989), suggesting involvement of IgE in the LPR of human asthma.
IgE molecules could induce LPRs by interacting with Fcg receptors on macrophages,
lymphocytes, eosinophils, mast cells or basophils (Rossi et al 1991).
An increased interest in the role of mast cells and basophils in LPRs has followed the
discovery of histamine releasing factors (HRFs) and histamine releasing inhibitory factors
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(HRIFs). These are a heterogeneous group of cytokines produced by inflammatory cells which
interact with a special type of IgE molecule, designated IgE+, present on mast cells and
basophils of atopic individuals, resulting in non cytotoxic degranulation of these cells
(reviewed by Lichtenstein 1988, Kaliner 1989). These are further discussed in Chapter 5.
Evidence against significant mast cell involvement in the bronchial LPR of human asthma
includes the failure of potent mast cell stabilisers, including B2-adrenoceptors, to block the
late phase pulmonary inflammatory response of human asthma (reviewed by Barnes 1989).
Furthermore, corticosteroids, which have no detectable direct action on mediator release from
human lung mast cells (Schleimer et al 1983) are highly effective in preventing LPRs in
human asthmatics (Cockcroft and Murdock 1987; Dutoit et al 1987; Kerrebijn et al 1987).
Corticosteroids also effectively alleviate the symptoms and reduce NSBHR in COPD affected
horses (Klein and Deegen 1985), suggesting that, if corticosteroids have no direct effect on
equine mast cells, mast cells do not have an important role in the LPR of equine COPD.
However, since corticosteroids effectively inhibit mediator release from basophils
(Lichtenstein and MacGlashan 1986), these findings do not preclude involvement of the
basophil in bronchial LPRs to allergen.
The potential role of mast cells and basophils in the pathogenesis of equine COPD was
further investigated in this study and is reviewed in Chapter 5.
(3) THE ROLE OF LYMPHOCYTES IN THE PATHOGENESIS OF LPRs
Increasing evidence suggests that activated T lymphocytes have an important role in inducing
LPRs, in perpetuating the inflammatory response during ongoing chronic bronchial
hypersensitivity and in inducing NSBHR in man and laboratory animals (Gonzalez et al 1987;
Diaz et al 1989; Brusasco et al 1990; Kay 1991).
The role of lymphocytes in the pathogenesis of equine COPD was further investigated in this
study and is reviewed in Chapter 4.
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(4) THE ROLE OF NEUTROPHILS IN THE PATHOGENESIS OF LPRs
Neutrophils have been implicated in ozone induced bronchial hyperreactivity in dogs (Lee et
al 1977) and in antigen induced bronchial hyperreactivity in rabbits (Chung et al 1985). The
absence of a detectable bronchoalveolar lavage fluid (BALF) neutrophilia in some human
asthmatics during the LPR suggests, however, that neutrophils do not necessarily contribute
significantly to the development of the LPR in all human asthmatics (Rossi et al 1991).
Whilst marked pulmonary neutrophilia is a characteristic feature of equine COPD (Nicholls
1978; Derksen et al 1985B), the role of neutrophils in the pathogenesis of this condition
remains unclear.
Winder and Von Fellenberg (1988) suggested that neutrophil derived enzymes, including
elastase, collagenase and myeloperoxidase, may cause airway damage in horses with COPD.
However, it seems unlikely that neutrophil proteases have a major role in the pathogenesis of
equine COPD as pulmonary fibrosis and emphysema are not major features of this condition
(Nicholls 1978).
While it was classically considered that extravasated neutrophils disintegrate and liberate
proteases, causing pulmonary damage, before being phagocytosed (Hurley 1983), it is now
clear that effete, intact neutrophils may undergo apoptosis and be removed by macrophages
without resultant pulmonary damage (Haslett et al 1989). The state of neutrophil activation
appears to be important in determining whether protease release occurs.
It seems likely that the large numbers of effete intrapulmonary neutrophils present in horses
with COPD are removed by apoptosis without release of significant quantities of proteases.
(5) THE ROLE OF EOSINOPHILS IN THE PATHOGENESIS OF LPRs
There is considerable evidence to suggest that the eosinophil is perhaps the most important
proinflammatory cell in human asthma (reviewed by Kay 1988).
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The finding that human asthmatics which showed LPRs following AICs had an earlier onset
bronchoalveolar lavage eosinophilia (Rossi et al 1991) and had increased BALF levels of
eosinophilic derived cationic protein (Dc Monchy et al 1985), compared with those showing
only ERs, was taken as evidence for involvement of eosinophils in the development of
bronchial LPRs in human asthmatics.
While a small proportion of horses with COPD show pulmonary eosinophilia (Derksen et al
1985B; Grammel 1989; Kaup et al 1990A; Fogarty pers comm 1991), the significance of this
finding is unclear. Grammel (1989) showed that COPD affected horses, given pretreatment
with the platelet activating factor (PAF) antagonist WEB 2086 prior to NC, showed reduced
BALF eosinophil ratios compared with untreated horses, while the clinical severity of their
COPD and their BALF neutrophil ratios were unaffected. It was concluded that eosinophils do
not have a major role in the pathogenesis of equine COPD.
INFLAMMATORY MEDIATOR STUDIES
It is unlikely that the entire pulmonary inflammatory response in horses with COPD could be
attributed to the action of a single mediator, the combined effects of several inflammatory
mediators and inflammatory cells being more likely.
Platelet activating factor (PAF), a mediator released from numerous cells including basophils,
mast cells, eosinophils, neutrophils, platelets, macrophages, monocytes and endothelial cells
(reviewed by Barnes 1991), may have a role in the pathogenesis of pulmonary inflammation
in other species (Morley et al 1984; Page et al 1984). However, as prctrcatment with a PAF
antagonist did not prevent the development of COPD in asymptomatic COPD affected horses
following NC, PAF was considered unlikely to have a major role in the pathogenesis of
equine COPD (Grammel 1989).
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Gray et al (1989) demonstrated that NC increased the concentration of the arachadonic acid
metabolite, thromboxane B2, in the plasma of COPD affected horses, while plasma PGI2 and
PGD2 concentrations were unaffected by this challenge. However, as prctreatmcnt of the
horses with the cyclooxygenase inhibitor, flunixin meglumine, prevented this challenge
induced increase in thromboxane B2, but did not prevent airway obstruction and bronchial
hyperreactivity it was concluded that thromboxane B2 docs not have an important role in the
development of airway obstruction and bronchial hyperreactivity in horses with COPD.
Watson et al (1990) demonstrated that, while prostaglandins were not detectable in BALF
from 3 control horses, BALF from all 3 COPD affected horses contained PGEvj and BALF
from one COPD affected horse contained immunorcaclivc PGF.
The potential role of histamine, which was further investigated in this study, in the
pathogenesis of equine COPD is reviewed in Chapter 5.
PATHOLOGY OF EQUINE COPD
While the lungs of asymptomatic horses and those with short duration COPD may appear
macroscopically normal, those of severely affected cases may fail to deflate following
opening of the thorax (Nicholls 1978).
Various changes have been observed in the major airways of horses with COPD using light
and electron microscopy, however these were considered to be focal and non specific (Kaup et
al 1990A).
The primary histological lesion characterising equine COPD is a chronic diffuse
bronchiolitis, with ciliary abnormalities, loss of ciliated epithelial cells, epithelial metaplasia
and hyperplasia, goblet cell metaplasia, Clara cell degeneration and degranulation,
peribronchial cellular infiltration with neutrophils, lymphocytes, mast cells, eosinophils and
plasma cells, airway smooth muscle hypertrophy and the presence of inflammatory exudate
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and excess mucus in the airway lumina (Thurlbcck and Lowell 1964; Gerber 1973; Nicholls
1978; Jubb and Kennedy 1985; Winder and Von Fellcnbcrg 1986; Kaup et al 1990A & B).
Immunofluorescent studies demonstrate that horses with COPD have increased numbers of
perivascular and peribronchiolar lymphocytes which bear either IgA, IgG or no tg, with
severely affected horses having large amounts of free intraepithelial IgA and IgG (Winder and
Von Fellenberg 1968 & 1988).
The limited histological changes occurring in the alveolar region include necrosis of the type
I epithelial cells, type II epithelial transformation, increased numbers of Kohn's pores and
alveolar hyperinflation and emphysema (Nicholls 1978; Kaup et al 1990B). Emphysema,
usually confined to the periphery of the lung, was considered to be a minor feature of COPD
which occurred late in the development of the disease. As emphysema was observed
predominantly in areas with obstructed bronchioles, it was considered to result from air
trapping (Nicholls 1978; Kaup et al 1990B). While Nicholls (1978) and Vicl (1983) found no
pulmonary fibrosis in horses with COPD. Kaup et al 1990B found that all horses with severe
disease had alveolar fibrosis which they considered commenced in the peribronchiolar area
and extended to the alveolar septae.
The pathological features of equine COPD were considered to bear no resemblance to those
of human chronic bronchitis or human emphysema (Nicholls 1978).
While Kaup et al 1990A demonstrated ultrastruclural changes suggestive of an asthmoid
reaction in one of 28 COPD affected horses, these changes were also present in one of 8
control horses. Furthermore, widening of the basement membrane, a characteristic feature of
human asthma was not observed in any of the horses in this study, suggesting that the
pathological features of equine COPD differ from those of human asthma.
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A granulomatous interstitial pneumonia similar to human hypersensitivity pneumonitis has
been reported in a number of horses with chronic pulmonary disease (Pauli et al 1972; Gerber
1973) but it seems likely that these cases represent a different disease process.
PATHOPHYSIOLOGY OF EQUINE COPD
The pulmonary dysfunction and impaired pulmonary gas exchange observed in horses with
COPD are due to airway obstruction. The pathophysiology of airway obstruction in the horse
was reviewed by Robinson and Sorenson (1978) and thus will be discussed only briefly.
Bronchial and bronchiolar obstruction may result from reflex neural bronchoconstriction and
from structural airway changes including luminal mucus plugging, mural oedema, cellular
infiltration and, in severe cases, intrathoracic airway collapse during expiration (Fischer
1980). Reflex neural bronchoconstriction is considered to be predominantly a consequence of
increased parasympathetic activity mediated by the vagus nerve and/or hypcrrcsponsivcncss
to acetylcholine (Armstrong et al 1986; Scott et al 1988). While horses with symptomatic
COPD may have increased numbers of alpha receptors and/or increased alpha receptor
activity compared with control horses, the contribution of alpha receptor activity to the
bronchospasm was considered to be minimal (Armstrong et al 1986; Scott et al 1988).
The effects of airway obstruction on pulmonary mechanics and pulmonary gas exchange in
horses with COPD are reviewed in Chapter 2.
In COPD affected horses, hypoxacmia resulting from pulmonary dysfunction results in
pulmonary hypertension and increased right ventricular workload (Dixon 1978). However,
while cor pulmonale has been reported in a small number of horses with COPD (Salutini
1959), this is an uncommon finding even in horses with chronic severe COPD (Dixon et al
1982).
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CLINICAL MANIFESTATIONS OF EQUINE COPD
Depending on the severity of the pulmonary dysfunction, some horses with COPD show no
detectable clinical signs, while others may show exercise intolerance, coughing, nasal
discharge, tachypnoea, hyperpnoca, dyspnoea, exaggerated expiratory abdominal muscular
contraction ('heaving'), hypertrophy of the external abdominal musculature ('heave line') and
flaring of the nostrils (McPherson and Thomson 1983).
CLINICAL AND LABORATORY DIAGNOSIS OF COPD
The various clinical and laboratory methods employed in the diagnosis of equine COPD are
reviewed in Chapter 2.
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CHAPTER 2
THE RESPONSES OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
AFFECTED HORSES TO ANTIGEN INHALATION CHALLENGES WITH
MICROPOLYSPORA FAENI, ASPERGILLUS FUMIGATUS AND
THERMOACTINOMYCES VULGARIS.
SUMMARY
To investigate the aetiology of equine chronic obstructive pulmonary disease (COPD), 8
control and 8 asymptomatic COPD affected horses were given nebulised inhalation challenges
with extracts of Micropolyspora faeni (MF), Aspergillus fumigatus (AF) and
Thermoactinomyces vulgaris (TV). Nebulised phosphate buffered saline challenges and
exposure to hay and straw i.e. 'natural challenges' (NCs) were performed as negative and
positive control challenges, respectively. Responses to the challenges were assessed by
clinical, pulmonary mechanics, arterial blood gas tensions, arterial blood pH and
bronchoalveolar lavage fluid (BALF) cytological examinations.
Pulmonary disease, similar to naturally occurring COPD, was induced in the COPD affected
horses by MF and AF challenges, implicating MF and AF in the aetiology of equine COPD.
Control horses were unaffected by these 2 challenges.
While TV challenge did not induce statistically significant changes in either group, it did
elicit a neutrophilic pulmonary inflammatory response in 4 COPD affected horses. This was
considered to represent non specific pulmonary toxicity, as 2 control horses, which were
unaffected by NCs, also showed neutrophilic pulmonary inflammation in response to this
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challenge. The experimental TV challenge was therefore considered to differ from the TV
challenge which occurs naturally, during exposure to hay and straw.
The absence of pulmonary disease in control horses following MF, AF and NC challenges
suggested that equine COPD is a pulmonary hypersensitivity, rather than a non specific toxic
response.
Examination of BALF cytology was found to be the most sensitive technique for the
detection of pulmonary disease induced by these challenges.
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INTRODUCTION
An improved understanding of the aetiology of equine COPD, which is currently speculative
(reviewed in Chapter 1), is a prerequisite to the selection of more rational managemental
approaches for this condition.
ANTIGEN INHALATION CHALLENGE (AIC)
Antigen inhalation challenge (AIC) is considered to be the most useful technique for
investigating the aetiology of pulmonary hypersensitivity, as it may yield more valuable
information than other, less invasive investigative techniques, such as intradermal antigen
testing and in vitro antigen induced basophil or mast cell dcgranulation (Spcctor and Farr
1974; McPherson et al 1979; Spector 1989).
FACTORS AFFECTING THE RESULT OF ANTIGEN INHALATION CHALLENGES
Several factors, besides the reactivity of the subject to the antigen, can influence the outcome
of AICs. These include the quantity of antigen administered, the quantity and location of
antigen deposited within the respirator}' tract, and the rate and mechanism by which the
deposited antigen is removed from the lungs.
(A) THE QUANTITY OF ANTIGEN ADMINISTERED
In human studies, allergens are commonly administered in incremental doses from KX^ to
10~2 wA (Anon. 1980; Salvaggio and Hcndrick 1989). Administration of excessive quantities
of antigen may induce clinically irrelevant, positive responses in normal humans (Townley et
al 1965; Cavanaugh et al 1977).
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(B) THE QUANTITY OF ANTIGEN DEPOSITED IN THE RESPIRATORY TRACT AND THE
SITE OF PARTICLE DEPOSITION
Only a small fraction of the aerosol delivered to the subject enters the respiratory tact, due to
losses into the conducting equipment and losses during exhalation.
On inhalation, particles are likely to be deposited at the site of initial contact with the moist
respiratory epithelial lining fluid (Brain et al 1989). Physical mechanisms affecting particle
motion within the tract include gravitational sedimentation, incrtial forces, Brownian motion,
electrostatic forces and interception (where particles become deposited as the airway
diametenparticle diameter ratio gets progressively smaller) (Brain et al 1989).
Antigen is conveniently delivered to the human lung via a mouthpiece. However, as the horse
is an obligate nasal breather, antigen is delivered via a facemask or a tracheostoma. If the
former route is used, a large proportion of inhaled panicles will deposit in the nasal cavities
and only a small proportion will reach the small airways, the major anatomical site affected in
equine COPD (Nicholls 1978) and the target site for particle deposition in investigations of
this condition.
The aerosol particle size is the primary factor affecting the site of particle deposition,
although the aerosol water and solute content and the temperature and relative humidity of the
air in which the particles are delivered are further variables (Fcrron and Gebhart 1988).
Aerosol particle size is most usefully defined by the aerodynamic diameter, which takes into
account the size, shape and the density of the particles, all of which have significant effects on
their deposition patterns. Aerodynamic particle size may be determined using cascade
impactors, aerosol centrifuges (Brain et al 1989) and laser particle vclocimetcrs (Bouchikhi ct
al 1988). Accurate measurement of aerosol particle size distribution is, however, complex
because particle size is frequently dynamic, due to evaporation, hygroscopic growth and
agglomeration (Ferron and Gebhart 1988).
Pace - 39
Human studies have demonstrated that most particles >8u and virtually all those >15u are
deposited within the oropharynx by inertial impaction (Swift 1980), while particles of 5-10u
deposit within the bronchi and bronchioles with a diameter greater than 2mm. Smaller
particles i.e. those <5u reach the alveoli, where those of 2-5u arc deposited by gravity.
Particles <lu, being aerodynamically stable, are predominantly exhaled (Clarke 1990).
Aerosol particle size distribution is, in turn, influenced by the viscosity and surface tension of
the antigen preparation and the type of nebuliscr used (Brain ct al 1989). An ultrasonic
nebuliser, which is widely and effectively used for AICs, and which was used in this study,
generates an aerosol when high frequency sound waves, produced by vibrations of a
piezoelectric crystal, are focusscd on the surface of the liquid (Mercer 1981). Aerosols
produced by ultrasonic nebulisers are polydisperse, i.e. they arc composed of particles of
widely varying size, and produce comparatively lower pulmonary deposition than
monodisperse aerosols (Brain et al 1989).
Breathing pattern, including tidal volume, lung volume, respiratory rale and (low rate, are
additional factors affecting the deposition of inhaled aerosols (Hcyder et al 1982). The effects
of ventilation pattern on the deposition of inhaled panicles in excised canine lungs showed
that increased ventilatory frequency reduced the deposition of panicles, while slow deep
ventilation produced uniform deposition throughout the lungs, but with little deposition in the
central airways. Rapid shallow ventilation resulted in a highly variable pattern with
predominantly large airway deposition, while slow and shallow ventilation enhanced small
airway deposition (Valberg et al 1982).
Species differences in airway morphology and/or breathing patterns may result in differences
in the sites of deposition of inhaled antigens. Such differences may account for the finding
that exposure to mouldy hay and straw causes predominantly an alveolitis (extrinsic allergic
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alveolitis) in susceptible humans (Newman Taylor 1990) and cattle (Pirie et al 1971) but
predominantly a bronchiolitis (COPD) in the horse (Nicholls 1978).
(C) REMOVAL OF ANTIGEN FROM THE RESPIRATORY TRACT
The rate and mechanism(s) by which deposited particles arc cleared from the respiratory tract
also affect the outcome of AICs.
Particle clearance is biphasic. The fast (half life of minutes to hours) and slow (half life of
days to thousands of days) phases of clearance arc considered to represent tracheobronchial
mucociliary clearance and alveolar clearance, respectively (Morrow et al 1967; Brain et al
1989). Thus the site of particle deposition determines, in pan, the mechanism and rate of
particle clearance.
Mucociliary clearance may be affected by the number of cilia, the frequency and amplitude
of ciliary strokes and mucus rheology (Brain et al 1989). In contrast to other species, equine
ciliated epithelium, and hence mucociliary clearance mechanisms, extend distally to the
terminal bronchioles and occasionally to the bronchoalvcolar duct junction (Piric et al 1990).
Equine mucociliary clearance may be reduced by pulmonary diseases, including influenza
(McChesney 1975; Willoughby and Ecker 1990) and COPD (Drommcr et al 1986; Torgut and
Sasse 1989).
Alveolar clearance involves particle translocation and/or catabolism by alveolar
macrophages, movement of free particles into the intcrstitium and/or lymphatics, particle
dissolution (Brain et al 1989) and mucociliary clearance.
Despite all of the aforementioned factors which could potentially influence the fate of
particles and hence the outcome of AICs, it appears that the pulmonary function disturbances
induced in susceptible subjects by inhalation challenges with polydisperse nebulised allergens
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are relatively reproducible (Brain et al 1989). This suggests that the pulmonary function
disturbances are mediated, in part, by reflex bronchoconstriction.
EVALUATING THE RESPONSE TO ANTIGEN INHALATION CHALLENGES
The response to AICs may be monitored using clinical, pulmonary function, arterial blood
gas tensions, arterial pH, and respiratory cytology examinations.
(A) CLINICAL EXAMINATION
While clinical examination is a relatively simple, non invasive technique, it is unfortunately
relatively insensitive in the detection of equine COPD, with only severely affected horses
consistently showing clinical abnormalities (McPherson et al 1978; Vicl 1983). The clinical
signs manifested by horses with COPD were reviewed in Chapter 1.
(B) PULMONARY FUNCTION TESTING
Pulmonary function tests (PFT), first performed in the horse by Amoroso et al (1962), have
been frequently utilised in the investigation of equine pulmonary dysfunction (Gillespie et al
1966; Muylle and Oyaert 1973; McPherson et al 1979; Willoughby and McDoncll 1979;
Derksen et al 1982). However, due to lack of patient cooperation, several of the PFTs which
are of greatest value in man, including timed forced expiratory volume, closing volume, static
compliance and vital capacity, cannot be conducted in animals.
The PFT parameters which have been measured in the horse include, respiratory rate (RR),
tidal volume (Vj), minute volume (Vmjn), expiratory and inspiratory flow rates,
inspiratory:expiratory ratios, dynamic (Cdyn) and static compliance, total pulmonary
resistance (RjJ, functional residual capacity, thoracic pressure changes, total lung capacity,
nitrogen washout times, physiological dead space, and work and power of breathing
(Willoughby and McDoncll 1979).
EQUINE PULMONARY MECHANICS TESTING
Many of the PFTs used in the horse are pulmonary mechanics tests i.e. tests which assess the
mechanical properties of the lung and the thoracic wall.
(1) Methodology for pulmonary mechanics testing in horses
Most equine pulmonary function studies have utilised integrated pncumotachography, with
the horse breathing through a pneumotachograph on an airtight facemask. The pressure
gradient across the pneumotachograph, which is linearly proportional to the flow through the
pneumotachograph when airflow is laminar (Guyatt 1983), is measured using a differential
pressure transducer, yielding expiratory and inspiratory How data.
Intrathoracic pressure changes are measured using a rapid response manometer, directly via
an intrapleural catheter or indirectly via an intraoesophageal balloon, the two techniques being
highly correlated (Gillespie et al 1966; Willoughby and McDoncll 1979). Indirect
measurement is more suitable for repeated measurements, but is affected by the intrinsic
oesophageal tone, swallowing, coughing, and by balloon location and volume, while
pneumothorax, catheter tip blockage by blood or contact with the pleural surfaces and
pleuritis arc possible complications of the direct method (Derkscn and Robinson 1980;
Boerma et al 1986).
(2) Repeatibility ofpulmonary mechanics testing in horses
Perhaps the greatest limitation of pulmonary mechanics testing in the horse is the marked
variability in the results obtained, there being considerable variation in the normal values
reported by different authors (Derkscn et al 1982; Stadler and Decgcn 1986). While part of
this variation may be attributed to differences in methodology, considerable variation is
observed with repeated examinations of the same horse, even if tests are conducted under
apparently identical conditions.
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In order to address this variability, Derksen et al (1982) determined the short term (hourly for
6h) and long term (at 2 month intervals on 4 occasions) repcatibility of pulmonary mechanics
testing in conscious standing sedated ponies. Total pulmonary resistance showed minor short
term variations, but varied considerably over the long term, possibly due to variation in
functional residual capacity, upon which it is dependent. Respiratory rate, tidal volume,
dynamic compliance and quasistatic compliance showed considerable variation over both
short and long term periods. Variation in static compliance and pulmonary resistance and the
possible effects of inertia, although assumed to be negligible in the calculation of dynamic
compliance (Mead and Whittenburger 1957), may have contributed to the observed variation
in dynamic compliance. Derksen et al (1982) concluded that, while this marked variability
makes pulmonary mechanics testing unsuitable for detecting mild or moderate lung disease in
individual horses, it is of value when assessing lung function in groups of horses.
(3) Pulmonary mechanics testing in COPD affected horses
Most studies of equine pulmonary mechanics have used horses with longstanding COPD
rather than those with early COPD induced by relatively short duration AICs.
Horses with chronic COPD have V-p, RR and Vmin which do not differ consistently from
those of controls, but have increased inspiratory and expiratory How rates (Willoughby and
McDonell 1979), enlarged pressure volume loops, increased non clastic work of breathing,
increased pulmonary resistance, reduced dynamic compliance and increased mean maximum
transpulmonary pressure change (dPtp) (Gillespie et al 1966; McPhcrson et al 1978;
Willoughby and McDonell 1979).
Viel (1983) considered pulmonary mechanics testing was an insensitive technique, capable of
detecting only those horses with severe COPD. Nuyttcn et al (1988) considered pulmonary
mechanics testing was poorly tolerated by horses.
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OTHER MEANS OF ASSESSING PULMONARY FUNCTION IN THE HORSE
Viel (1983) considered the nitrogen washout test, which determines the efficacy of clearance
of nitrogen from the lungs during oxygen breathing, and which showed the best correlation
with pulmonary histological changes, to be the most reliable pulmonary function test for the
diagnosis of equine COPD.
Nuytten et al (1988) suggested that measurement of the pulmonary artery pressure and
pulmonary wedge pressure and assessment of the pulmonary driving pressures, i.e. the
difference between the pulmonary artery pressure and the pulmonary wedge pressure, was
better tolerated than pulmonary mechanics testing and more suitable for the diagnosis and
monitoring of COPD and for evaluating the severity of disease. However, as pulmonary
wedge pressures were not significantly different in affected horses, measurement of
pulmonary artery pressure alone would have provided the same information. Furthermore, as
pulmonary artery pressure is largely inversely proportional to Pa02 (Dixon 1978),
measurement of Pa02, which is more readily achieved, is probably as valuable.
(C) ARTERIAL BLOOD GAS TENSIONS AND ARTERIAL pH
Arterial blood oxygen (PaC^) and carbon dioxide (PaCC^) determinations provide a
convenient and reliable measurement of overall pulmonary ventilation and gas exchange
(Willoughby and McDonell 1979). In comparison with pulmonary mechanics measurements,
blood gas determinations show little long or short term variation in individual horses (Derksen
etal 1982).
Horses with COPD usually have normocapnic hypoxaemia and normal arterial pH
(Willoughby and McDonell 1979; Nyman et al 1991). McPhcrson et al (1978) and Littlejohn
(1978) suggested that COPD affected horses had Pa02 values below 82 Torr and 76 Torr,
respectively.
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(D) EXAMINATION OF RESPIRATORY FLUID CYTOLOGY
Examination of bronchoalveolar lavage fluid (BALF) cytology is currently considered to be
the most sensitive technique for the detection of equine COPD. This technique has made
possible the detection of subclinical COPD, which is undetectable using pulmonary
mechanics testing or clinical examination (Viel 1983). Furthermore equine BALF cytology
and pulmonary histopathological findings are closely correlated (Viel 1983; Fogarty 1990).
Bronchoalveolar lavage (BAL), however, induces a pulmonary neutrophilic response in
horses which persists at least for 48h (Sweeney et al In Press). In man, BAL induces a
pulmonary neutrophilia which resolves by 72h (Von Essen et al 1991). To avoid the BAL
induced pulmonary inflammatory response influencing the outcome of an AIC, prechallenge
BALs should be performed at least 72h prior to AIC.
Tracheal aspirate cytological examinations may be used to diagnose COPD. While collection
of equine tracheal aspirates is relatively non invasive, examination of tracheal aspirate
cytology is less valuable than BALF cytology examination, as it is poorly correlated with
BALF cytology (Derksen et al 1989) and pulmonary histopathology in horses with pulmonary
disease (Larson and Busch 1985).
To investigate the aetiology of equine COPD, control and asymptomatic COPD affected





Eight control (median age 15.5 years, range 7-25 years; median body weight 577kg, range
212-652kg) and 8 COPD affected (median age 15.5 years, range 6-25 years; median body
weight 482kg, range 371-546kg) geldings and mares of mixed breeds were used (Appendix
2.1).
'CONTROLLED ENVIRONMENT
This refers to a hay and straw free environment which would be expected to contain minimal
levels of the allergens implicated in the aetiology of COPD (McPherson et al 1979). When
possible, it was achieved by keeping the horses continuously at pasture, 500m from the
nearest hay and straw. Supplementary feeding, when necessary, was with ensiled grass
(Horsehage, Mark Westaway, Paignton).
During winter, or when pasture was unavailable, horses were housed in a separate row of
large (4.5m x 4.3m) stables, situated 50m from the nearest hay and straw. To maximise
ventilation, the top half door and a back wall vent (40cm x 125cm) were kept permanently
open. The airspace of each stable had no direct communication with adjacent stables. Horses
were fed ensiled grass and concentrates and were bedded on dry wood shavings or dry
shredded newspaper with damp bedding being removed daily.
'NATURAL CHALLENGE' (NC) ENVIRONMENT
Horses were housed in smaller (3.4m x 2.6m) stables which were, owing to the absence of
back wall or roof vents, poorly ventilated. The horses were bedded on deep litter straw which
had accumulated for several weeks, while other horses were being kept in the stables. They
were fed poorly saved hay. The hay and straw used frequently had grossly visible fungal
contamination and a mouldy odour.
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Microscopic examination of airborne dust collected from NC environments, using a hand
held particle sampler (Equigiene, Avon,) revealed large numbers of fungal spores, dust mites
and dust mite faeces.
COPD AFFECTED HORSES
These horses had known histories of more than 2 years duration and all suffered from chronic
pulmonary disease. Whilst in the NC environment they showed clinical signs of COPD and
were thus termed 'symptomatic'. The time of onset, severity and range of clinical signs
following NC differed among the horses but tended to be consistent for each individual
subject. All COPD affected horses showed clinical disease within 5h of NC, including some of
the following signs; coughing, tachypnoea, hyperpnoea, double expiratory lift ('heave'),
bilateral mucopurulent nasal discharge and increased and abnormal tracheal and lung sounds.
Bronchoscopic examination of horses with 'symptomatic' COPD consistently revealed
abnormal accumulations of mucopurulent secretions, containing large numbers of neutrophils
(usually >90%), in the horizontal trachea, and swelling and hyperaemia of the respiratory
mucosa. In all cases, BALF contained greater than 5% neutrophils.
Previous investigations had also determined that these horses, when 'symptomatic', had
increased dPtp and R^, and decreased Cdyn and Pa02-
All clinical and laboratory abnormalities reverted to normal when horses with symptomatic
COPD were moved to a 'controlled environment' (vide supra). Horses tended to have their
own individual rates of remission of usually between 2 and 6 weeks, the BALF cytological
changes consistently being the last parameter to revert to normal. All COPD affected horses
had received multiple alterations of NC and 'controlled', environments and had responded
consistently as described above.
Prior to each AIC, all COPD affected horses were confirmed by clinical examination, arterial
blood gas tensions and pH analyses and BALF cytology (< 5% neutrophils) to be in
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remission. Horses in remission were termed 'asymptomatic'. BALF samples were collected at
least 72h prior to AICs to minimise possible iatrogenic effects of prior lavage on the outcome
of the AICs (Sweeney et al In Press).
CONTROL HORSES
These horses had shown no evidence of respiratory disease for 2 years and were found to be
normal on clinical, bronchoscopic, arterial blood gas tensions and pH, pulmonary mechanics
and BALF cytology examinations when maintained in either a controlled environment or in a
'natural challenge' environment. In all control horses neutrophils consistently accounted for
less than 5% of BALF cells.
MAINTENANCE OF HORSES
All horses were maintained in a controlled environment prior to and during the challenges,
except during the NC period. They were given anthelmintics monthly and given tetanus
toxoid (Coopers Pitman Moore, Crewe) every 2 years.
ANTIGEN INHALATION CHALLENGES (AIC) AND 'NATURAL CHALLENGES' (NC)
Horses were given separate nebulised AICs with 20 000 protein nitrogen units (pnu)
Aspergillus fumigatus (AF), 5mg Thermoactinomyccs vulgaris (TV) or 5mg Micropolyspora
faeni (MF) (Greer Laboratories, Lenoir, North Carolina, USA) in 20ml phosphate buffered
saline (PBS) pH 7.4 (Sigma, Poole). Nebulised inhalation challenge with 20ml PBS acted as a
diluent and a protocol control. Solutions were prepared immediately prior to use.
An ultrasonic nebuliscr, with a reported average particle size output of 0.5-5u (UltraNcb 65,
Devilbiss Health Care, Hounslow), was used to generate the challenge aerosols. The aerosol
was delivered over a 5-15min period via a face mask incorporating a one way valve system
and inspiratory reservoir bag, to minimise aerosol loss during expiration (Fig. 2.1).
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NC, which represented a positive control challenge for the COPD affected horses, was
performed by housing horses within a NC environment (vide supra). The top door of the box
was closed 8h prior to and throughout the 5h duration of this challenge.
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Fig. 2.1 Photograph of unsedated horse receiving antigen inhalation challenge, showing




Fig. 2.2 Photograph of standing, unscdated horse during pulmonary mechanics testing,
showing airtight facemask and heated pneumotachograph.
 
MONITORING THE RESPONSE TO CHALLENGES
Clinical examination of the respiratory system, arterial blood gas tensions and pH analyses
and pulmonary mechanics testing were performed immediately prior to and at 1.5 and 5h after
each challenge. After the 5h examinations, bronchoalveolar lavage (BAL) was performed
(vide infra).
CLINICAL EXAMINATION
The horses were examined for coughing, nasal discharge, hyperpnoea and dyspnoea. The
trachea and lung fields were auscultated, before and after inducing hyperpnoea by occluding
the horse's nostrils for 30s to lmin.
ARTERIAL BLOOD COLLECTION AND Pa02, PaC02 AND ARTERIAL pH
DETERMINATIONS
Carotid arterial blood samples, collected using a 21g 4cm needle into precooled heparinised
glass syringes, were stored on ice and analysed, always within 30min of collection, for PaC^,
PaCOj and arterial pH, using a Coming 168 blood gas analyser (Coming, Halstead), at an
altitude of 180m. Blood gas tensions data were corrected to the rectal temperature of the
horse.
PULMONARY MECHANICS TESTING
All horses were given 2 training periods prior to the collection of data to familiarise them
with the experimental protocol and to minimise anxiety which may influence lung function
(Deegen and Klein 1985). All measurements were performed on standing, unsedated horses
restrained only with a headcollar. No sedation was administered to the horses prior to or
during pulmonary mechanics testing to avoid any drug induced effects on pulmonary function
(Reitmeyer et al 1986). Two horses that could not be safely restrained by headcollars were
excluded from this study.
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As some horses became restless during prolonged recording periods, recording was
commenced immediately after the horses were connected to the apparatus, and continued until
at least 5 consecutive representative, artifact free breaths were recorded.
Respiratory flow was measured using a heated pneumotachograph (No.4, A.Fleisch,
Bilthoven, Holland), mounted on an air tight facemask and connected to an elcctrospirometer
(Mercury CS9, Mercury Electronics, Glasgow) which electronically integrated the flow signal
to derive inspiratory and expiratory volume data. The clectrospirometer incorporated an auto-
zero circuit which automatically corrected the baseline at lOmin intervals. The dead space of
the mask, calculated by the technique of An and Lekcux (1988) was approximately 0.751,
which was, for most recordings, less than that which significantly affects pulmonary function
and gas exchange i.e. <25% tidal volume (Lckeux et al 1984). A llcxiblc rubber seal attached
to the exterior of the mask and a 65cm x 10cm x lem strip of closed cell foam rubber attached
to its inner edge made the mask airtight. The face mask was positioned inside the halter, to
which it was fastened (Fig. 2.2).
An oesophageal balloon catheter, consisting of a latex condom secured over the end of a
polythene catheter (length 250cm, O.D.=6mm, I.D.=4mm, ARCO, Linlithgow) which had a
series of spirally arranged holes distally, and a lateral mask catheter (OD=5mm, ID=3mm,
ARCO), were connected to opposite ports ol the elccirospiromcter to measure transpulmonary
pressure (Ptp). The oesophageal catheter was positioned at the midpoint of the thoracic
oesophagus, just behind the heart, at a length from the external narcs predetermined by
holding the tubing at the side of the horse (Art and Leukeux 1988). The catheter was passed to
the same point for each individual horse. The catheter-balloon assembly was filled with 7ml
air, this volume being within the range of high compliance of the balloon.
The electronic output from the elcctrospiromcter was directed to a paper trace recorder (Both
a M19, Devices, Letchworth Garden City and a Multitrace 4, Lectromcd, Welwyn Garden
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City, were used) to produce permanent records. The baseline drifts of these recorders were
<1% per minute (M19) and <0.5% per minute (Multitrace 4) at the chart speed used in this
study. As the frequency responses of these recorders (Ml9 100Hz, Multitrace 4 40Hz) were
more than 10 times the fundamental frequency of equine respiratory patterns, they were
considered suitable for this purpose (Guyatt 1983).
Row, volume and pressure calibrations were made using, respectively, a rotating vane flow
meter (Rotameter 2000, G.E.C. Elliot, Croydon), a 2 litre calibrated syringe, and a water
manometer. All outputs were linear over the working ranges. The frequency response
characteristics of the flow and pressure recording systems were phase matched up to 5Hz,
using standard techniques (Macklem 1974).
Measurement was performed at an altitude of 170m above sea level. All electronic measuring
and recording equipment was allowed to warm up overnight prior to use.
ANALYSIS OF PULMONARY MECHANICS DATA
Five representative breaths, devoid of artifacts, were analysed for each recording. Respiratory
rate (RR), mean tidal volume (Vj), minute volume (Vmin), mean maximum change in
transpulmonary pressure (dPtp), dynamic compliance (Cdyn) and 'average' pulmonary flow
resistance (R^) were determined. Cdyn and R[ were calculated by the methods of Amdur and
Mead (1958). Pulmonary resistance calculated by this method represents the average
inspiratory and expiratory resistance near peak inspiratory and peak expiratory flows,
respectively.
COLLECTION OF BRONCHOALVEOLAR LAVAGE FLUID (BALF)
Transendoscopic (CF-1T10L, Olympus Optical Co., Japan) bronchoalvcolar lavage (BAL)
was performed under sedation using intravenous O.Olmg/kg delomidine (Domoscdan,
SmithKline Beecham Animal Health, Tadworth) and O.Olmg/kg butorphanoi (Torbugcsic, C-
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Vet, Bury St.Edmunds). Topical anaesthesia of the tracheal carina and major bronchi (10ml of
0.2% xylocaine, Astra, King's Langley) was used to minimise coughing during bronchoscopy.
The horses were restrained using a nose twitch.
The 13mm diameter endoscope, introduced via the rhinopharyngcal route into the larynx and
trachea, was passed distally until it 'wedged' in a third or fourth generation bronchus of the
accessory lobe of the right lung. 300ml freshly prepared room temperature PBS was instilled
via the biopsy channel of the endoscope into the occluded bronchus and immediately aspirated
using 60ml plastic syringes. Instillation and recovery of the lavage lluid look less than 45s.
The BALF was immediately filtered through a single layer of gauze into a precoolcd
polythene measuring cylinder and maintained on ice until processed, always within 20min of
collection.
PROCESSING OF BRONCHOALVEOLAR LAVAGE FLUID (BALF)
Total BALF cell counts were determined using a haemacylometcr (Improved Neubacur,
Hawksley and Sons, London) and cell viabilities determined using trypan blue exclusion.
The degree of blood contamination in BALF samples was estimated by determining BALF
haemoglobin concentrations using reagent strips (Ames Multiple Reagent Strips, Miles
Laboratories, Stoke Poges). The strips had a reported sensitivity of 150-620ug/l haemoglobin,
which is approximately equivalent to 5-20 intact erythrocytes per microlitre.
Cytospin preparations, prepared by centrifuging lOOul BALF at 400rpm for 5min (Shandon
Elliott, Cambcrlcy), were air dried and fixed using a water soluble aerosol fixative (Smear fix,
Vale Laboratories, London).
Differential counts of 300 BALF cells were made on Leishman's (Appendix 2.2) stained
preparations. Several preparations were also stained with toluidine blue (Appendix 2.2),
Giemsa (Appendix 2.2), Perl's stain (Perl 1867) and periodic acid Schiff (McManus 1946).
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Absolute BALF cell counts were determined for each cell type by multiplying the cell ratio
(%) by the total BALF cell count/100.
As total and absolute BALF cell counts are not only dependent on the cell count of the fluid
lining the airways, termed the pulmonary epithelial lining fluid (PELF), but also on the
variable volume of PELF recovered by BALs, comparison of total and absolute PELF cell
counts is more valuable than comparison of total and absolute BALF cell counts. Total and
absolute PELF cell counts were calculated from total and absolute BALF cell counts using the
urea dilution technique reported by Rennard ct al (1986). This technique is reviewed in
Chapter 7. Plasma and BALF urea concentrations were determined as described in Chapter 7.
In addition to employing the urea dilution technique, the variable dilution which occurs
during BAL was corrected for by determining the albumen adjusted BALF cell counts. This
technique is reviewed in Chapter 7. Plasma and BALF albumen concentrations were
determined as described in Chapter 7.
The remainder of the BALF was immediately centrifuged at 15(X)g at 4°C for 5min (MSE
Chilspin 2, Fisons, Crawley) and the supernatant stored at -2(VC.
STATISTICAL ANALYSES
Cell counts, cell ratios, BALF volumes and pulmonary mechanics data were non normally
distributed. Paired and unpaired analyses of these data were performed using, respectively, the
Wilcoxon Rank Sum test and the Mann Whitney lest, while correlations were performed using
the Spearman Rank Sign Test.
Arterial blood gas tensions and arterial pH data were normally distributed. Paired and
unpaired analyses of these data were perfonncd using the paired and the two sample T test
respectively.
The effects of each AIC and of NC on arterial blood gas tensions and pH and on pulmonary
mechanics were determined using both within and between group analyses.
P:m<^ - S7
Within group analyses were performed by comparing the changes which occurred in each
parameter during the challenge with those occurring during the PBS (negative control)
challenge. Thus the differences between measurements at Oh and 1.5h, between Oh and 5h and
between 1.5 and 5h for each challenge were compared with the corresponding changes for the
PBS challenge.
Within group analysis of the PBS challenge was achieved by direct comparison of the actual
data recorded during this challenge, rather than by comparisons of their changes.
Between group analyses, performed for all challenges, involved comparison of the changes
occurring in the control group with those occurring in the COPD affected group.
All statistical analyses was performed using Minitab (Minitab Inc., Pennsylvania, USA),




No detectable clinical pulmonary dysfunction was induced in the control group (Appendix
2.3) by any of the challenges, nor in the COPD affected group by the PBS challenge.
Two COPD affected horses became hyperpnoeic at 1.5 and 5h following AF and MF
challenges, at 5h following TV challenge and at 1.5h after NC. At 5h following NC, 7 of the 8
COPD affected horses showed exaggerated expiratory effort ('heaving').
At 5h following NC, auscultation of the lung fields and distal cervical trachea, at rest and
after forced breathing, revealed increased breath sounds in 3 COPD affected horses, although
no adventitious sounds were evident.
EXAMINATION OF BALF
BAL was satisfactorily accomplished in all cases. All horses coughed several times as the
endoscope tip passed from the trachea into the wedge site.
Most samples contained either a 'trace' or a 'small' amount of haemoglobin, and BALF cell
viability always exceeded 90%.
RECOVERY OF BALF
BALF recovery was not significantly affected by any of the challenges and was not
significantly different between the two groups (Table 2.1, Appendix 2.4).
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Table 2.1 The percentage recovery of BALF from control (CONT) (n=8) and COPD affected
(n=8) horses at 5h following AICs with PBS, AF, MF and TV and following NC (median and
range).
CHALLENGE CONTROL COPD
PBS 32.7 (12.3-54.0) 19.2 (9.0-35.3)
AF 34.0 (13.7-45.0) 31.0 (13.3-53.3)
TV 39.7 (16.0-45.0) 30.5 (23.0-48.0)
MF 30.5 (17.7-42.3) 29.3 (18.0-37.7)
NC 45.0 (12.7-50.0) 38.3 (13.0-60.0)
BRONCHOALVEOLAR LAVAGE FLUID (BALF) CYTOLOGY
Examination of BALF revealed neutrophils, macrophages, lymphocytes, ciliated columnar
epithelial cells, non ciliated cuboidal epithelial cells, Clara cells, lymphocytes, plasma cells,
eosinophils, mast cells, 'basophiloid cells' and erythrocytes.
Neutrophils (Fig. 2.3), which exhibited varying maturity, as indicated by their varied
lobulation, were usually readily identifiable. However, following NC, BALF from several
horses with COPD contained numerous small, intensely basophilic, pyknotic neutrophils,
which required careful differentiation from lymphocytes. Toxic degeneration of BALF
neutrophils was not observed.
Macrophages (Fig. 2.3) were readily recognised when large and vacuolated, however
differentiation of small macrophages and large lymphocytes was found difficult in some
instances.
Macrophages were of varied size and morphology, with large multinucleate macrophages,
mitotic forms and occasional haemosiderophages (macrophages containing haemosidcrin)
being identified in both control and COPD affected horses.
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Many large macrophages had 'foamy cytoplasm'. Occasionally macrophages were found to
contain phagocytosed lymphocytes, neutrophils, fungal spores and smaller, unidentified
particles.
Lymphocytes (Fig. 2.3) were predominantly small cells with scant cytoplasm. Many
lymphocytes contained approximately 5-15 small intracytoplasmic granules.
Cells resembling atypical lymphocytes, which have been described in other species (Haslam
et al 1987), i.e. showing marked irregular invagination of the nucleus, were apparent in some
BALF samples from COPD affected horses following NC (Fig. 2.3).
Occasional plasma cells were observed. They were, for the purposes of this study, counted as
lymphocytes.
Epithelial cells (Fig. 2.3). Ciliated columnar and non ciliated columnar and cuboidal
epithelial cells were commonly observed in clumps, when they were readily identified. Single
non ciliated epithelial cells, however, were considered difficult to differentiate from
macrophages.
Clara cells (Fig. 2.3) were frequently observed in epithelial clumps in association with
ciliated epithelial cells. The prominent, large, variably sized basophilic intracytoplasmic
granules made these cells easily recognisable.
No rounded clusters of ciliated epithelial cells similar to creola bodies (Johnston and Frablc
1979) were observed.
Mast cells (Fig. 2.3) were more readily identified when stained with toluidinc blue and
Leishman's than with Giemsa.
Mast cells exhibited varying degrees of degranulalion. Occasional cells were observed with
eosinophilic cytoplasm, similar to that of mast cells, but without intracytoplasmic granules.
These were possibly fully degranulatcd mast cells.
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'Basophiloid cells' (Fig. 2.3). These uncommonly recognised cells showed some similarities
to mast cells but had considerably larger and more densely staining cytoplasmic granules. In
most instances the prominent granules prevented visualisation of the internal cell structure.
The identity of these cells was not known.
'Total basophilic cells'. This was a classification which, for the purposes of this study,
included both mast cells and 'basophiloid cells'.
Eosinophils were readily identified by their large eosinophilic cytoplasmic granules.
Most BALF preparations from COPD affected horses contained strings of material which
appeared basophilic when stained with Lcishman's, and which stained positively with periodic
acid Schiff. This was considered to be mucus. Interestingly, a large proportion of the cells
present within this material were neutrophils, while others (Fig. 2.3) resembled fully
granulated mast cells.
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Fig. 2.3 Photomicrographs of BALF cells.
(i) Two macrophages (M), a lymphocyte (L), a granulated lymphocyte (GL) and a
'basophiloid cell' (BC), x3500.
(ii) Two macrophages (M), a neutrophil (N) and two mast cells (MA), xl400.
(iii) Bronchial epithelial cell clump, containing ciliated columnar epithelial cells (C) and a
Clara cell (CL), xl400.
(iv) An 'atypical lymphocyte' (AL), showing marked invagination of the nuclear membrane,
xl400.




TOTAL BALF CELL COUNTS
Coefficients of variation for total BALF cell counts, determined by performing 8 counts on 2
BALF samples, were 8.5% and 17.7%.
After PBS challenge, COPD affected horses had significantly lower total BALF cell counts
than control horses (p<0.05) (Table 2.2, Appendix 2.5). Total BALF cell counts of COPD
affected horses were significantly higher after NC than after PBS challenge (p<0.05).
Table 2.2 Total BALF cell counts (/ul) from control (n=8) and COPD affected (n=8) horses
following inhalation challenges with PBS, AF, MF, TV and following NC (median and
range).
CHALLENGE CONTROL COPD
PBS 237 (98-1125) 135 (45-200)1
AF 245 (60-387) 173 (73-360)
TV 241 (112-640) 159 (75-240)
MF 238 (120-400) 270 (113-680) ,
NC 335 (175-787) 372 (222-3737)2
}. Significantly lower than for the control group (p<0.05).2 Significantly higher than after PBS challenge (p<0.05).
TOTAL PULMONARY EPITHELIAL LINING FLUID (PELF) CELL COUNTS AND TOTAL
ALBUMEN ADJUSTED BALF CELL COUNTS
The plasma and BALF urea (Appendix 2.6) and albumen (Appendix 2.7) concentrations,
which were used to determine PELF cell counts and albumen adjusted BALF cell counts,
respectively, were not significantly affected by any of the challenges.
Within and between group statistical analyses of the total PELF cell counts yielded the same
statistical results as did analyses of the albumen adjusted total BALF cell counts.
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NC elicited a significant increase in the total PELF cell counts (Table 2.3, Appendix 2.8) and
the albumen adjusted total BALF cell counts (Table 2.4, Appendix 2.9) of COPD affected
horses when compared with PBS challenge (p<0.()5), although they were not significantly
different from those of the control group.
DIFFERENTIAL BALF, ABSOLUTE PELF CELL COUNTS AND ALBUMEN ADJUSTED
ABSOLUTE BALF CELL COUNTS
Within and between group statistical analyses of the absolute PELF cell counts yielded the
same statistical results as did analyses of the albumen adjusted absolute BALF cell counts.
BALF cell ratios (Table 2.5, Fig. 2.4, Appendix 2.10), absolute PELF cell counts (Table 2.6,
Appendix 2.11) and albumen adjusted absolute BALF cell counts (Table 2.7, Appendix 2.12)
from control horses were not significantly affected by any of the challenges.
BALF cell ratios (Table 2.5, Fig. 2.4, Appendix 2.10), absolute PELF cell counts (Table 2.6,
Appendix 2.11) and albumen adjusted absolute BALF cell counts (Table 2.7, Appendix 2.12)
from COPD affected horses were not significantly affected by PBS and TV challenges.
When the responses of individual COPD affected horses were examined, 4 COPD affected
horses and 2 control horses did, however, show increased BALF neutrophil ratios (i.e. >5%)
following TV challenges (Fig. 2.4, Appendix 2.10).
AF challenge significantly increased BALF neutrophil ratios (Table 2.5, Fig. 2.4, Appendix
2.10), absolute PELF neutrophil counts (Table 2.6, Appendix 2.11) and albumen adjusted
absolute BALF neutrophil counts (Table 2.7, Appendix 2.12) in COPD affected horses when
compared both with PBS challenge and with control horses (p<0.05).
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In COPD affected horses, MF challenge increased BALF neutrophil ratios (Table 2.5, Fig.
2.4, Appendix 2.10), absolute PELF neutrophil counts (Table 2.6, Appendix 2.11) and
albumen adjusted absolute BALF neutrophil counts (Table 2.7, Appendix 2.12), when
compared both with PBS challenge (p<0.05) and with control horses (p<0.01).
After MF challenge, BALF macrophage ratios of COPD affected horses were significantly
lower than those of the control horses (p<0.05) (Table 2.5, Fig. 2.4, Appendix 2.10).
NC increased BALF neutrophil ratios (Table 2.5, Fig. 2.4, Appendix 2.10), absolute PELF
neutrophil counts (Table 2.6, Appendix 2.11) and albumen adjusted absolute BALF neutrophil
counts (Table 2.7, Appendix 2.12) in COPD affected horses, when compared with PBS
challenge (p<0.05) and with the control horses (p<0.01).
After NC, absolute PELF macrophage counts, albumen adjusted absolute BALF macrophage
counts and BALF macrophage ratios were lower in the COPD affected horses than in the
controls (p<0.05).
After NC, BALF mast cell and 'total basophilic cell' ratios were lower in the COPD affected
horses than in the controls (p<0.05).
COPD affected horses had significantly higher BALF neutrophil ratios after NC than after
MF and AF (p<0.05).
The BALF neutrophil ratios of control and COPD affected horses after NC were significantly
correlated with those after AF (rs=0.691, p<0.01) and MF (rs=0.734, p<0.01) challenges.
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NEUT=neutrophils,LYMlymphocytes,MACmacr phage ,EOSeosinophils,AST=ascells,BASObaso i idl ,TOTBAt t lbas p ili cells,EP=epitheliall s. 1Significantlyhi herthanfollowi gPBSchallengeandhi h rtho trols(p<0.05). 2Significantlyhi herthanfollowi gPBSchallenge(p<0.05)a dhi rt ontrols(p<0.01). 3Significantlylowerthancontrols(p<0.05).4Significantlyhigherthanfollowi gPBSchallenge(p<0.05)andhi rthcontrols(p<0. 01). 3Significantlylowerthancontrols(p<0.01).
Figure 2.4 BALF cell ratios for control (CONT) (n=8) and COPD affected (n=8) horses at 5h





































































































OOKT OOPO OONT OOPO OOMT OOPO OOKT OOPO OOKT OOPO
PBS AF TV MF NC
1 Significantly higher than following PBS challenge and higher than controls (p<0.05).
Significantly higher than following PBS challenge (p<0.05) and higher than controls
(pcO.Ol).
J Significantly lower than controls (p<0.05).




* Significantly lower than controls (p<0.05).
2 Significantly lower than controls (p<0.01).
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NEUT=neutrophils,LYMlymphocytes,MACmacrophage ,EOSeosinophils,MAST=asc lls,B Obaso i ide TOTBAS=totalbasophiliccells,EPepithe iall s.
1Significantlyhigherthanfollowi gPBSchallenge(p<0.05)a dhi rthcontrolroup(p<0.05). 2Significantlyhi herthanfollowi gPBSc allenge(p<0.05)a dhi h rthcontrolgroup(p<0.01). 3Significantlylowerthancontrolroup(p<0.05).























































































































































































NEUT=neutrophils,LYMlymphocytes,MAC=macr phag s,EOSeosin hils,MASTm stcells,BASO=basoph idc l , TOTBAS=totalbasophiliccells,EPepithelialcells. Ŝignificantlyhi herthanfollowingPBSc allenge(p<0.()5)a dhig rtcontrolgr up(p<0. 5). 2Significantlyh herthanfollowi gPBSc allenge(p<0.()5)a dhig rthcontrolgr up(p<0. 1). 3Significantlylowerthancontrolroup(p<0.05).
PULMONARY MECHANICS TESTING
These were satisfactorily performed in all cases, without complications. The data are
presented in Tables 2.8-2.13, in Figs. 2.5-2.8, and in Appendices 2.13-2.18.
The challenges had no significant effect on pulmonary mechanics of the control horses.
There were no significant differences between pulmonary mechanics of control and COPD
affected horses prior to any of the challenges.
PBS, TV and MF challenges had no significant effect on the pulmonary mechanics of the
COPD group.
At 5h following AF challenge, COPD affected horses showed increased Vmin (p<0.05)
compared with PBS challenge although the values were not different from those of the control
horses (Table 2.10, Fig. 2.5).
At 1.5h following NC, the COPD affected group had reduced Vmin (p<0.05) when compared
with PBS challenge although the values were not significantly different from those of the
control horses (Table 2.10, Fig. 2.5). At 5h following NC, COPD affected horses showed
increased dPtp (p<0.01) compared with controls (Table 2.11, Fig. 2.6) and decreased Cdyn
compared with PBS challenges (p<0.05) (Table 2.12, Fig. 2.7). COPD affected horses showed
increased Rp at 1.5 and 5h (p<0.05) following NC when compared with PBS challenge, this
parameter being also significantly increased when compared with the control group at 5h
(p<0.05) (Table 2.13, Fig. 2.8).
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Figure 2.5 Minute volumes (1) of control (CONT) (n=8) and COPD affected (n-8) horses at
0, 1.5 and 5h after inhalation challenges with PBS, AF, TV and MF and after NC.
0 1-5 5h
1 Significantly higher than for COPD affected horses at 5h after PBS challenge (p<0.05).2 Significantly lower than for COPD affected horses at 1.5h after PBS challenge (p<0.05).
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Figure 2.6 Mean maximum changes in transpulmonary pressure (cml-^O) of control (CONT)
(n=8) and COPD affected (n=8) horses at 0, 1.5 and 5h after inhalation challenges with PBS,
AF, TV and MF and after NC.
1 Significantly higher than controls (p<0.05).
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Figure 2.7 Dynamic compliance values (l/cmP^O) of control (CONT) (n=8) and COPD
affected (n=8) horses at 0, 1.5 and 5h after inhalation challenges with PBS, AF, TV and MF
and after NC.
Ohr« 1.5hr» 5hr* Ohit l.Shri 5hTf
* Significantly lower than at 5h after PBS challenge (p<0.05).
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Figure 2.8 Average total pulmonary resistances (crnfbO/l/s) of control (CONT) (n-8) and
COPD affected (n=8) horses at 0, 1.5 and 5h after inhalation challenges with PBS, AF, TV
and MF and after NC.
CONT
MP
Ohr« 1.5hrs 5 hrs Ohrs 1.5hrs 5hr»
]. Significantly higher than at 1.5h after PBS challenge (p<0.05).1 Significantly higher than at 5h after PBS challenge and significantly higher than for controls
(p<0.05).
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Table 2.8 Respiratory rates (mirf*) of control (n=8) and COPD affected (n=8) horses
immediately prior to (Oh) and at 1.5 and 5h after inhalation challenges with PBS, AF, MF and
TV and following NC (median and range).
CHALLENGE TIME RESPIRATORY RATE
(h) CONTROL COPD
PBS 0 13.5 (10.7-23.2) 12.0 (7.5-15.0)
1.5 16.8 (11.8-21.3) 12.2 (9.3-19.7)
5 15.1 (11.9-21.4) 11.8 (7.2-19.0)
AF 0 12.4 (8.2-28.0) 10.5 (7.5-16.0)
1.5 12.8 (8.6-19.0) 11.8 (7.9-20.1)
5 11.8 (10.0-30.0) 13.4 (7.2-17.0)
TV 0 13.6 (6.2-26.0) 13.9 (5.1-33.0)
1.5 15.0 (6.8-34.3) 13.3 (7.1-19.5)
5 13.9 (5.1-22.0) 14.0 (5.3-28.4)
MF 0 10.0 (5.1-14.4) 12.0 (6.9-21.0)
1.5 10.8 (6.9-33.3) 13.0 (4.5-43.0)
5 10.6 (6.3-21.3) 14.4 (7.2-20.0)
NC 0 12.3 (8.2-26.7) 11.0 (9.0-21.4)
1.5 10.0 (7.5-19.2) 10.3 (7.2-17.9)
5 9.0 (6.1-23.3) 15.6 (5.9-33.3)
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Table 2.9 Tidal volumes (1) of control (n=8) and COPD affected (n=8) horses immediately
prior to (Oh) and at 1.5 and 5h after inhalation challenges with PBS, AF, MF and TV and
following NC (median and range).
CHALLENGE TIME TIDAL VOLUME
(h) CONTROL COPD
PBS 0 7.32 (0.57-9.01) 6.95 (4.64-9.34)
1.5 6.35 (0.46-9.92) 5.87 (3.61-9.38)
5 5.40 (1.92-7.50) 5.75 (3.14-8.77)
AF 0 6.55(1.11-10.91) 7.18 (5.15-9.72)
1.5 6.19 (0.40-9.96) 7.17 (4.77-8.81)
5 6.53 (0.78-11.03) 6.21 (3.98-8.32)
TV 0 6.97 (0.72-8.55) 5.86 (4.06-7.48)
1.5 5.55 (0.89-10.15) 5.38 (3.64-7.30)
5 5.55 (1.69-9.48) 5.68 (3.97-7.55)
MF 0 6.81 (1.33-9.43) 5.74 (4.18-9.55)
1.5 7.28 (1.36-9.16) 5.89 (1.62-12.15)
5 6.07 (1.12-8.88) 6.10(4.25-11.54)
NC 0 6.99 (1.47-9.34) 8.13 (5.10-9.96)
1.5 6.55 (1.28-9.63) 6.78 (4.75-8.77)
5 6.84 (1.19-9.90) 5.57 (3.24-9.15)
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Table 2.10 Minute volumes (1) of control (n=8) and COPD affected (n-8) horses immediately
prior to (Oh) and at 1.5 and 5h after inhalation challenges with PBS, AF, MF and TV and
following NC (median and range).
CHALLENGE TIME MINUTE VOLUME
(h) CONTROL COPD
PBS 0 123.1 (24.3-185.6) 77.2 (34.8-107.5)
1.5 106.1 (11.6-154.5) 87.9 (36.9-111.3)
5 97.2(41.0-135.4) 63.4 (25.8-100.8)
AF 0 98.9(15.3-153.3) 71.9 (50.7-103.6)
1.5 74.9(16.6-106.8) 78.6 (48.6-157.6)
5 81.6(19.0-172.0) 84.1 (49.3-135.8)1
TV 0 83.1 (18.8-136.0) 82.1 (26.6-246.8)
1.5 77.1 (19.4-126.1) 72.1 (39.5-182.1)
5 70.9(17.9-117.0) 94.8(31.2-244.3)
MF 0 52.9 (16.7-89.6) 94.1 (29.9-164.1)
1.5 72.2 (40.6-115.7) 62.7 (28.1-146.5)
5 59.6 (23.9-85.8) 74.3 (36.9-208.9)
NC 0 83.5 (39.2-126.0) 82.9 (56.6-213.1)
1.5 67.8 (9.6-118.3) 68.9 (49.1-150.0)2
5 61.0(10.7-120.9) 69.3(53.5-136.2)
* Significantly higher than for COPD affected horses at 5h after PBS challenge (p<0.05).2 Significantly lower than for COPD affected horses at 1.5h after PBS challenge (p<0.05).
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Table 2.11 Mean maximum transpulmonary pressure changes (cml-^O) of control (n=8) and
COPD affected (n=8) horses immediately prior to (Oh) and at 1.5 and 5h after inhalation
challenges with PBS, AF, MF and TV and following NC (median and range).
CHALLENGE TIME
(h)















































1 Significantly higher than controls (p<0.()5).
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Table 2.12 Dynamic compliance (l/cmHjO) of control (n=8) and COPD affected (n=8)
horses immediately prior to (Oh) and at 1.5 and 5h after AICs with PBS, AF, MF and TV and


















































* Significantly lower than at 5h after PBS challenge (p<0.05).
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Table 2.13 Average total pulmonary resistance (cmF^O/l/s) of control (n=8) and COPD
affected (n=8) horses immediately prior to (Oh) and at 1.5 and 5h after inhalation challenges


















































1 Significantly higher than at 1.5h after PBS challenge (p<0.05).2 Significantly higher than at 5h after PBS challenge and significantly higher than for controls
(p<0.05).
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ARTERIAL BLOOD GAS TENSIONS AND pH
Arterial blood samples were obtained in all cases, without complications, with the exception
of transient local, self resolving haematomas.
PBS, AF,TV and MF challenges had no significant effect on arterial blood gas tensions and
arterial pH of either group (Tables 2.14-2.16, Fig. 2.9, Appendices 2.19-2.21).
COPD affected horses had significantly reduced PaC>2 (p<0.01) at 5h following NC when
compared with the PBS challenge and with the control horses (Table 2.14, Fig. 2.11).
CORRELATIONS BETWEEN PULMONARY MECHANICS, ARTERIAL BLOOD GAS
TENSIONS, ARTERIAL pH AND BALF NEUTROPHIL RATIOS
When the data for all the challenges were pooled and analysed, significant correlations were
found between the changes in the following pairs of parameters; RR and Vmin, Vmin and Vj,
V-p and Cdyn, Vmin and Cdyn, Rl and dPtp, Vmin and PaC>2, (all p<0.01) and Vmin and
dPtp (p<0.05). BALF neutrophil ratios were not significantly correlated with any of these
other parameters.
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Table 2.14 Arterial O2 tensions (Torr) for control (n=8) and COPD affected (n=8) horses
immediately prior to (Oh) and at 1.5 and 5h after inhalation challenges with PBS, AF, MF and
TV and following NC (mean+S.D.).
CHALLENGE TIME ARTERIAL OXYGEN TENSION
(h) CONTROL COPD
PBS 0 92.6+8.9 88.2 +9.0
1.5 92.7 +6.4 89.2 +5.4
5 94.4 ±8.2 89.6 ±4.8
AF 0 96.2+14.6 91.0 +6.6
1.5 94.4 +7.0 89.4 +5.7
5 95.3 ±8.2 90.7 ±6.2
TV 0 93.3 +6.8 89.5 +6.8
1.5 92.6+8.2 87.8 +7.4
5 90.0 ±5.7 86.8 ±7.0
MF 0 90.6 +7.4 87.7 +8.2
1.5 91.6+3.6 86.5+12.3
5 89.8 ±5.2 87.1 ±8.7
NC 0 89.4+12.7 97.1 + 10.4
1.5 88.5 +4.7 86.6 +7.5
5 86.6+4.3 80.5 +9.9
1 Significantly lower than at 5h after PBS challenge and significantly lower than for controls
(p<0.05).
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Figure 2.9 Arterial oxygen tensions (Torr) of control (CONT) (n=8) and COPD affected
(n=8) horses at 0, 1.5 and 5h after inhalation challenges with PBS, AF, TV and MF and after
NC.
1 Significantly lower than at 5h after PBS challenge and significantly lower than for controls
(p<0.05).
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Table 2.15 Arterial CO2 (Torr) tensions for control (n=8) and COPD affected (n=8) horses
immediately prior to (Oh) and at 1.5 and 5h after inhalation challenges with PBS, AF, MF and
TV and following NC (mean±S.D.).
CHALLENGE TIME ARTERIAL CARBON DIOXIDE TENSION
(h) CONTROL COPD
PBS 0 38.3+3.1 42.0+2.3
1.5 38.9 +3.1 42.5 +5.4
5 39.0 ±1.9 42.1 ±4.8
AF 0 38.7 +2.9 41.6+6.6
1.5 39.2 +3.6 42.2 +5.7
5 38.8 ±5.5 44.1 ±6.2
TV 0 38.4 +2.4 41.8 +6.8
1.5 36.3 +3.9 42.9 +7.4
5 39.0 ±3.6 40.7 ±7.0
MF 0 38.5 +4.4 39.3 +8.2
1.5 39.8 +4.3 39.4+12.3
5 40.0 ±7.0 41.2 ±8.7
NC 0 38.1 +3.7 42.5+10.4
1.5 38.1 +3.6 45.5 +7.5
5 37.7 +4.9 44.1 +9.9
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Table 2.16 Arterial pH values for control (n=8) and COPD affected (n=8) horses immediately
prior to (Oh) and at 1.5 and 5h after inhalation challenges with PBS, AF, MF and TV and
following NC (mean+S.D.).
CHALLENGE TIME ARTERIAL pH
(h) CONTROL COPD
PBS 0 7.391 +0.035 7.394 +0.039
1.5 7.418 +0.029 7.389 +0.024
5 7.408 ±0.021 7.402 ±0.031
AF 0 7.401 +0.025 7.386 +0.030
1.5 7.395 +0.023 7.393 +0.028
5 7.418 ±0.031 7.395 ±0.050
TV 0 7.422 +0.045 7.391 +0.020
1.5 7.447 +0.082 7.396 +0.032
5 7.399 ±0.024 7.398 ±0.027
MF 0 7.404 +0.024 7.396 +0.030
1.5 7.403 +0.028 7.403 +0.030
5 7.409 ±0.017 7.398 ±0.017
NC 0 7.390 +0.027 7.378 +0.026
1.5 7.385 +0.047 7.401 +0.030
5 7.389 +0.020 7.403 +0.025
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DISCUSSION
To investigate the aetiology of equine chronic obstructive pulmonary disease (COPD),
control and COPD affected horses were given antigen inhalation challenges (AICs) with
extracts of Micropolyspora faeni (MF), Aspergillus fumigatus (AF) and Thermoactinomyces
vulgaris (TV).
Previously, a similar inhalation challenge study performed by McPherson et al (1979) had
suggested that MF and AF were common causes of respiratory hypersensitivity in horses
affected with COPD, while an unidentified Actinomycete was a less common cause. However,
some of the conclusions of this study may be questioned following the recent finding that
horses with COPD, when symptomatic, may show an exaggerated bronchospasm in response
to a wide range of inhaled agents such as cold air, histamine, mcthacholinc, inorganic dusts
and citric acid, a phenomenon termed non specific bronchial hyperrcsponsiveness (NSBHR)
(Klein 1984; Derksen et al 1985A). As a number of the horses used by McPhcrson et al were
partially symptomatic prior to antigen challenges, some of the reported positive clinical,
pulmonary mechanics and arterial blood gas tensions responses may have been simply due to
NSBHR rather than to specific pulmonary hypersensitivity reactions to these antigens.
To eliminate the problem of NSBHR, only asymptomatic COPD affected horses, which do
not exhibit NSBHR (Derksen et al 1985A), were used in the present study. Thus all horses
were shown to be asymptomatic, by clinical, arterial blood gas tensions, arterial pH and
bronchoalveolar lavage fluid (BALF) cytological examinations, prior to all challenges.
PHOSPHATE BUFFERED SALINE (PBS) CHALLENGE
Inhalation challenge with nebulised isotonic PBS, which represented a negative diluent and
protocol control challenge, did not elicit pulmonary disease in any control or COPD affected
horses.
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However, after PBS challenge, the control horses had unaccountably higher total BALF cell
counts than the COPD affected horses. This finding is unlikely to indicate the presence of
pulmonary inflammation in either group as the absolute and total pulmonary epithelial lining
fluid (PELF) cell counts of the two groups were not significantly different after this challenge.
NATURAL CHALLENGE (NC)
NC, which was a positive control challenge for the COPD affected horses and a negative
control challenge for the control horses, elicited pulmonary disease only in the COPD affected
horses as evidenced by changes in clinical, pulmonary mechanic, arterial blood gas tension,
arterial pH and BALF and PELF cytology parameters.
Clinical signs consistent with those of COPD (McPherson et al 1978) were detected in 7 of 8
COPD affected horses at 5h after NC. One COPD affected horse showed no clinical evidence
of COPD after NC, despite having a markedly increased BALF neutrophil ratio (19%).
While clinical evidence of pulmonary dysfunction was most marked at the late phase (i.e. at
5h) after NC, 2 COPD affected horses developed clinically detectable early phase (i.e. at 1.5h)
pulmonary dysfunction. This is consistent with previous findings that COPD affected horses
may exhibit biphasic responses to NC (Mansmann et al 1975; Halliwcll et al 1979;
McPherson et al 1979; McPherson and Thomson 1983; Thomson 1989).
All COPD affected horses showed an, often marked, BALF and PELF neutrophilia after NC.
This is consistent with the findings of previous BALF cytology studies (Viel 1983; Dcrksen et
al 1985B and 1988), with the histopathological classification of COPD as a neutrophilic
endobronchiolitis (Nicholls 1978) and with the recent observation that NC elicited pulmonary
recruitment of peripheral blood neutrophils (Fairbairn,S. pers comm. 1991). The BALF
neutrophilia induced by NC was found to be the most useful technique for the detection of
equine COPD, in agreement with Viel (1983).
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NC also significantly increased the total BALF cell counts, albumen adjusted total BALF cell
counts and total PELF cell counts of COPD affected horses. In contrast, Derkscn et al
(1985B) found that the total BALF cell count did not increase significantly after NC, but as
they collected BALF at a different time after challenge than the present study, this could
account for the discrepancy. PELF cell counts and albumen adjusted BALF cell counts were
not determined by Derksen et al (1985B).
After NC, COPD affected horses showed uncxplainablc reductions in PELF and albumen
adjusted BALF macrophage counts. Similar findings were observed in COPD affected horses
after NC in a previous study (Derksen et al 1985B), in horses with bacterial pneumonia and
pleuropneumonia (Rossier et al 1991) and in ozone exposed dogs (Fabbri ct al 1984) and
rabbits (Alpert et al 1971).
BALF, albumen adjusted BALF and PELF eosinophil counts were unaffected by NC. In
contrast, Derksen et al (1985B) found increased BALF eosinophil counts in 3 of 6 ponies at 3-
7days after NC. Some horses with longstanding COPD also show increased BALF eosinophil
ratios (Grammel 1989; Fogarty,U. pers comm. 1990). Eosinophilic pulmonary infiltrations
were observed histologically in a proportion of COPD affected horses by Nicholls (1978) and
by Kaup et al (1990A), who regarded them as exceptional findings.
The differences between the results of these studies may reflect heterogeneity of COPD
affected horses with regard to their cellular responses, differences in the antigens to which the
horses were exposed or differences in the timing of the BALF collection relative to the onset
of the disease.
Similarly, human asthmatics have an unaccountably heterogeneous cellular response, with
some showing a BALF eosinophilia while others show a BALF neutrophilia (Kay 1988).
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NC did not alter PELF mast cell, basophiloid cell or total basophilic cell counts in either
group. While BALF mast cell and total basophilic cell ratios were reduced in the COPD
affected horses after NC, this was considered to be a result of the markedly increased
neutrophil ratios, rather than an alteration in the absolute cell counts. Similarly, Derksen et al
(1985B) found that absolute and differential BALF mast cell counts were unaffected by NC.
In other studies, however, horses with longstanding COPD have shown increased BALF mast
cell ratios compared with controls (Vrins et al 1989; Winder et al 1990). Again the differing
findings of these studies may reflect heterogeneity of the pulmonary cellular response in
COPD horses, differences in the allergens encountered or differences in the timing of BALF
collection relative to the antigen challenge.
Albumen adjusted BALF and PELF lymphocyte counts were unaffected by NC. Thus while
immunohistochemical studies suggest that lungs from horses with COPD have increased
numbers of perivascular and peribronchiolar lymphocytes (Winder and Von Fellenberg 1986
& 1988), this lymphocytic infiltration appears not to extend to the pulmonary tissues sampled
by bronchoalveolar lavage (BAL).
At 1.5h after NC the COPD affected group showed significantly reduced Vmin and increased
R^. This suggests that pulmonary ventilation was compromised due to central airway
obstruction, probably, in view of the site and the rapid onset of the airway obstruction, by
bronchospasm. While the resultant ventilation perfusion mismatching and/or hypoventilation
did not statistically alter blood gas tensions, 7 of 8 COPD affected horses showed reduced
Pa02 and 6 showed increased PaC02-
At 5h after NC, COPD affected horses showed increased dPtp, and reduced Cdyn and
Pa02, suggestive of central and peripheral airway obstruction possibly due to bronchospasm,
mucosal swelling and accumulation of mucus, cells and inflammatory exudate (Nicholls
1978).
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Comparison of the clinical, pulmonary mechanic, arterial blood gas tensions and pH and
BALF cytology findings of this study with those from other studies should be made with
caution, as most other studies have investigated horses with longstanding COPD. It is likely
that there are important differences in the pathophysiological disturbances and, in particular,
in the severity of the pulmonary inflammatory responses between horses given acute
challenges, as performed in this study, and those given chronic challenges.
ASPERGILLUS FUMIGATUS CHALLENGE
AF challenge induced pulmonary disease, in 7 of 8 COPD affected horses, which was similar,
but less severe, to that which followed NC.
With the exception of slightly elevated BALF neutrophil ratios in 2 control horses (5% and
5.7%), no evidence of pulmonary disease was observed in the control group after this
challenge. While the marginal BALF neutrophilia in the 2 control horses could not be
explained, administration of excessive antigen was unlikely, as the concentration used was ten
fold lower than the upper limit recommended for human A1C studies (Speclor 1989).
AF challenge significantly increased PELF and albumen adjusted BALF neutrophil counts,
and BALF neutrophil ratios only in the COPD group. These BALF neutrophil counts were
significantly correlated to those which followed NC, but were significantly lower.
Only 2 of the 7 COPD affected horses which showed increased BALF neutrophil ratios
following AF challenge showed clinical signs consistent with COPD. This again emphasises
the relative insensitivity of clinical examination in the diagnosis of equine COPD.
Interestingly the 2 clinically affected horses showed both early and late phase clinical
responses to this challenge.
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In contrast to NC, AF challenge induced less marked pulmonary dysfunction in COPD
affected horses, as determined by pulmonary mechanics and arterial blood gas tensions. The
only significant change observed was an increase in the Vmin of COPD affected horses at
1.5h after challenge.
MICROPOLYSPORA FAENI (MF) CHALLENGE
MF challenge induced pulmonary disease in 7 of 8 COPD affected horses which was similar,
but less severe, to that which followed NC.
MF challenge induced clinical signs consistent with COPD (McPherson et al 1978) in 3
COPD affected horses, one horse showing only an early response, one showing only a late
response and the other showing a dual response.
MF challenge significantly increased PELF neutrophil counts, albumen adjusted BALF
neutrophil counts and BALF neutrophil ratios of COPD affected horses. Increased BALF
neutrophil ratios were considered to be the most useful indicator of pulmonary inflammation
caused by this challenge.
BALF neutrophil ratios of control and COPD affected horses after MF challenges correlated
significantly with those at 5h after NC, although the latter were significantly higher. The
PELF and albumen adjusted BALF macrophage counts of the COPD affected horses were
unaccountably reduced by MF challenge, as had occurred with NC.
MF challenge induced no significant changes in pulmonary mechanics or arterial blood gas
tensions in either group.
In contrast to the findings of this study, Dcrksen et al (1987 and 1988) found that MF
challenge elicited a BALF neutrophilia in both control and COPD affected ponies, but
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induced significant pulmonary dysfunction, as indicated by increased RR, Vmin and R^ and
reduced PaC^, only in horses with COPD.
Four possible explanations could account for the contradictory results of the previous
(Derksen et al 1987 & 1988) and present studies.
Firstly, Derksen et al (1987 & 1988) proposed that the controls used in their study could have
been previously hypersensitised to MF and that a specific hypersensitivity response to MF
could have induced the pulmonary neutrophilia which followed this challenge. This, however,
is unlikely since the control ponies did not show a pulmonary neutrophilia after NC, despite
this NC environment containing high levels of MF acroallcrgen (Robinson,N.E. et al pers
comm. 1991).
Secondly, the use of different antigen preparations could account for the contradictory results,
with soluble and particulate MF preparations being used in the present and previous studies,
respectively. While MF shows no detectable antigenic variation between strains (Edwards
1972), considerable variation in the composition of antigenic extracts may follow the use of
different culture, extraction and purification techniques (Pepys 1981). Particulate antigens
may more readily elicit hypersensitivity pneumonitis and granulomata in laboratory animals
than soluble components, possibly via macrophage activation (Salvaggio et al 1975;
Salvaggio and Karr 1979).
It is possible that the neutrophilia observed in both the control and COPD affected groups by
Derksen et al (1987 & 1988) was induced by a non specific toxic agent in the MF preparation.
The use of commercial antigenic preparations, which are less likely to show antigenic
variation than those prepared by individual laboratories, would facilitate more rational
comparison of different antigen inhalation studies.
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Thirdly, the contradictory results of the two studies could reflect differences in the quantity of
antigen deposited in the horses' lungs. The present study administered 20ml 2.5x10^ w/v MF
via a facemask, while Derksen et al (1987 & 1988) administered a higher concentration (30ml
10~2 w/v) of MF via a tracheostoma, a route likely to yield greater pulmonary deposition of
antigen. The concentration of antigen used by Derksen et al was higher than that
recommended for AIC in man (<10"2 w/v; Spcctor 1989). This antigen concentration has been
shown to be induce clinically irrelevant false positive responses in humans which have no
history of clinical disease attributable to the administered antigen (Townlcy et al 1965;
Cavanaugh et al 1977). Administration of excessively high antigen concentrations by Dcrkscn
et al (1987 & 1988) may have induced the pulmonary neutrophilic responses in control horses
and the severe pulmonary dysfunction in COPD affected horses, findings which contrast with
those of the present study.
Fourthly, the BALF neutrophilia observed by Derksen et al (1988) in control ponies after MF
challenge could have been induced by the repeated bronchoscopy and BAL performed during
the short study period, consistent with previous findings for horses, humans, dogs and
monkeys (Kazmierowski et al 1977; Cohen and Batra 1980; Von Essen et al 1991).
However, a sham protocol performed on 3 ponies by these authors, involving repeated BALs
in the absence of MF challenges, did not elicit a neutrophilic pulmonary response, and an
attempt was made to minimise this potential problem by performing consecutive BALs at
different sites within the lungs.
Derksen et al (1987) demonstrated that, while MF inhalation challenge elicited pulmonary
neutrophilia in both control and COPD affected horses, and pulmonary dysfunction in COPD
affected horses, it did not induce NSBHR to histamine in horses which had been sensitised to
MF by subcutaneous administration of MF in Freund's adjuvant. Since NSBHR is a feature of
naturally occurring equine COPD, its absence was considered to indicate that the pulmonary
inflammation elicited by MF challenge in their study differed from that of naturally occurring
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COPD, and/or that the immunological responsiveness of the experimentally sensitised horses
differed from those with naturally occurring COPD. Bronchial reactivities of COPD affected
horses following MF challenges were not investigated in the present study.
It is thus apparent that the experimental MF challenge model used by Derksen et al (1987 &
1988) elicited pulmonary disease which differed in several important respects from naturally
occurring COPD.
Both the MF and AF challenges used in this study elicited pulmonary disease, which closely
resembled naturally occurring COPD, only in horses with a history of COPD. These findings
further implicate MF and AF as important aetiological agents of equine COPD.
The pulmonary inflammatory response and the associated pathophysiological disturbances
elicited by MF and AF challenges were, however, less severe than those elicited by NC. Four
possible explanations may account for this finding.
Firstly, NC may have induced more severe pulmonary dysfunction because horses were
exposed to antigen for longer or were exposed to higher concentrations of antigen during this
challenge. While the relative magnitudes of the antigen burden encountered by horses during
NC and AIC are unknown, the former involved continuous exposure of the horses to hay and
straw for 5h, while AICs involved exposure to antigens for only 5-15min.
Secondly, as the duration of antigen challenge influences the release of inflammatory
mediators during human cutaneous allergen challenges (Shalit et al 1988), the dynamics of the
inflammatory mediators released during NC may have differed from those of the mediators
released during the shorter duration AICs.
Thirdly, the pulmonary response induced by NC could have been caused or exacerbated by
exposure to antigens other than AF and MF or to non specific toxic agents, including
ammonia, endotoxins, bacteria, plant material and forage mites, which are present in stable
environments containing hay and straw (Clarke 1987).
Fourthly, the alpha 2 agonist xylazine, used by Derksen et al (1987 & 1988) to sedate the
ponies prior to MF challenge and bronchoalveolar lavage (BAL), may have altered the ponies'
pulmonary reactivities to the inhaled MF, also possibly accounting for the differences in the
two studies. Alpha agonists have been shown to enhance mediator release from human lung
mast cells via interaction with cell surface alpha adrenergic receptors (Kaliner et al 1972).
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However, the finding that alpha agonists reduced the allergen inhalation challenge induced
microvascular leakage in guinea pig airways does not support this proposal (Boschetto et al
1989). Furthermore, alpha-2-agonists would be expected to antagonise cholinergic mediated
bronchoconstriction via interaction with inhibitory alpha-2-receptors on cholinergic nerves
(Andersson et al 1986) and reduce the vagally mediated bronchoconstriction induced in
COPD affected horses by NC (Scott et al 1988).
Non specific pulmonary toxicity was unlikely to have caused the pulmonary disease observed
in the COPD affected horses after AF and MF challenges and after NC, as all individuals
exposed to a non specific toxic agent would have been equally affected (Salvaggio and
Hendrick 1979), and the control horses in this study were unaffected by these challenges.
Differences in pulmonary deposition patterns, rather than differences in the immunological
reactivity to the challenge antigens, could have determined whether-or not horses responded to
the challenges. However, as pulmonary deposition is influenced considerably by ventilation
patterns (Heyder et al 1982; Valberg et al 1982), which vary considerably over long term
periods (Derksen et al 1982) and are thus unlikely to remain consistently different between
control and COPD affected horses, this is unlikely.
Ideally the breathing patterns of subjects undergoing AICs should be standardised to
minimise variations in the pulmonary deposition of antigen, which can influence the outcome
of challenges (Valberg et al 1982). Due to lack of subject cooperation this is not possible in
equine studies, However, as all the horses in the present study breathed slowly and deeply
during antigen inhalation, due to excessive resistance in the inspiratory valve of the facemask,
pulmonary deposition patterns are likely to have been relatively constant. This slow, deep
respiration is likely to have resulted in a uniform deposition of antigen throughout the lungs,
with little deposition in the large airways (Valberg et al 1982).
Differences in the rates and/or mechanisms by which inhaled antigens are cleared from the
lung are unlikely to have determined whether or not horses responded to the challenges, since
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the antigen elicited pulmonary inflammation and dysfunction shortly after administered, i.e.
before significant differences in the pulmonary clearance of antigen would have been
expected.
In conclusion, COPD was induced in the COPD affected horses, and not in the control horses,
by AF and MF inhalation challenges and by numerous NCs, performed over a 2 year period.
This is clear evidence that equine COPD is a pulmonary hypersensitivity to inhaled allergens,
including AF and MF.
TV CHALLENGE
TV challenge did not significantly affect any of the measured parameters in either group.
However, after this challenge, 2 COPD affected horses showed clinical signs consistent with
COPD (McPherson et al 1978), and 4 COPD affected and 2 control horses had increased
BALF neutrophil ratios (i.e. >5%).
The 2 control horses which showed a BALF neutrophilia after TV challenge, had shown no
clinical, arterial blood gas tension, pulmonary mechanic or BALF cytological evidence of
pulmonary disease over a 2 year period, while being maintained in both NC and controlled
environments. This suggests that the TV challenge employed in this study differed from the
challenge encountered by horses when exposed to hay and straw. Thus, unfortunately, little
valid information regarding the potential role of TV in the aetiology of equine COPD can be
obtained from this study.
The TV challenge may have exposed horses to antigens which were not encountered in NC
environments. Alternatively, while the concentration of TV antigen used (2xlCT^ w/v) was
within the range recommended for human AICs (i.e. <10"^ to 10"^ w/v; Spector 1989), it may
have exceeded levels of TV aeroallergen present in the NC environment. Supportive of this
possibility are the findings of a recent study which quantified the respirable aeroallergens in
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North American horse barns by enzyme linked immunosorbent assay (ELISA) techniques and
demonstrated that, in NC environments, TV is present at lower levels (approximately
500ng/m3) than MF (approximately 1500ng/m3) and AF (approximately 1800ng/m3)
(Woods,P. et al, pers comm. 1991).
Further studies of aeroallergen concentrations in stables should help the selection of antigen
concentrations to be used for future AICs, by ensuring that they are relevant to those
encountered naturally.
BAL was accomplished without apparent complications in all cases. While most samples
contained trace amounts of erythrocyte and free haemoglobin, it was considered unlikely that
a significantly influx of cells and humoral components from the blood into the BALF had
occurred. To minimise possible regional differences in cellular and humoral BALF
components (see Chapter 8), BAL was always performed in the accessory lobe of the right
lung.
The median recovery of BALF was slightly lower than that reported for other studies (Viel
1983; Derksen et al 1985B, 1987 & 1988), probably because aspiration of BALF was
discontinued at 45s after instillation rather than after there was no further BALF recovery.
BALF aspiration was discontinued at 45s after instillation to minimise the time dependent
diffusion of urea and albumen, from the pulmonary tissues into the lavage fluid, which would
have affected the accuracy of the PELF and albumen adjusted cell counts, which were
calculated using the BALF urea and albumen concentrations, respectively (see Chapter 7).
As BALF represents a mixture of PELF and PBS, in variable proportions, the total and
absolute PELF cell counts and the albumen adjusted total and absolute BALF counts were
considered to be more useful than the total and absolute BALF cell counts.
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Between and within group statistical analyses of PELF and albumen adjusted cell counts
yielded identical results. Albumen adjusted BALF cell counts were, however, significantly
higher than the PELF cell counts, consistent with the finding that the plasma:PELF albumen
ratio is higher than that of urea (Rennard et al 1986). The albumen and urea dilution
techniques were further evaluated in this study and arc reviewed in Chapter 7.
Lymphocytes with marked irregular invaginations of their nuclear membrane were observed
in BALF collected from some COPD affected horses after NC. While the identity of these
cells was unknown, they resembled atypical lymphocytes which have been described in BALF
from humans with allergic alveolitis (Haslam et al 1987) and in the lamina propria and
submucosa of bronchial biopsies from symptomatic asthmatics (Jeffrey et al 1989). Haslam et
al (1987) considered that these cells may represent activated delayed hypersensitivity T
(Tdr) ce^s or mast ce^ precursors.
BALF from control and COPD affected horses contained small numbers of an unidentified
cell type which were designated 'basophiloid cells'. These cells contained many large
cytoplasmic granules, which were intensely basophilic when stained with Lcishman's and
which tended to obscure visualisation of the remainder of the cell. These cells were not
identified on preparations stained with loluidine blue. They were easily differentiated from
BALF mast cells and peripheral blood basophils, owing to their larger, intensely staining
cytoplasmic granules.
Mast cells in BALF from both control and COPD affected horses showed varying degrees of
degranulation. Occasional cells resembling fully degranulating mast cells were identified.
Consistent with these findings, Fox et al (1981) and Lamb and Lumsdcn (1982) demonstrated
mast cells in various stages of degranulation in human pulmonary epithelium.
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Considerable variation was noted in pulmonary mechanic tests and arterial blood gas
tensions, even in control horses which had no detectable pulmonary inflammation, consistent
with previous findings (Derksen et al 1982; Stadler and Deegen 1986). Possible causes of this
variation, which limit the value of these techniques in the detection of COPD, were reviewed
in the introduction to Chapter 2.
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CHAPTER 3
INTRADERMAL MOULD ANTIGEN TESTING IN CONTROL AND CHRONIC
OBSTRUCTIVE PULMONARY DISEASE (COPD) AFFECTED HORSES: RESULTS
AND COMPARISON OF INTRADERMAL AND BRONCHIAL REACTIVITIES
SUMMARY
Intradermal endpoint titres for commercial extracts of Micropolyspora faeni (MF),
Thermoactinomyces vulgaris (TV) and Aspergillus fumigatus (AF) were determined in control
(n=8) and chronic obstructive pulmonary disease (COPD) affected (n=8) horses.
The intradermal endpoint titres of control and COPD affected horses were found to be not
significantly different.
Comparison of the intradermal endpoint titres for each antigen with the changes in pulmonary
mechanics, arterial blood gas tensions, arterial blood pH and with BALF neutrophil ratios
which had followed previous MF, AF and TV inhalation challenges and 'natural (hay and
straw) challenges' revealed no significant correlations. This suggests divergence of the dermal
and pulmonary reactivities to these antigens in the horse.
This study provides further evidence that intradermal antigen testing is of limited value in the
investigation of equine pulmonary hypersensitivity to moulds.
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INTRODUCTION
Successful management of pulmonary hypersensitivity conditions often necessitates
identification of the causal allergens. This may be attempted using antigen inhalation
challenges (AICs) (see Chapter 2), endobronchial antigen challenges (see Chapter 9),
intradermal antigen testing, antigen induced in vitro basophil or mast cell degranulation
testing, or in vitro antigen challenges of airway smooth muscle preparations.
Intradermal antigen testing and antigen induced in vitro basophil or mast cell dcgranulation
testing offer advantages over the other techniques as they facilitate testing of larger numbers
of putative allergens, require less antigen, cause minimal suffering, are less likely to induce
untoward complications and are relatively simple to perform.
Intradermal antigen testing is performed routinely at several veterinary centres as an
additional diagnostic procedure for the investigation of suspected equine pulmonary
hypersensitivity. However the value of this technique remains speculative.
Numerous intradermal antigen studies have been performed in the horse and positive
intradermal responses to a wide variety of putative allergens including fungi, actinomycetes,
pollens, mites, feedstuffs, beddings and chicken scrum have been reported in control and
chronic obstructive pulmonary disease (COPD) affected horses (Lowell 1964; Eyre 1972;
Schatzmann and Gerber 1972; Mansmann et al 1975; McPherson et al 1979; Halliwell ct al
1979; Beech and Gunson 1981).
Lowell (1964) found no difference in the dermal responsiveness of 6 control and 6 COPD
affected horses to plant and tree pollens, hay dust extract and moulds. Micropolyspora faeni
(MF), Thermoactinomyces vulgaris (TV) and Aspergillus fumigatus (AF) antigens were,
however, not used in this study.
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Schatzmann and Gerber (1972) found no correlation between intradermal responses to
pollens, dusts and moulds and the presence of pulmonary disease in 3(X) horses.
Eyre (1972) observed marked dermal reactions to a range of mould antigens in horses with
COPD, and weak responses to these antigens in most (60%) control horses, and concluded
that intradermal testing was of limited value in the diagnosis of COPD.
McPherson et al (1979) showed that horses with COPD had a higher incidence of positive
responses to MF and AF than controls, although many control horses also showed positive
responses. These antigens elicited biphasic intradermal responses in many horses with COPD,
with a weak immediate (maximum at 30-90min) reaction being followed by an Arthus-typc
late phase response at 4-8h.
Halliwell et al (1979) investigated the intradermal response to 24 moulds, 4 thermophilic
actinomycctes, bam and hay dust, grain mix and soya dust. The early and late intradermal
responses to these antigens were shown, by histological examination of skin biopsies, to be
consistent with Type 1 and Type III hypersensitivity responses, respectively. Horses with
COPD showed a higher incidence of positive early and late phase reactions to most antigens,
especially to the moulds Rhizopus, Ccphalosporium and MF. No correlation was found
between intradermal responses of individual horses and the presence of moulds in their
environments.
Beech and Gunson (1981) demonstrated that horses which suffered from chronic coughing
showed a higher incidence of positive 3()min and 4h intradermal reactions than control horses
and concluded that allergen skin testing was a useful diagnostic procedure.
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Hockenjos et al (1981) performed intradermal testing with forage mite extracts on 2 control
and 7 COPD affected horses, but strong positive responses to control injections of mite culture
medium precluded meaningful analysis.
Eriksen (1985) found that a large proportion of horses with COPD showed positive early and
late intradermal responses to MF and to hay mites, however control horses were not included
in this study.
Sasse et al (1985) found that horses showed a high incidence of late positive intradermal
responses to MF, hay dust and meal mites, but few responded positively to hay dust mite. It
was not reported whether control or COPD affected horses were used in this study.
IN VITRO ANTIGEN TESTING IN THE INVESTIGATION OF EQUINE PULMONARY
HYPERSENSITIVITY
There exist only a few, conflicting, reports of antigen induced in vitro basophil dcgranulation
testing in the investigation of equine pulmonary hypersensitivity.
Hockenjos et al (1981) showed that extracts of hay, aspcrgillus, Candida and vcrticillium
induced histamine release from peripheral blood leucocytes of horses with COPD. However,
Dieckmann (1986) was unable to confirm this and suggested that the histamine release
reported by Hockenjos and colleagues could have followed non specific basophil cytolysis
induced by excessively high antigen concentrations.
Abdel-Salam (1989) investigated antigen induced histamine release from peripheral blood
leucocytes and from cells in tracheobronchial washings from control horses and horses which
they classified as having 'probable allergic COPD' or 'probable non allergic COPD', the latter
two questionable categories being differentiated by the number of mast cells and eosinophils
in the tracheobronchial secretions. Timothy pollen and house dust mite extracts were found to
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be secretogogues only for tracheobronchial cells, with those from COPD affected horses with
a 'probable allergic' aetiology releasing more histamine than those from 'non allergic' COPD
affected horses. It is possible, however, that the tracheobronchial eosinophilia of the 'probable
allergic' group may have been due to lungworm infection (MacKay and Urquhart 1979).
To evaluate intradermal mould antigen testing as a diagnostic technique for equine COPD,
endpoint titres to AF, MF and TV extracts were determined for control and COPD affected




Eight control (median age 15.5 years, range 7-25 years; median body weight 577kg, range
212-652kg) and 8 COPD affected (median age 15.5 years, range 6-25 years; median body
weight 482kg, range 371-546kg) geldings and mares of mixed breeds, which had been given
allergen inhalation challenges (Chapter 2) 3-6 months previously, were used (Appendix 2.1).
The criteria used to define the two populations are described in Chapter 2.
INTRADERMAL TESTING TECHNIQUE
Animals were given intradermal antigen challenges with aqueous preparations of MF, TV
and AF antigens (Greer Laboratories, Lenoir, North Carolina, USA), administered in ten fold
dilutions within the range Kp - 10"^ mg/ml for MF and TV and 4x10"^ - 4xl(P PNU/ml for
AF. Sterile phosphate buffered saline (PBS) (Greer Laboratories, Lenoir, North Carolina,
USA) was used as the diluent. The positive and negative controls were, respectively, 0.01%
histamine phosphate in sterile PBS and PBS.
Intradermal injections of 0.05ml were given on a clipped neck site, using a 25g needle. The
mean of the maximum wheal diameter and the diameter perpendicular to this was determined
at 1.5 and 5h after injection. Positive reactions were those which elicited wheals with mean
diameter exceeding the mean of the negative and positive control tests obtained at 1.5h for
each individual horse. End point titrcs were the maximum dilution which elicited a positive
response.
STATISTICAL ANALYSIS
Paired and unpaired endpoint data, which were not normally distributed, were compared by
the Wilcoxon Rank Test and the Mann Whitney tests respectively.
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Early (1.5h) and late (5h) phase endpoint titres were correlated, using Spearman's Rank
Correlation, with the early (between 0 and 1.5h post challenge) and the late (between 0 and 5h
post challenge) changes in respiratory rate (RR), minute volume (Vmin), tidal volume (Vj),
mean maximum change in transthoracic pressure (dPtp), pulmonary resistance (R^)> dynamic
compliance (Cdyn), arterial oxygen tension (PaCb), arterial carbon dioxide tension (PaCO^)
and arterial pH which followed AICs with AF, MF and TV and followed NCs.
The early and late phase endpoint titres were also correlated with the neutrophil ratios of
BALF collected at 5h after AICs and NCs.
Statistical analyses were performed using Minitab (Minitab, Pennsylvania, USA), assuming a
significance level of 5%.
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RESULTS
There were no differences between the endpoint titres of the control and COPD affected
groups for any of the antigens (Table 3.1). The early and late phase endpoint titres were not
significantly different.
The endpoint titres for the MF extract were significantly lower than those for the TV extract
(p<0.05). Comparison with the endpoint tilrcs for MF and TV with those for AF was not
possible due to the antigen concentrations being expressed in different units.
The early and late phase intradermal endpoint titres for AF, TV and MF were not
significantly correlated with the early and the laic phase changes in RR, Vmin, V-p, dPtp, R^,
Cdyn, PaC>2, PaCC>2 and arterial pH which followed AICs with AF. MF and TV and which
followed NC.
The early and late phase intradermal endpoint titrcs for AF, MF and TV were not correlated
with the neutrophil ratios of BALF collected at 5h alter AICs with each of these antigens and
after NC.
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Table 3.1 Early (1.5h) and late (5h) intradermal endpoint titrcs of (A) control (n=8) and (B)
COPD affected horses (n=8) for extracts of Micropolyspora faeni (MF), Thermoactinomyces









1 4000 4000 >1 1 >1 0.01
2 400 400 >1 >1 0.01 0.1
3 >4000 >4000 >1 1 >1 0.01
4 >4000 4000 >1 >1 >1 0.1
5 400 4000 >1 0.1 1 0.1
6 >4000 >4000 >1 >1 >1 >1
7 40 400 1 0.1 0.01 0.01
8 >4000 >4000 >1 >1 >1 1








1 400 40 0.1 0.1 0.001 0.001
2 4000 >4000 0.1 0.01 0.1 0.01
3 400 4000 >1 >1 1 1
4 400 40 >1 0.1 0.1 0.001
5 >4000 400 >1 >1 0.001 0.001
6 >4000 4000 >1 >1 0.1 0.1
7 >4000 400 >1 0.1 >1 0.1
8 >4000 4000 >1 >1 0.01 0.001
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DISCUSSION
The value of intradermal mould antigen testing in the diagnosis of equine COPD, which is
currently speculative, was investigated.
There were no significant differences in the dermal reactivities of control and COPD affected
horses to AF, MF and TV antigens.
Furthermore intradermal endpoint titrcs to these antigens were not significantly correlated
with the changes in pulmonary mechanics, arterial blood gas tensions, arterial blood pH and
BALF neutrophil ratios which had followed antigen inhalation challenges with these antigens.
These findings suggest that equine pulmonary and dermal reactivities differ and provide
further evidence that intradermal testing is of limited value in the investigation of equine
COPD.
Lack of correlation between bronchial and dcnnal reactivity, which has also been reported in
man (Spector and Farr 1974; Aas 1975; Nelson 1989), may be attributed to local production
of allergen specific IgE within the respiratory tract or skin (Huggins and Borstoff 1975)
and/or to regional heterogeneity in mast cell responsiveness (Patterson ct al 1972; Aas 1975;
Warner et al 1989).
While a positive intradermal response usually indicates that previous exposure has induced
dermal hypersensitivity to that antigen, it docs not indicate whether this hypersensitivity has
clinical significance. Similarly the presence of scrum precipitins to the fungi and thermophilic
actinomycetes found in stable dust may merely reflect previous exposure to these antigens and
does not imply clinical significance (Lawson et al 1979; Madclin et al 1991) as these
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precipitins have been demonstrated in COPD affected horses and in horses with no evidence
of pulmonary disease.
The interpretation of intradermal antigen tests is also further complicated by the occurrence
of false positive and false negative responses.
False positive responses, i.e. those occurring in individuals which are not hypersensitive to
that antigen, may follow administration of excessive concentrations of antigen, placement of
the intradermal injections too close to a large positive reaction, physical trauma to the test site,
iatrogenic dermal haematoma formation or non specific irritant responses caused by
contaminants in the extract.
False negative responses may occur with reduced allergen potency, fluctuation in the
individual's sensitivity, suppression of sensitivity by medication or following a systemic
reaction to that allergen (Beech 1983; Nelson 1989).
As excessively high concentrations of antigen may elicit false positive dermal responses,
while excessively low concentrations may fail to demonstrate clinically relevant positive
responses, selection of the appropriate antigen concentration for intradermal testing is
essential. Determination of dermal endpoint titrcs, which involves testing with a wide range of
antigen concentrations, effectively overcomes this problem.
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CHAPTER 4
PHENOTYPIC ANALYSIS OF PERIPHERAL BLOOD AND BRONCHOALVEOLAR
LAVAGE FLUID (BALF) LYMPHOCYTES IN CONTROL AND CHRONIC
OBSTRUCTIVE PULMONARY DISEASE (COPD) AFFECTED HORSES, BEFORE
AND AFTER 'NATURAL (HAY AND STRAW) CHALLENGES'
SUMMARY
Phenotypic analyses of lymphocytes in peripheral blood (PB) and bronchoalvcolar lavage
fluid (BALF) of control and chronic obstructive pulmonary disease (COPD) affected horses,
both before and after 'natural (hay and straw) challenges', were successfully performed using
immunofluorescent labelling with monoclonal antibodies and flow cytometry. This technique
has several advantages over other currently available techniques, and should prove to be a
valuable technique for the investigation of pulmonary immune responses.
This is the first reported phenotypic analysis of equine BALF lymphocytes. BALF
lymphocytes were shown to be predominantly EqCD5+ cells, approximately half of which
were also EqCD8+, with a smaller proportion (<10% in control horses) of B cells. In
comparison with PB, BALF contained higher proportions of EqCD5+ cells and EqCD8+ cells
and a lower proportion of B cells.
Horses with asymptomatic COPD had a higher proportion of BALF B cells and a lower
proportion of BALF EqCD5+CD8- cells (considered to be predominantly EqCD4+ cells) than
controls. This suggests that B cells, via humoral immune mechanisms, have a role in the
pathogenesis of equine COPD.
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Hay and straw challenge increased the ratio of BALF EqCD5+CD8- cells and reduced the
ratio of BALF EqCD8+ cells in COPD affected horses, but not in controls. This finding is
similar to the pulmonary recruitment of CD4+ cells reported for human asthmatics following
allergen challenges and suggests that T lymphocytes may have an important role in the
pathogenesis of equine COPD.
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INTRODUCTION
There is considerable evidence to suggest that B and T lymphocytes, via humoral and cellular
immune mechanisms respectively, have a pivotal role in the pathogenesis of a number of
pulmonary inflammatory conditions affecting man and some animals (Bernardo and Center
1981; Berman et al 1990; Crump et al 1991; Kay et al 1991). However, the role of the
lymphocyte in the pathogenesis of equine chronic obstructive pulmonary disease (COPD) has
not been determined.
Mair et al (1987) surveyed the extensive mucosal lymphoid tissue of the normal equine
respiratory tract, which may comprise part of a common mucosal immune system. Solitary
lymphocytes were located throughout the epithelium and lamina propria of the bronchi and
bronchioles. Organised lymphoid patches and nodules were adjacent to bronchioles and less
commonly to bronchi, and small lymphoid accumulations were present in the pulmonary
interstitium.
Immunohistochcmical studies have shown that most lymphocytes within equine
peribronchiolar lymphocytic nodules and follicles do not express surface immunoglobulin (Ig)
and are considered to be T lymphocytes (Winder and Von Fel'enbcrg 1986 & 1988).
A role for the antibody producing B lymphocyte in the pathogenesis of equine COPD was
implied by those who considered this condition to be a Type 1 and/or a Type III
hypersensitivity response (Gerbcr 1973; Schat/mann et al 1973; Halltwell et at 1979; Wilkic
1982; McPherson and Thomson 1983). Such a role is supported by the observations that lungs
from horses with COPD have increased numbers of perivascular and peribronchiolar
lymphocytes which bear either IgA. IgG or no Ig, and that severely affected horses have large
amounts of free intraepithelial IgA and IgG (Winder and Von Fellenbcrg 1986 & 1988).
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Little attention has been given to the role of the T lymphocyte in equine COPD. The T
lymphocyte is a major source of proinflammatory lymphokines, soluble mediators which are
produced following antigen induced cell activation. Lymphokines could be responsible for
inducing many of the immunopathological features associated with COPD. Furthermore, as
the T lymphocyte has a central role in the regulation of humoral and cellular immune
mechanisms (Moretta et al 1979; Berman et al 1990), this cell may determine the nature of the
response, if any, mounted by an individual when exposed to inhaled antigens.
THE USE OF MONOCLONAL ANTIBODIES IN LYMPHOCYTE PHENOTYPIC ANALYSIS
The introduction of monoclonal antibodies (mAb) which delineate lymphocytes and
lymphocyte subpopulations has revolutionised the investigation of lymphocyte biology. MAb
technology, pioneered by Kohler and Milstcin (1975), enables the production of antibodies,
which are chemically, immunologically and physically homogeneous, in virtually unlimited
quantities. The methodology employed in the production of mAbs has been extensively
reviewed elsewhere (Mason ct al 1983; Kipps and Her/.enbcrg 1986) and thus will be
discussed only briefly.
MAb production involves fusion of immunoglobulin producing B lymphocytes with cells
which are capable of replicating continuously in tissue culture media. Fusion occurs in the
presence of a fusion reagent, commonly polyethylene glycol (Pontccorvo 1976).
The B lymphocytes are usually splenocytes from a donor previously immunised with the
antigen of interest, while their fusion partners are myeloma cells which arc selected for lack of
immunoglobulin production and their lack of hypoxanthine phosphoryl transferase (HPRT)
activity. Following fusion, which is a relatively inefficient process, there exist three
populations, namely splenocytes, myeloma cells and hybrids. As the splenocytcs are incapable
of prolonged survival in tissue culture they die spontaneously. The myeloma cells arc unable
to synthesise the purines and pyrimidincs necessary for survival, due to the presence in the
culture medium of aminopterin, which inhibits endogenous nucleic acid synthesis and their
lack of HPRT activity, which prevents their utilisation of exogenous nucleic acids, and thus
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also die. The hybrids in contrast, having a combined genome, survive and eventually extrude
chromosomes until a diploid state is achieved.
The hybrids are then cloned by limiting dilution methods and the culture supernatant tested
for presence of the mAb of required specificity. Suitable clones can then be used to produce
mAb either by tissue culture methods or by intraperitoneal inoculation of the myeloma cells
into laboratory animals with subsequent harvesting of mAb in the ascitic fluid.
The nature of mAbs affords them several advantages over conventional polyclonal antisera;
The range of antigens which may be detected using mAbs is theoretically greater, not being
restricted to those antigens which can be purified to homogeneity.
MAbs are produced by cells derived from a single clone and thus are specific for a single
antigen, indeed usually for a single epitope on an antigen. As a consequence, cross reactions
and non specific reactions are rarely encountered when using monoclonal reagents, especially
those obtained by tissue culture. A mAb may. however, react specifically with two different
antigens if they share the epitope to which the mAb is specific.
In comparison with mAbs, only a limited proportion of the immunoglobulin present within
polyclonal antisera, is specific for the immunising antigen. Furthermore, polyclonal antisera
comprises antibodies which arc specific to several epitopes on the immunising antigen. The
remainder is non specific for the antigen and thus represents a major potential source of non
specific staining.
Monoclonal antibodies are more homogeneous than polyclonal reagents, which may vary
from batch to batch. MAb may be manufactured in relatively unlimited quantities and,
following the initial development phase, arc considerably cheaper to produce than polyclonal
reagents.
THE USE OF FLOW CYTOMETRY IN LYMPHOCYTE PHENOTYP1C ANALYSIS
The introduction of the flow cytomcter has proved invaluable in the phenotypic analysis of
cells stained by immunofluorescent techniques, and has been successfully employed in the
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phenotypic analysis of BALF cells from several species including man (Yamada et al 1986),
mice (Curtis and Kaltreider 1989), rabbits (Shellito et al 1981), rats (Thrall and Barton 1984),
pigs (Gehrke and Pabst 1990) and sheep (Cordier et al 1990). Phenotypic analysis of equine
BALF cells has apparently not been reported.
Flow cytometry makes quantitative, correlated, multi parameter analyses of each individual
cell (Parks et al 1986). Cells pass from the flow chamber of the fluorescent activated cell
sorter (FACS) analyser into the centre of a laminar How of sheath fluid where they become
spatially separated. Each individual cell then passes through a focussed beam of laser light
which excites the fluorescent molecules on the cell surface or in the cytoplasm of the cells.
The resultant fluorescence emitted by individual cells is collected and quantified, at 9lP to the
incident beam, by several detectors, each detecting different wavelength ranges. The FL1
detector is most suitable for the detection of the light emitted by the fiuorophore fluorescein.
As each cell passes through the laser beam it scatters the laser light at various angles to the
incident beam, with the direction of scatter providing very useful information regarding cell
morphology. Scatter of light at small angles (0-15°) to the incident beam, termed forward
scatter (FSC), is most dependent on cell size, while cell granularity and internal structure more
significantly affect the scatter detected at larger angles (70-11 (P), termed side scatter (SSC)
(Parks et al 1986). Quantification of FSC and SSC for each cell may enable discrimination of
cell types which differ in cell size or internal structure, such as erythrocytes, lymphocytes,
monocytes and granulocytes.
Furthermore, using this facility, it is possible to perform selective flow cytometric analysis of
specified populations by analysing only those cells within an 'analysis gate', defined by the
light scatter parameters of the cell type under investigation. This 'light scatter gating' enables
selective analysis of chosen populations even in complex mixtures, without the necessity of
preparatory population separation using biophysical techniques, such as density gradient
centrifugation.
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The quantitative fluorescence and FSC and SSC data obtained from the FACS analyser are
displayed in two modes.
Firstly as a dot plot, which typically displays the FSC values for cells against their SSC
values, to enable delineation of populations differing in cell morphology and permit light
scatter gating prior to selective flow cytometry.
Secondly as a histogram, usually displaying cell frequency against fluorescence intensity.
Computerised comparison of the fluorescence histograms from control and positively labelled
samples enables definition of the limits of negative and positive staining and hence
computation of the ratio of positively staining cells.
The use of flow cytometry for the phcnotypic analysis of equine peripheral blood (PB) and
BALF lymphocytes affords several potential advantages over methods employing fluorescent
microscopic analysis;
1. While the fluorescence microscopy technique is simpler to perform than flow cytometry, its
interpretation is subjective and necessitates considerable expertise (Loken and Herzenberg
1975).
2. The number of cells which can be reasonably assessed by the microscopy technique is
limited (commonly 300-500), diminishing its suitability in studies requiring accuracy and
those involving rare subpopulations. In comparison, flow cytometry enables rapid analysis of
large numbers of cells (commonly 5000-10000).
3. Flow cytometry provides quantitative data which is essential for phenotypic analysis, since
subpopulation differentiation is frequently based on the relative magnitudes of particular
parameters rather than merely by their absence or presence. In contrast such quantification is
unavoidably subjective when microscopy is employed.
4. As the FACS analyser performs simultaneous multi-parameter measurements on each
individual cell, selective analysis of cell populations is possible using light scatter gating.
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Phenotypic analyses of PB and bronchoalveolar lavage fluid (BALF) lymphocyte from
control and COPD affected horses, both before and after 'natural challenges' (NCs), are
described.
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MATERIALS AND METHODS
SUBJECTS
Six control (median age 17 years, range 7-24; median body weight 604kg, range 212-652)
and 6 COPD affected (median age 20 years, range 13-30; median weight 495kg, range 371 -
537) horses of mixed breeds were used (Appendix 4.1). The criteria used in the diagnosis of
COPD were described in Chapter 2.
SAMPLE COLLECTION AND PROCESSING
Baseline PB and BALF samples were collected (Chapter 2), from the horses after they had
been maintained in a 'controlled environment' (Chapter 2), in the case of the controls for at
least one week, in the case of the COPD affected horses until they were demonstrated to be
fully asymptomatic, according to criteria previously described (Chapter 2).
PB samples were collected into vaculaincrs containing potassium ethylene diamine tetra
acetic acid (Becton Dickinson, Rutherford, USA).
Post challenge PB and BALF samples were collected 72h after moving the horses to a NC
environment (Chapter 2).
ANTIBODIES USED IN THE STUDY
Two murine mAbs, HT23A (EqCD5) and HT14A (FqCDH) (VMRD, Pullman, Washington,
USA) and three rat mAbs, MAC291 (Equine major histocompatability complex Class I),
MAC284 (putative pan T cell marker) and MAC292 (B cell) (kindly provided by Dr.J.Kydd,
Animal Health Trust, Newmarket) were used as primary stage reagents, the second stage
conjugate being a F(ab')2 fragment of rabbit anti mouse immunoglobulins conjugated to
fluorescein isothiocyanatc (FITC) (Dako, High Wycombe). An alternative rabbit anti mouse
FITC conjugate (SAPU, Law Hospital, Carluke) was evaluated, but discarded because of high
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non specific staining. The specificities of the primary mAbs used in this study have been
previously reported (Crump etal 1988; Kydd 1990; Kydd and Antc/.ak 1991).
All mAbs and both FITC conjugates were titrated to determine their optimal working
dilutions. The mouse mAbs were used at 1:1000 dilution in PBA, the rat mAbs were used
undiluted and the FITC conjugate was used at 1:50 dilution.
IMMUNOFLUORESCENT LABELLING TECHNIQUE
BALF cells were washed three times in 20ml of ice cold phosphate buffered saline (PBS)
containing lmg/ml bovine serum albumen (Sigma, Poole) and lmg/ml sodium azide (Sigma,
Poole) (PBA) and transferred in aliquots of 1x10" cells into test tubes.
Equine peripheral blood leucocytes (PBL) were harvested from PB, following removal of
erythrocytes by gravitational sedimentation and osmotic lysis using the technique of Watson
et al (1987). Briefly, the PB samples were scdimcnted at lg for 30min and the leucocyte rich
supernatant collected and centrifuged at 2000g for 5min (MSE Chilspin 2, Fisons, Crawley).
The pelleted cells were resuspendcd in 1ml Hank's balanced salt solution pH 7.2 (Sigma,
Poole), containing 20mM HEPES (Row Laboratories, Irvine). Residual erythrocytes were
then lysed osmotically by the addition of 4.5ml distilled water, the isotonicity being restored
after 30s by addition of 0.5ml lOx HBSS. Cells were washed three times in ice cold PBA and
transferred in aliquots of 1x10^ cells into test tubes.
BALF and PBL cells were then centrifuged at 300g for 3min, the supernatant discarded and
the cell pellet resuspended in 50ul mAb or control reagent and incubated at 4°C overnight.
Three negative primary stage controls, namely PBA, 1:500 normal mouse serum and 1:500
normal rat serum (Sigma, Poole), were used with each sample. The cells were then washed
three times in PBA and incubated in 50ul FITC conjugate for 30min at 4°C in the dark. Prior
to use, the FITC conjugate was preadsorbed with 10% pooled normal equine serum for 30min
at 4°C and centrifuged at 11500g for lOmin to remove immune complexes. PBA was used as
a negative second stage control reagent for each sample.
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Following three further washes, the cells were resuspcnded in lOOul PBS containing 1% w/v
paraformaldehyde (BDH, Poole) and maintained at 4°C in the dark pending analysis, which
was always within 6 days of labelling.
MODIFICATIONS OF THE IMMUNOFLUORESCENT LABELLING TECHNIQUE
The possibility of reducing non specific labelling oflymphocytes was investigated. Five PBL
and 5 BALF preparations were prcincubated for 30min at 4°C with 50ul 10% pooled normal
rabbit serum (SAPU, Law Hospital, Carluke), which had been prcadsorbcd with an equal
volume of 10% pooled normal equine serum in PBA for 30min at 4°C, followed by
centrifugation at 11500g for lOmin to remove immune complexes. The ratios of non
specifically labelled lymphocytes in these preparations were compared with those in untreated
duplicate samples, after routine labelling using PBA as the first stage reagent.
The effect of hypotonic lysis on the immunofluorcscent labelling of PB lymphocytes was also
determined. The ratios of positively labelled lymphocytes, and their mean channel numbers, in
4 PBL samples prepared by hypotonic lysis and erythrocyte sedimentation, were compared
with those of 4 duplicate samples prepared solely by erythrocyte sedimentation.
The effect of paraformaldehyde fixation and delayed How cytometric analysis on the
immunofluorescent labelling of lymphocytes was determined. The ratios of positively labelled
lymphocytes in 4 PB and 4 BALF samples, which had been fixed using paraformaldehyde
after routine labelling and analysed 6 days later, were compared with those of duplicate
samples which had been analysed immediately after labelling and which had not been fixed.
The effect of prcadsorbing the FITC conjugate with 10% pooled normal equine serum for
30min at 4°C, followed by centrifugation at 11500g for lOmin, on the non specific
immunofluorescent labelling of lymphocytes was determined. The ratios of non specifically
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labelled lymphocytes in 4 duplicate PB and BALF cell preparations, after incubation with
either preadsorbed or untreated FITC, were compared.
FLOW CYTOMETRIC ANALYSIS
A fluorescent activated cell sorter (FACS IV, Becton Dickinson, Los Angeles, USA) was
used to analyse light scatter gated BALF and PB lymphocytes by single colour flow
cytometry. Lymphocyte gates were set for each BALF and PBL sample, based on correlated
forward light scatter (FSC) and perpendicular light scatter (SSC) when a well circumscribed
lymphocyte cluster was evident. In the absence of a well circumscribed lymphocyte cluster,
the gates were defined by positive fluorescence gating of EqCD5+, EqCD8+ cells and B cells.
A minimum of 5000, and in most cases 10000, gated cells were analysed.
STATISTICAL ANALYSIS
As data were not normally distributed, paired and unpaired sample comparisons were made
using, respectively, the Wilcoxon Rank Test and the Mann-Whitney Test, with a significance




While preincubation of cells with prcadsorbcd normal rabbit serum generally reduced the non
specific labelling of lymphocytes (Table 4.1), as this technique increased the non specific
labelling in some samples, this treatment was not further employed.
Table 4.1 The effect of preincubation of PBL (n=5) and BALF cell preparations (n=5) with
preadsorbed normal rabbit serum on the ratios of non specifically labelled gated cells, using






PBL NMS 6.5 (1.3-9.1) 3.5 (1.7-12.6)
PBL NRS 1.9 (1.2-4.7) 1.5 (1.0-12.6)
BALF NMS 6.0 (1.2-11.2) 0.9 (0.2-9.4)
BALF NRS 3.1 (1.9-9.5) 3.0 (1.9-9.9)
As preadsorption of the FITC conjugate with equine sera reduced non specific labelling to
<1% (Table 4.2), all FITC conjugate was treated in this way prior to use.
Paraformaldehyde fixation and delayed flow cytometric analysis reduced the ratios of
lymphocytes showing specific positive labelling and increased those showing non specific
labelling and autofluorescence, although these effects were not statistically significant (Table
4.3).
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TABLE 4.2 The effect of prior adsorption of the rabbit FITC conjugate with pooled normal








Table 4.3 The ratios of positively fluorescent gated PBL and BALF cells from 4 horses
following fixation in PBS containing 1% w/v paraformaldehyde (PF) for 6 days prior to
analysis (PF-treated) and following analysis of unfixed cells within 4h of completion of the
immunolabelling procedure (untreated) (median and range).
PRIMARY PBL BALF
ANTIBODY UNTREATED PF-TREATED UNTREATED PF-TREATED
PBA * 0.7 3.3 0.8 4.1
(0.3-0.9) (2.0-4.0) (0.3-1.2) (4.0-5.4)
NMS ** 0.7 2.5 1.8 6.8
(0.6-0.9) (1.9-3.4) (0.9-2.1) (4.5-7.2)
HT23A 70.8 63.3 88.4 82.7
(56.9-82.1) (56.1-70.1) (40.6-94.7) (19.5-60.5)
HT14A 27.7 26.9 47.9 51.1
(23.6-32.7) (24.3-29.4) (24.0-61.6) (19.5-60.5)
MAC291 98.5 97.5 87.1 83.7
(95.6-99.4) (93.4-98.9) (38.2-97.9) (30.5-90.7)
MAC284 68.4 62.6 76.4 76.3
(63.8-85.3) (52.8-77.5) (25.0-95.3) (17.3-82.3)
MAC292 40.3 24.8 5.2 5.3
(21.7-62.7) (14.6-39.7) (1.4-6.3) (4.0-11.0)
* As no fluorophore was used
autofluorescent cells.
with this control. the positively labelled cells were
** As no primary mAb was used with this control, the positively labelled cells were non
specifically labelled.
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While hypotonic lysis did not affect the ratios of positively labelled lymphocytes, it did
significantly increase their mean channel numbers (p<0.05) (Table 4.4).
TABLE 4.4 Ratios of positively labelled gated cells in 4 PBL samples, prepared with (LYS)
or without (NON) hypotonic lysis. The mean channel numbers arc displayed in brackets.
ANTIBODY SAMPLE 1 SAMPLE 2 SAMPLE 3 SAMPLE 4
LYS NON LYS NON LYS NON LYS NON
MAC291 99.9 97.9 99.5 96.4 99.8 97.5 99.9 96.1
(82) (74) (78) (89) (113) (153) (81) (60)
HT23A 82.8 84.2 80.6 80.2 76.2 82.5 77.2 77.7
(95) (163) (120) (47) (123) (86) (199) (44)
HT14A 28.4 21.3 19.2 17.7 20.9 21.8 20.1 21.1
(156) (23) 095) (26) (168) (24) (172) (23)
MAC292 20.1 16.1 14.0 17.7 14.2 14.9 14.1 13.2
(26) (27) (43) (75) (24) (39) (52) (33)
LIGHT SCATTER PROFILES OF PBL AND BALF CELLS
Four cell populations were readily identified on light scatter profiles of most PBL samples
(Fig. 4.1). In contrast light scatter profiles of BALF cells (Fig. 4.2) were less easily delineated,
with only three clusters being evident. The populations identified were;
(a) a variable density low FSC and low SSC cluster which was often more dense in BALF
samples and which was considered to contain erythrocytes and dead cells.
(b) a low SSC and low to intermediate FSC cluster. This was distributed as a double cluster in
many samples, with the higher and lower FSC peaks predominating in PBL and BALF
samples, respectively. This population, which contained the vast majority of EqCD5+,
EqCD8+ and B cells, was considered be predominantly lymphocytes.
(c) an often poorly delineated, low density cluster with high FSC and intermediate SSC,
which was absent in BALF samples and which was considered to contain predominantly
monocytes.
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(d) a population with high SSC and intermediate to high FSC values, which was very
extensive and dense in BALF samples and which was considered to contain granulocytes and
macrophages.
While no consistent differences were observed in the scatter profiles of PBL samples from
control and COPD affected horses, either before or after NC, 2 COPD affected horses had
increased granulocyte/macrophage clusters after NC (Fig. 4.1).
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Fig. 4.1 Light scatter profiles of ungated PBL from a control horse and a COPD affected
horse, before (A and C, respectively) and at 72h after NC (B and D, respectively). The four
cell populations identifiable on these profiles are labelled in (A) and were considered to
represent (1) erythrocytes/dead cells, (2) lymphocytes, (3) monocytes and (4) granulocytes.
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Fig. 4.2 Light scatter profiles of ungated BALF cells from a control horse and a COPD
affected horse, before (A and C, respectively) and at 72h after NC (B and D, respectively).
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THE FLUORESCENT (FL1) PROFILES OF LIGHT SCATTER GATED PBL AND BALF
LYMPHOCYTES FOLLOWING LABELLING WITH INDIVIDUAL MONOCLONAL
ANTIBODIES
Typical FL1 profiles of light scatter gated BALF cells from a control horse, at baseline,
stained with the panel of mAbs are displayed in Fig. 4.3.
Fig. 4.3 Fluorescence (FL1) profiles of light scatter gated BALF cells from a control horse, at
baseline, after using, as the primary stage reagent (a) PBA, (b) NMS, (c) HT23A, (d) HT14A,
(e) MAC292 and (1) MAC284.
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In samples free from autofluorescence, satisfactory negative controls were obtained using
normal mouse or rat sera or PBA as the primary reagent. EqCD5+ cells frequently showed a
biphasic FL1 profile. CD8+ cells were predominantly of high fluorescence, although a smaller
population, which expressed fluorescence only slightly greater than that of the negative cells,
appeared as a shoulder on the negatively stained cell peak. Class 1+ cells showed fairly
uniform, intermediate intensity staining, which was usually well delineated from the
negatively stained cells. MAC284+ staining was found to be fairly variable, appearing either
with the biphasic pattern similar to that of the EqCD5+ cells, or as a single broad peak, with
poor definition between positively and negatively stained cells. While B cells showed fairly
low intensity staining they were clearly delineated from the negatively stained population in
all samples.
AUTOFLUORESCENT CELLS
Autofluorescent cells, i.e. cells exhibiting positive fluorescence in the absence of exogenous
fluorophore, were identified in all ungated BALF samples and in 10 out of 24 gated BALF
samples from COPD affected and control horses. In some samples a proportion of the cells
were autofluorescent, appearing, on the FL1 profile, as a secondary shoulder adjoining the
negative peak or as a separate peak. In other samples, all cells, including those within the
analysis gate, were autofluorescent as indicated by a right shift in the entire FL1 profile.
Analysis of the FSC/SSC scatter profiles of autofluorescent BALF cells, following positive
fluorescence gating, showed that they exhibited a wide range of cell sizes and complexities,
with the majority exhibiting high FSC and SSC values. They were excluded from the analyses
by light scatter gating in all but 10 samples. Three of these 10 samples were successfully
analysed after altering the sensitivity of the FL1 detector. Attempts to analyse the remaining 7
samples using the FL2 detector, on the basis that this detector may preferentially detect the
emission spectrum of the specific fluorescence, were unsuccessful, as both types of
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fluorescence were detected with apparently similar sensitivity. These 7 samples were
discarded, necessitating repetition of sample collection and analysis.
Fluorescent microscopic examination of 2 BALF cell preparations exhibiting both specific
positive fluorescence and autofluorescence revealed that the autofluorescence was mainly a
feature of large, macrophage-like cells. While autofluorescence manifested as a light yellow
colour and the specific staining as greenish yellow, differentiation of specific staining and
autofluorescence using fluorescent microscopy was considered subjective.
VALIDITY OF THE LYMPHOCYTE GATE
Valid flow cytometric analysis was only achieved when the analysis was restricted, by light
scatter gating, to a population of cells within a lymphocyte gate. This technique generally
eliminated autofluorescent and positively labelled non lymphocyte populations from the
analyses.
For every sample, the validity of the analysis gate was confirmed by examining the FSC/SSC
profiles of EqCD5+, EqCD8+ and B cells, which were generated by positive fluorescence
gating.
Further validation of the analysis gate was sought by determining the ratios of total
lymphocytes (i.e. the sum of the CD5+ ratio and the B cell ratio) within the gated population
of PBL and BALF samples (Table 4.5).
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TABLE 4.5 Total lymphocyte ratios (sum of CD5+ ratio and B cell ratio) within the analysis
gates of PBL and BALF samples from control (N=6) and COPD affected (N=6) horses at
'baseline' (B) and at 72h post NC (median and range).
SAMPLE RATIO TOTAL LYMPHOCYTES IN GATE
PBL BALF
CONTROL B 99.4 (77.2-110.9) 83.5 (63.0-95.1)
COPD B 97.7 (88.1-114.7) 78.8 (66.0-89.3) *
CONTROL NC 103.1 (90.8-107.0) 90.1 (70.0-93.8) *
COPD NC 96.5 (94.6-102.0) 65.9(32.9-88.1) *
* significantly lower than the values for the corresponding PBL samples (p<0.05).
Lymphocytes accounted for most (median ratios 96.5-103.1%) of the gated cells in the PBL
samples, but were significantly lower (p<0.05) in the gated BALF populations in all cases
except for the samples from the control horses at baseline.
NC had no significant effect on the ratio of total lymphocytes within the gated populations in
control or COPD affected horses (p>0.05).
THE RATIOS OF CLASS /+ CELLS IN THE GATED POPULATION
In all PBL samples, most (median ratios 93.6-98.8%) of gated cells expressed Class I antigen
(Table 4.6, Appendix 4.2). COPD affected horses had significantly reduced ratios of gated
Class 1+ PBL cells compared with control horses at 72h after NC (p<0.05).
The proportion of gated Class 1+ cells was significantly lower in the BALF samples than in
PBL samples (p<0.05) (Table 4.6).
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TABLE 4.6 The ratios of Class 1+ gated PBL and BALF cells from control (CONT) (n=6)
and COPD (n=6) affected horses at baseline (B) and at 72h following NC (median and range).


















^ significantly lower than control horses (p<0.05).1 significantly lower than PBL samples (p<0.()5).
COMPARISON OF MAC284 AND HT23A LABELLING
In BALF, ratios of MAC284+ cells were significantly lower than those of EqCD5+ cells
(PcO.Ol) (Table 4.7, Appendix 4.3). Positive fluorescent gating localised the majority of
HT23A+ cells to the lymphocyte cluster, consistent with the reported specificity of this mAb,
however, many MAC284+ cells had scatter profiles different from those of lymphocytes. As
these findings cast doubt on the specificity of MAC284, the data obtained using this mAb was
not used in further calculations and analyses.
Table 4.7 The ratios of gated CD5+ and MAC284+ cells in PBL (n=24) and BALF (n=24)
samples from control and COPD affected horses (median and range).
SAMPLE RATIO POSITIVE CELLS
PBL BALF
CD5+ 73.0(55.0-89.0) 76.9(29.3-91.4)
MAC284+ 75.3 (43.8-96.9) 68.2 (17.3-93.6)*
significantly lower than the CD5+ cell ratio (p<0.01).
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COMPARISON OF THE LYMPHOCYTE PHENOTYPE DISTRIBUTIONS OF PB AND
BALF SAMPLES FROM CONTROL AND COPD AFFECTED HORSES BEFORE AND
AFTER NC
The ratios of B cells and EqCD5+, EqCD8+ and EqCD5+CD8- lymphocytes were expressed
as ratios of the total lymphocytes present within the gated population (calculated as the sum of
the EqCD5+ ratio and the B cell ratio). The ratio of EqCD5+CD8- lymphocytes were
determined by subtracting the ratio of EqCD8+ lymphocytes from the ratio of EqCD5+
lymphocytes.
PB lymphocytes (Fig. 4.4, Table 4.8, Appendix 4.4) were predominantly EqCD5+ (median
65.1%, range 52.3-82.8 in control horses at baseline), with less than half of these (32.1%,
20.5-37.1 in control horses at baseline) being EqCD8+, and smaller proportions of B cells
(30.1%, 17.2-37.7 in control horses at baseline).
PB lymphocyte phenotype ratios of control and COPD affected horses were not significantly
different, either before or after NC (Fig. 4.4), and were not significantly affected by NC.
Table 4.8 The ratios of EqCD5+, EqCD8+, EqCD5+CD8- and B lymphocytes in PB from 6
control (CONT) and 6 COPD affected horses at baseline (B) and at 72h post NC (median and
range).
GROUP RATIO POSITIVE CELLS
EqCD5+ B cells EqCD8+ EqCD5+CD8-
CONT B 65.1 30.1 32.1 41.5
(52.3-82.8) (17.2-37.7) (20.5-37.1) (26.1-55.7)
CONT NC 73.7 26.4 30.7 44.4
(64.1-85.1) (14.9-35.9) (21.8-35.0) (32.6-55.2)
COPD B 75.5 24.5 27.4 51.0
(64.3-87.6) (12.4-35.8) (12.9-37.5) (33.7-70.0)
COPD NC 77.4 22.6 35.6 41.7
(59.8-94.1) (5.9-40.2) (19.8-43.7) (29.0-67.8)
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Fig. 4.4 The ratios of gated EqCD5+, EqCD8+, EqCD5+CD8- and B lymphocytes in PB











































Oh 72h Oh 72h Oh 72h
CD8+ CD5+CD8- B CELL
BALF (Fig. 4.5, Table 4.9, Appendix 4.5) had significantly higher ratios of EqCD5+ (median
95.3%, range 94.4-97.6 in control horses at baseline) and EqCD8+-(median 51.4%, range
48.0-63.0 in control horses at baseline) lymphocytes and a significantly lower ratio of B cells
(median 4.7%, range 2.4-5.6 in control horses at baseline) than PB (p<0.05).
Before NC, the asymptomatic COPD affected horses had a significantly higher ratio of B
cells (p<0.01) and a significantly lower ratio of EqCD5+CD8- cells (p<0.05) than the
controls. NC significantly increased the ratio of EqCD5+CD8- lymphocytes and significantly
decreased the ratio of EqCD8+ lymphocytes in the BALF of COPD affected horses (p<0.05).
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Table 4.9 The ratios of CD5+, CD8+, CD5+CD8- and B lymphocytes in BALF from 6
control (CONT) and 6 COPD affected horses at baseline (B) and at 72h post NC (median and
range).
GROUP RATIO POSITIVE CELLS
EqCD5+ B cells EqCD8+ EqCD5+CD8-
CONT B 95.3 A 4.7 B 51.4 A 43.3
(94.4-97.6) (2.4-5.6) (48.0-63.0) (32.8-49.7)
CONT NC 96.3 A 3.7 B 49.0 A 47.7
(93.6-97.9) (2.1-6.4) (43.6-50.7) (43.3-53.8)
COPD B 86.8 A 13 2 BD 54.7 A 32.1 C
(85.8-90.7) (10.5-14.2) (47.9-65.3) (21.2-40.8)
COPD NC 92.6 A 7.4 B 48.1 AE 45.5 F
(83.6-97.9) (2.1-16.4) (41.7-54.6) (32.6-56.2)
A Significantly higher than values for corresponding PBL samples (p<0.05)B Significantly lower than values for corresponding PBL samples (p<0.05)
:: Significantly lower than values for the control group (p<0.05)
{? Significantly higher than values for the control group (p<0.01)
p Significantly lower than the baseline values (p<0.05)B Significantly higher than the baseline values (p<0.05)
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Fig. 4.5. The ratios of gated EqCD5+, EqCD8+, EqCD5+CD8- and B lymphocytes in BALF











































Oh 72h Oh 72h Oh 72h
CD8 + CD5+CD8- B CELL
^ Significantly lower than before NC (p<0.05)J; Significantly lower than the control group (p<0.05)
~ Significantly higher than before NC (p<0.05)
Significantly higher than the control group (p<0.01).
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The EqCD5+CD8-:CD8+ ratios (Fig. 4.6, Table 4.10) were significantly (p<0.05) lower in
the BALF of the COPD affected horses at baseline than in the PB. This ratio significantly
increased in the BALF of COPD affected horses following NC (p<0.05).
Table 4.10 The EqCD5+CD8-:CD8+ ratios for gated PBL and BALF cells from 6 control















A Significantly higher than baseline values (p<0.05).
" Significantly lower than values for corresponding PBL samples (p<0.05).
Fig. 4.6 The ratios of EqCD5+CD8-:CD8+ cells in PB and BALF from control (n=6) and









































Oh 72h Oh 72h
A Significantly lower than in PBL samples from the same horses (p<0.05)
" Significantly higher than before NC (p<0.05).
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DISCUSSION
This is the first reported study to enumerate equine BALF lymphocyte phenotypes using
immunofluorescent labelling with monoclonal antibodies (mAbs) and flow cytometry, a
technique which should prove valuable for future investigations of equine pulmonary immune
phenomena.
The recent development of monoclonal antibodies (mAbs) which identify equine leucocyte
differentiation antigens has greatly facilitated detailed investigation of equine cellular immune
responses. However, in comparison with other species, the range of mAbs which define
equine leucocyte antigens is, as yet, limited and their specificities less well defined (Kydd and
Antczak 1991).
In the absence of a mAb specific for equine CD3, which identifies T cells, a mAb specific for
EqCD5, namely HT23A, was used. It is considered likely that HT23A is identical to the pan T
cell marker EqT3, described by Wyatt et al (1988).
While HT23A defines most, if not all, T cells, a small proportion (2-5%) of B cells are also
labelled (Davis et al 1984; Crump et al 1988). As B cells comprised only a small proportion
of the gated cells (maximum ratio = 40.2% and 16.4% in PB and BALF, respectively), the
cross reactivity of this mAb to B cells would have resulted in only a minor overestimation of
the T cell ratios.
MAbs specific for EqCD4, which identifies T helper cells, became available only after
completion of this study (Lunn et al 1991). The EqCD5+CD8-MAC292- population identified
and enumerated in this study, however, was considered to be predominantly EqCD4+ cells,
although a small proportion of these were probably the equine homologuc of the CD3+CD4-
CD8- cells identified in other species (Bank et al 1986).
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Contrary to the findings of Kydd (1990), MAC284 was considered not to be a pan T
lymphocyte marker. Many MAC284+ PB and BALF cells showed light scatter profiles
inconsistent with those of lymphocytes, fluorescent microscopic examination revealed some
MAC284+ BALF cells with a macrophage-]ike morphology and the ratios of EqCD5+ and
MAC284+ BALF cells were found to be significantly different. Data derived using MAC284
was thus not included in the analyses.
Leucocytes were harvested from PB using gravitational sedimentation and hypotonic lysis.
While hypotonic lysis did affect lymphocyte labelling, this effect was considered to be
unimportant. All FITC conjugate was adsorbed with normal equine serum prior to use as this
reduced non specific labelling, consistent with the findings of Kydd (1990). Paraformaldehyde
fixation of cells, to permit storage of cells and prevent capping and shedding of surface
proteins prior to analysis (Lanier and Warner 1981), did affect lymphocyte labelling, although
this effect was considered be unimportant. In contrast, Lanier and Warner (1981) found that
paraformaldehyde fixation did not significantly alter the volume, light scatter or fluorescent
properties of a variety of cell types. The reason for this discrepancy is not known.
Analysis of forward (FSC) and perpendicular (SSC) scatter profiles of PBL cells enabled
delineation of 4 populations, considered to represent dead cells/erythrocytes, lymphocytes,
monocytes and granulocytes. While the scatter profiles of BALF cells were less well
delineated, 3 populations, which were considered to represent dead cells/erythrocytes,
lymphocytes and macrophage/granulocytes, were usually identified.
Lymphocytes frequently showed a biphasic light scatter distribution, with differing FSC
values, suggesting that 2 sizes of lymphocytes were present. While CD5+, CD8+ and B
lymphocytes were equally distributed between the two populations, the smaller and larger
subpopulations predominated in PBL and BALF samples, respectively.
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Light scatter gating enabled selective lymphocyte analysis. In most cases, litis procedure
eliminated intensely autofluorescent cells and positively labelled non lymphocytic cells from
the analysis. This technique, previously used to analyse human (Wallace 1989) and murine
(Curtis and Kaltreider 1989) BALF lymphocytes, eliminates the necessity for prior separation
of lymphocytes by biophysical methods and hence eliminates the problems of incomplete
population separation, population subselection or reduced cell labelling which arc associated
with these techniques.
The gating of a cell population prior to analysis, however, is not without potential problems.
It is important that the gate selected is valid, optimally containing all the lymphocytes in the
sample, while excluding all other cell types.
In this study, for every sample, analysis of the light scatter profiles oflymphocytes, identified
by positive fluorescent gating of cells labelled with lymphocyte markers, confirmed that the
vast majority of lymphocytes were included in the analysis gates.
Gated PBL cells were almost entirely positively labelled lymphocytes (the median sum of
EqCD5+ and B cells always exceeded 96%), indicating that most non lymphocytic cells had
been excluded from the analysis. However, compared with gated PB cells, gated BALF cells
contained a significantly higher proportion of unlabellcd cells, which could have been non-T,
non-B lymphocytes (null cells), granulocytes, erythrocytes, macrophages or dead cells. Dead
cells could have been identified and excluded from the flow cytometric analyses using
propidium iodide staining (Parks et al 1986).
In previous studies, the identity of gated lymphocyte populations in human and murine BALF
has been determined by (a) morphological, histochcmical and immunochemical examination
of gated cells after collection by fluorescent activated cell sorting, and (b) by enumeration of
the macrophages and granulocytes within the gated population using single colour fluorescent
analysis with population specific mAbs. Using these techniques, gated BALF cells were
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shown to be predominantly lymphocytes (Curtis and Kaltrcider 1989), with, in man, less than
10% (Yamada et al 1986) or less than 1% (Wallace 1989) macrophage contamination.
Autofluorescent cells were identified in all BALF samples, consistent with the findings of
Edelson et al (1984) for human BALF.
While the cause of autofluoresccnce remains unclear, it may originate from normal cell
constituents such as flavins and cytochromes (Benson et al 1979), or from intracellular 'ageing
pigments' such as ceroid or lipofuschin (Elledcr 1981), or reflect changes in the fluorescence
of pyrimidine nucleotides following alterations in the intracellular redox state (Jongkind et al
1982; Edelson et al 1985).
Most autofluorescent BALF cells were shown, by positive fluorescence gating, to exhibit
scatter profiles similar to macrophages/granulocytes in most instances. However, in 7 samples
all BALF cells were intensely autofluorescent, precluding their analysis by flow cytometry.
The autofluorescence spectrum of alveolar macrophages has excitation maxima at 370nm and
490nm and an emission maximum at 541nm with a shoulder at 580nm (Edelson et al 1985).
As the emission wavelength maxima are remarkably similar to those of fluorescein and
rhodamine (Pesce et al 1971; Shapiro 1983), autofluorcscence may prevent computerised
subtraction of 'baseline' fluorescence and may preclude valid flow cytometric analysis
(Edelson et al 1985).
Several strategies to overcome this problem have been used or postulated. Autofluorescence
may be overcome by using a fluorophore which is not active in the region of the BALF cells'
autofluorescence, such as Texas Red, which has an absorption maximum at 595nm and an
emission maximum at 620nm (Parks et al 1986). Incubation of alveolar macrophages with
0.5mM cyanide reduced the intensity of their autofluorcscence (Edelson et al 1985), although,
as this technique resulted in cell death, it precluded FACS sorting of live cells for subsequent
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functional studies. Alternatively, exposure of the cells, prior to staining, to light which excites
the endogenous fluorophore, leading to attenuation of autofluorescence, may prove to be a
useful technique (Edelson et al 1985).
Equine BALF lymphocytes were shown to be predominantly EqCD5+ T cells, approximately
half of which are also EqCD8+, with a smaller proportion of B cells.
While the ratio of CD5+ cells in BALF from other species has not been reported, the ratios of
CD3+ cells reported for man (63.0+11.4%, Yamada et al 1986; 75.6+2.2%, Wallace 1989)
and for rats (>88%, Thrall and Barton 1984) are lower than the ratio of EqCD5+ gated cells in
equine BALF (median 95.3%, range 94.4-97.6).
The ratio of EqCD8+ gated cells in equine BALF (median 51.4%, range 48.0-63.0) was
similar to that reported for rats (approximately 50%, Thrall and Barton 1984), but higher than
that reported for man (27.8+2.4%, Wallace 1989; 25.3+5.5%, Yamada et al 1986) and for
mice (23±8%, Curtis and Kaltrcider 1989).
The ratio of equine BALF EqCD5+CD8- cells (median 43.3%, range 32.8-49.7)
approximated the ratios of BALF CD4+ cells reported for man (48.9+3.8%, Wallace 1989;
45.4+12.9%, Yamada et al 1986) and for rats (approximately 50%, Thrall and Barton 1984),
but was higher than that reported for mice (23+8%, Curtis and Kaltrcidcr 1989).
The ratio of EqCD5+CD8-:CD8+ cells in normal equine BALF (0.84, range 0.52-1.04) was
lower than the CD4:CD8 ratio reported for human BALF (1.5-1.8, Reynolds 1987; 1.2+0.3,
Meyer et al 1989; 1.99±0.34, Wallace 1989).
The ratio of gated B cells in equine BALF (median 4.7%, range 2.4-5.6) was similar to that
reported for man (5-10% Reynolds 1987), rats (<12%, Thrall and Barton 1984) and mice
(6+3% Curtis and Kaltreider 1989).
The apparent differences in the lymphocyte phenotype distributions reported for different
species may reflect true species differences and/or differences in the methods used to
enumerate the phenotype ratios, with, in the present study, null cells and gated non
lymphocyte cells being excluded from the calculations.
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While the presence of null cells could not be confirmed in this study, their presence in murine
(Curtis and Kaltreider 1989) and human (Warr et al 1976; Daniele et al 1977) PB and BALF
suggests their presence is likely. In man, null cells account for between 5% (Reynolds 1987)
and 40% (Warr et al 1976; Daniele et al 1977) of BALF lymphocytes.
The lymphocyte phenotype distributions of equine BALF and PBL were significantly
different, as was demonstrated in man (Yamada et al 1986). Equine BALF contained higher
EqCD5+ and EqCD8+ lymphocyte ratios and significantly lower B cell and gated Class 1+
cell ratios. While it is possible that BAL may selectively harvest certain lymphocyte
phenotypes, it is considered more likely that the immune control mechanisms operating within
the two sites differ (Yamada et al 1986).
BAL, being a safe and repeatable technique which yields large numbers of lymphocytes,
offers advantages over alternative techniques for the collection of lower respiratory tract cells.
As the BALF lymphocyte phenotype distribution has been shown to be identical to that of
minced lung preparations (Curtis and Kaltreider 1989) and transbronchial lung biopsies
(Tomichi et al 1989), BALF lymphocytes are considered to be representative of those
throughout the lung.
Horses with asymptomatic COPD had increased ratios of BALF B cells and reduced ratios of
BALF EqCD5+CD8- cells compared with control horses. As there was no overlap between
the ratios of BALF B cells within the control (range 2.4-5.6%) and asymptomatic COPD
affected horses (range 10.5-14.2%), quantification of BALF B cells permitted differentiation
of the control and asymptomatic COPD affected horses.
These lymphocyte phenotype differences may be important in determining whether or not a
horse exposed to poor quality hay and straw develops COPD. B cells, via humoral immune
mechanisms, may have a role in the pathogenesis of equine COPD. The finding the BALF
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from horses with COPD has significantly elevated levels of allergen specific IgG, IgA and IgE
(Halliwell et al, In preparation) supports this proposal.
These differences in BALF lymphocyte phenotype distributions of control and asymptomatic
COPD affected horses were unlikely to be a sequel to pulmonary inflammation, since, as the
COPD affected horses were asymptomatic, they were considered to have no ongoing
pulmonary inflammation. It is possible however, that the phenotype differences represent
pulmonary inflammation which was undetected by the other investigative technique used to
confirm that the horses were asymptomatic. The finding that abnormal accumulations of
certain T lymphocyte subpopulations have been identified in BALF from humans which have
no evidence of pulmonary disease detectable by other methods (Leatherman et al 1984;
Wallace 1989) supports this hypothesis.
No significant differences were demonstrated between PB lymphocyte phenotype
distributions of control and COPD affected horses, either before or after NC. Additionally, the
PB lymphocyte phenotype distributions of either group were unaffected by NC.
While natural challenge (NC) had no effect on PB or BALF lymphocyte phenotype
distributions of controls, it increased EqCD5+CD8- lymphocyte ratios and decreased EqCD8+
lymphocytes ratios in BALF from COPD affected horses, resulting in an increased
EqCD5+CD8-:CD8+ ratio. This suggests that NC initiates a selective recruitment of
EqCD5+CD8- lymphocytes from the PB to the pulmonary tissues and/or a redistribution of
EqCD8+ lymphocytes from the pulmonary tissues to the PB. The former is consistent with the
pulmonary recruitment of CD4+ lymphocytes demonstrated in human allergic asthmatics
following allergen challenges (Gerblich et al 1984; Metzger et al 1987; Gerblich et al 1991),
in humans with sarcoidosis (Berman et al 1990) and in humans with some types of
hypersensitivity pneumonitis (Tomichi et al 1989; Ando et al 1991).
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This selective pulmonary recruitment of lymphocyte phenotypes suggests that cellular
immune mechanisms have a role in the pathogenesis of equine COPD. Activated T cells, by
producing lymphokines, which have numerous effects including regulation of IgE production,
regulation of mast cell differentiation, chemoattraction of neutrophils, eosinophils and
basophils and activation of mast cells, neutrophils, monocytes and macrophages (Kay 1989),
are potentially capable of inducing the pulmonary inflammation characteristic of equine
COPD.
While the mechanism by which allergen induces pulmonary recruitment of lymphocyte
subpopulations is unknown, human CD4 cells have been shown to respond to chemotactic
stimuli including interleukins (Komfeld et al 1985) and arachadonic metabolites (McCarty
and Goetzl 1979; Bacon et al 1988) and C5a (El-Naggar et al 1981). In addition, certain mast
cell mediators, notably histamine, which has been shown to increase within PELF during the
late phase response of equine COPD (Chapter 5), may induce the elaboration by CD8+ cells
of a CD4+ chemoattractant lymphokine termed lymphocyte chemoattractant factor (Center et
al 1983; Berman et al 1984). Pulmonary lymphocyte recruitment has been recently reviewed
by Berman et al (1990).
Antigen induced alterations in lymphocyte phenotype distributions are considered to be
specific immunological responses as they were not elicited by challenge with equal amounts
of inappropriate antigens (Gerblich et al 1984). Furthermore their absence in patients with
severe hypoxaemia due to other pulmonary diseases indicates they are not simply a sequel to
hypoxaemia (Corrigan et al 1988).
Alternatively, it is possible that the lymphocyte phenotype alterations observed in COPD
affected horses after NC, rather than indicating selective phenotype recruitment to the lung,
could reflect antigen induced alteration in the phenotypic expression of individual T cells.
Lymphocyte phenotype alterations have been induced in vitro by histamine (Verhaegen et al
Page - 153
1977), cyclic nucleotides (Grieco et al 1976), various drugs (Limatibul et al 1978),
cholinergic and alpha-adrenergic stimulation (Lang et al 1978) and the H2 agonist
impromidine (Birch et al 1982). Such in vitro changes occurred within minutes, consistent
with the rapid onset phenotype changes observed in vivo following bronchial allergen
challenge in human asthmatics (Gerblich et al 1984).
While this study was unable to determine whether the state of activation of the lymphocytes
was altered by challenge, there is considerable evidence that CD4+ cells, in addition to being
recruited to the lungs of human asthmatics, are also activated by antigen inhalation challenges
and that these cells have an important role in the pathogenesis of this condition (Gerblich et al
1984; Corrigan and Kay 1990). Investigation of the state of activation of CD4+ cells in horses
with COPD is thus warranted.
Pharmacological modulation of the antigen induced lymphocyte phenotypic changes may
prove to be an alternative strategy for the control of equine COPD. In man, inhaled albuterol,
a B2 sympathetic agonist, has been shown to abolish the antigen induced PB T cell phenotype
changes in asthmatics (Varghesc et al 1990). In addition, cyclophosphamide, a drug which is
believed to exert its immunosuppressive actions primarily by inhibition of T lymphocyte
activation (Kahan 1989), has been shown to, often dramatically, control the clinical symptoms
in chronic human asthma (Alexander et al 1992).
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CHAPTER 5
QUANTIFICATION OF HISTAMINE IN PLASMA AND PULMONARY FLUIDS
FROM HORSES WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
(COPD) BEFORE AND AFTER 'NATURAL (HAY AND STRAW) CHALLENGES'
SUMMARY
A commercial radioimmunoassay kit was used to quantify histamine in plasma and
bronchoalveolar lavage fluid (BALF) of 8 control horses and 9 horses with chronic
obstructive pulmonary disease (COPD), before and after 'natural (hay and straw) challenges'
(NC). In addition, the pulmonary epithelial lining fluid (PELF) histamine and albumen
adjusted BALF histamine concentrations were determined from the bronchoalveolar lavage
fluid (BALF) histamine concentrations using the urea and albumen dilution techniques,
respectively.
There were no significant changes in the concentrations of histamine in plasma or BALF at
0.5 or 5h aftei NC, but Lite PELF histamine concentration of COPD affected hoises was
significantly increased at 5h, but not at ().5h, following NC.
As the histamine concentrations of whole BALF lysates were significantly correlated with the
numbers of metachromatically staining cells, presumed to be mast cells and/or basophils,
these findings support involvement of a late phase, mast ccll/basophil mediated,
hypersensitivity reaction in the pathogenesis of equine COPD.
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INTRODUCTION
Mast cells and/or basophils are considered to have an important role in the pathogenesis of
several human pulmonary inflammatory conditions including extrinsic allergic asthma
(Holgate and Finnerty 1989), exercise induced asthma (Shcffer et al 1983), extrinsic allergic
alveolitis (Haslam et al 1987) and hypersensitivity pneumonitis (Soler et al 1987). Increased
concentrations of histamine, an inflammatory mediator released from degranulating mast cells
and basophils, and its metabolites, have been identified in plasma and/or BALF from
individuals suffering from these conditions.
BIOCHEMISTRY OF HISTAMINE
Histamine, 2-(4-imidazolyl) ethylaminc or 5-bcta-aminoethylimidazole, molecular weight
111, is synthesised in mast cells and basophils by the decarboxylation of the amino acid
histidine by histidine decarboxylase (Plaut and Lichtcnstein 1983), and is stored, closely
associated with the anionic side chains of proteoglycans, in cytoplasmic granules.
Histamine, along with a wide spectrum of preformed and newly synthesised mediators, is
liberated from mast cells and basophils in response to a wide variety of immunological and
non immunological stimuli (vide infra). It is then rapidly deactivated (Kcyzer 1984) by N-
methyltransferase or monoamine oxidase (White et al 1987) mainly to N-methyl histamine,
N-methylimidazolacetic acid and imidazoleacetic acid (Kcyzer 1984), with only 2-3% of the
histamine being excreted unchanged in the urine.
TECHNIQUES FOR QUANTIFICATION OF HISTAMINE IN BIOLOGICAL SAMPLES
The quantification of histamine, which is present at low levels within biological fluids,
necessitates sensitive and specific techniques (Keyzcr 1984) and has proved problematic until
relatively recently.
Page - 156
There exist several different assay techniques, as outlined below;
1. Bioassay using guinea pig ileum has now been largely superseded (Cromwell et al 1986)
since it is insensitive below lng/ml (Ind et al 1983).
2. Radioenzymatic assay, using either single or double isotope techniques may be employed.
In the former the histamine specific enzyme, N-methyltransferase, isolated from rat kidney,
transfers a tritiated methyl group from a substrate (s-[mcthyl-^H]-adenosyl-L-methionine) to
histamine, to produce labelled 1-methylhistamine. The tritiatcd histamine derivative is then
extracted organically, isolated by thin layer chromatography and quantified radioactively
(Dyer et al 1982; Ind et al 1983). The double isotope technique involves addition of a second
tracer, which improves the sensitivity to 25 pg/ml (Kay 1987).
3. Fluorimetric assay is less expensive than the radioenzymatic assay and has also been fully
automated (White et al 1987), but requires preliminary sample purification by ion exchange
column chromatography and butanol extraction for adequate specificity and sensitivity (1-
5ng/ml) (Lorenz and Doenicke 1978). Histamine, at an alkaline pH, is then reacted with o-
phthalaldehyde to form a fluorescent compound which can then be quantified fluorimetrically.
4. Gas chromatographic assay, with nitrogen phosphorus detection, involve protracted
sample preparation and require expensive equipment available only in specialist laboratories
(Cromwell et al 1986). Standard quantities of synthetic homologues of histamine metabolites
are added to the sample as internal standards. After extraction and dcrivatisalion, the mixtures
are separated on a capillary column and the nitrogen containing compounds selectively
detected. The ratio of the natural metabolites and the internal standard is then related to the
amount of histamine metabolite in the sample (Kcyzcr 1984).
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5. For the isotope dilution assay a fixed amount of non radioactively labelled histamine,
which is several mass units heavier than the naturally occurring histamine, is added to the
sample. After extraction and derivatisation, gas chromatographic separation is performed,
followed by mass spectrometric detection (Kcyzer 1984).
6. Radioimmunoassay (RIA) techniques have revolutionised the assay of histamine in
biological samples, being sensitive, specific, relatively inexpensive and comparatively simple
to use. Consequently RIA was selected for this study.
COLLECTION AND PROCESSING OF SAMPLES FOR HISTAMINE ASSAY
While RIA has simplified the quantification of histamine in biological samples, accurate
results are dependent on optimal sample collection and processing.
Guidelines for sample collection and preparation of human plasma for histamine
determination were given by Lorenz et al (1982). Briefly, samples should not be collected
within lOmin of alcohol disinfection of the vcnupuncturc site, within 3()min after minor
surgery, work, stress or anaesthesia or within 6h of a meal, although explanations for these
recommendations were not given. Following collection, the samples should be placed on ice
and processed within 30min, before changes in the histamine concentration occur. Ind et al
(1983) advised that only the top two thirds of plasma should be aspirated when collecting
plasma from centrifugcd whole blood samples, to minimise basophil contamination.
PROBLEMS ASSOCIATED WITH QUANTIFICATION OF HISTAMINE IN BIOLOGICAL
SAMPLES
'Leakage' of histamine from mast cells and basophils during sample collection or processing
may lead to, possibly marked, overcstimation of the histamine concentration of biological
fluids (Ind et al 1983) but can be minimised by the use of calcium free solutions and by
maintaining samples at low temperatures (Kalenderian et al 1988).
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The quantification of histamine is further complicated by the short (approximately lmin,
Keyzer et al 1984) half life of histamine in body tissues and body fluids. Consequently,
transient increases in histamine concentrations, which occur prior to sampling, may not be
detected.
ALTERNATIVES TO HISTAMINE QUANTIFICATION IN THE INVESTIGATION OF
BASOPHILIMAST CELL DEPENDENT HYPERSENSITIVITY PHENOMENA
Keyzer (1984) considered that quantification of the urinary histamine metabolites, N-methyl
histamine and N-methylimidazolacetic acid, was more useful than quantification of histamine,
since the metabolites have longer half lives. Furthermore these metabolite levels are less
affected by inadvertent contamination of samples with basophils or mast cells. Both
metabolites have been assayed in human urine and plasma by the isotope dilution technique,
with mass spectrometric detection, and by gas chromatography (Keyzer 1984) and N-methyl
histamine has been quantified by radioimmunoassay (Stephan et al 1988).
There are, however, potential problems associated with the quantification of histamine
metabolites in the investigation of basophil/mast cell dependent hypersensitivity phenomena.
Taylor et al (1990) found that urinary N-mcthyl histamine was only increased with persistent
hyperhistaminaemia and that increased local histamine release in the lung or the upper airway
did not cause a detectable change in its basal excretion. Furthermore, assay of urinary
histamine metabolites may be affected by histamine produced by bacteria in the urogenital
tract, although this problem may be minimised by collecting the urine by cathcterisation
(Keyzer 1984). As the concentration of N-methylimidazolacctic acid appears to be strongly
dependent on the dietary histamine intake, exclusion of histamine containing foods from the
diet is necessary prior to its assay (Keyzer 1984).
There appear to be no reports of the quantification of histamine metabolites in the horse.
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HISTAMINE AND PULMONARY MAST CELLS IN THE HORSE - A REVIEW
While it has been proposed that equine chronic obstructive pulmonary disease (COPD) may
involve Type I hypersensitivity (Cook and Rossdale 1963; Lowell 1964; Eyre 1972; Halliwell
et al 1979; McPherson and Thomson 1983), little is known about the role of mast
cells/basophils or histamine in the pathogenesis of this condition.
(A) HISTAMINE
A wide range of immunological and pharmacological agents may induce in vitro histamine
release from equine peripheral blood leucocyte preparations. While the effect of anti equine
IgE on basophils/mast cells has not been reported, anti rat IgE, anti human IgE, anti equine
Fab (Magro et al 1988) and an anti-horse IgG antiserum (Kings and de Week 1980) were
shown to induce degranulation of equine basophils. Non IgE mediated equine basophil
secretagogucs include cocanavalin A (Kings and de Week 1980), calcium ionophore and
human C5a fragment (Abdel-Salam 1989). Kings and de Week (1980) found that calcium
ionophore A 23187, compound 48/80 and poly-L-lysine, which are well recognised
secretagogues for basophils/mast cells of other species, had no effect on equine
basophils/mast cells. Equine basophil degranulation is calcium, but not magnesium, dependent
and is potentiated by deuterium oxide (Kings and dc Week 1980; Magro et al 1988).
Hockenjos et al (1981) found that extracts of hay, aspergillus, Candida and verticillium could
induce histamine release from peripheral blood leucocytes (PBL) collected from horses with
COPD. However, Dieckmann (1986) was unable to demonstrate degranulation of equine
peripheral blood basophils from control and COPD affected horses, as assessed by
microscopic examination of toluidine blue preparations, following incubation with these
antigen extracts, and proposed that the histamine release reported by Hockenjos and
colleagues had been associated with basophil cytolysis induced by excessively high (100-
500ug/ml) antigen concentrations. Dieckmann (1986) found that, while incubation of
peripheral blood leucocytes with high concentrations of these antigens in the absence of
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exogenous calcium elicited histamine release, there was no concomitant release of lactate
dehydrogenase, an intracellular enzyme which is released during cytotoxic reactions. The
significance of the findings of Hockenjos and colleagues thus remain unclear.
Abdel-Salam (1989) investigated histamine release from peripheral blood leucocytes and
tracheobronchial cells from control horses and horses with 'probable allergic COPD' and with
'probable non allergic COPD', the 2 questionable categories being differentiated by the
number of mast cells and eosinophils in their tracheobronchial secretions. Calcium ionophore
and human C5a elicited histamine release from peripheral blood leucocytes and
tracheobronchial cells, while extracts of timothy pollen and house dust mite were
secretagogues only for tracheobronchial cells. Tracheobronchial cells released more histamine
than peripheral blood leucocytes, and tracheobronchial cells from horses with 'probable
allergic COPD' released more histamine than those from horses with 'probable non allergic
COPD'.
Burka et al (1976) demonstrated that isolated lung segments from horses sensitised to bovine
plasma in Freund's complete adjuvant liberated histamine and 5-hydroxytryptamine, but not
slow-reacting substance of anaphylaxis, after subsequent challenge with bovine plasma.
However, as the yield of histamine was low they suggested that histamine was less important
in equine hypersensitivity than in man, guinea pigs and cattle, or that the antigen sensitisation
was not optimal in their study. They also demonstrated that equine chopped lung preparations
and sensitised PBL preparations released similar amounts of histamine.
During equine anaphylaxis, Lewis et al (1972) demonstrated that whole blood histamine and
plasma 5-hydroxytryptamine were unaffected while whole blood kinins increased 4 fold. Eyre
and Lewis (1973) found there was a 5-6 fold increase in plasma histamine approximately 2-
4min after allergen induced anaphylaxis, with levels returning to normal by 20min.
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Eyre (1972) found the level of whole blood histamine elevated in only 1 of 11 horses with
COPD, while plasma 5-hydroxytryplamine was elevated in 5 of the horses. Unfortunately
plasma histamine concentrations were not determined in this study.
Increased plasma histamine concentrations have been reported in horses with early grass
sickness (Hodson et al 1989).
(B) PULMONARY MAST CELLS
The normal equine lung contains large numbers of mast cells, with approximately 20% being
located within the bronchiolar walls, which is the primary site of histological changes in
horses with COPD (Nicholls 1978; Mair et al 1988; Winder and Von Fellenberg 1990). Some
pulmonary mast cells are located in the airway epithelium (Mair et al 1988) and in the airway
and alveolar lumina (Kaup et al 1990A & B), where they are strategically located to interact
with inhaled antigens.
The finding that sodium cromoglycate, which allegedly has mast cell stabilising properties,
was prophylactically effective in equine COPD, in a proportion of studies, was considered as
evidence that mast cell dcgranulation plays a central role in the pathogenesis of this condition
(Murphy et al 1979; Thomson and McPhcrson 1983; Soma et al 1987). However, more recent
studies in man indicate that the beneficial effect of sodium cromoglycate is more likely to be
attributable to its many other antiinflammatory properties (Richards et al 1986; Kay et al
1987) rather than to mast cell stabilisation.
Winder and von Fellcnberg (1990) demonstrated histological evidence of pulmonary mast
cell hyperplasia in horses with undifferentiated chronic pulmonary disease. Some other
studies (Yamashiro et al 1986; Vrins et al 1989; Winder et al 1990), have demonstrated
increased numbers of mast cells in bronchoalveolar lavage fluid (BALF) from COPD affected
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horses, although the findings of the present study (Chapter 2) and of Derksen et al (1985B)
dispute this finding.
Yamashiro et al (1986) demonstrated that many BALF mast cells from a horse with COPD
showed ultrastructural evidence of degranulation, while those from 3 control horses did not.
While the authors considered this was evidence that mast cell degranulation is important in
the pathogenesis of equine COPD, the small numbers of horses in this study and the presence
of pulmonary inflammatory disease in the control group, as indicated by their excessively
high BALF neutrophil ratios, casts doubt on the validity of this study.
In the present study, the role of pulmonary mast cclls/basophils in the pathogenesis of equine
COPD was investigated by quantifying histamine in plasma, BALF and pulmonary epithelial
lining fluid (PELF) from control and COPD affected horses, before and at 0.5 and 5h after




Eight control horses (median age 15.5years, range 7-25; median body weight 577kg, range
212-652) and 9 COPD affected (median age 13.5years, range 6-25; median body weight
482kg, range 371-642) horses of various breeds were used (Appendix 5.1). All animals were
maintained in a 'controlled', hay and straw free environment until they were shown to be fully
asymptomatic, as described in Chapter 2.
NATURAL CHALLENGE
All horses received two separate NCs, as described in Chapter 2.
SAMPLE COLLECTION AND PROCESSING
The horses did not receive medication and no skin cleansing agent was used prior to
venupuncture. Venous blood was collected immediately prior to and at 1.5 and 5h after one
NC, by jugular venupuncture into precooled, sterile glass vacutainers containing potassium
EDTA (Becton Dickinson, Meylan, France) and the samples placed immediately on ice. The
blood was cenlrifuged, within 30min of collection, at 500g in a refrigerated centrifuge at 4°C
(MSE Chilspin 2, Fisons, Crawley) for 5min. The top two thirds of the plasma was aspirated
without disturbing the cell pellet and was stored at -20° C until assayed.
Baseline BALF samples were collected at least 72h prior to one NC, when horses were
shown to be free from pulmonary disease by clinical, endoscopic and BALF cytological
examinations, as described previously (Chapter 2). Post challenge BALF samples were
collected 0.5h after one NC and 5h after the other. The baseline and the 2 post challenge
BALF samples were collected on separate occasions to avoid possible interference caused by
pulmonary inflammation induced by a recent (within 48h) lavage (Sweeney et al, In press B).
BALF was processed and stored as described previously (Chapter 2).
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HISTAMINE ASSAY
One commercial histamine RIA kit (Pharmacia Histamine RIA, Pharmacia, Milton Keynes),
was found to be too insensitive, having a reported working range of 2-100ng/ml. Plasma and
BALF histamine concentrations were, however, satisfactorily determined using a commercial
competitive RIA kit developed by Morel and Delaage (1988) (Immunotech, Marseille,
France). In this assay, histamine in the sample competes with an iodinated histamine tracer for
binding sites on monoclonal antibody (mAb) coated tubes. A mAb specific for acylated
histamine was employed to overcome problems associated with the production of a mAb
specific for the small, and hence poorly immunogenic, histamine molecule. As a consequence
histamine in the samples had to be acylated prior to assay. As sample pH can affect this assay
(Morel and Delaage 1988), the pH of 10 BALF samples was determined using a SA520 pH
meter (Orion Research, Cambridge, Mass. USA) and found to be (median 7.31, range 7.14-
7.44) within the range in which acylation of histamine occurs almost instantaneously, but
lower than that required for optimal binding of histamine to the histamine tracer (pH 8.2). The
kit was used according to the manufacturers' instructions, total and bound radioactivity being
determined using a gamma counter (NE1600, Nuclear Enterprises, Edinburgh).
As BALF histamine concentrations arc not only dependent on the concentration of the
histamine in the PELF, but also on the variable volume of PELF recovered by
bronchoalveolar lavages (BALs), comparison of PELF histamine concentration is more
rational than comparison of BALF histamine concentrations. PELF histamine concentrations
were calculated from BALF histamine concentrations using the urea dilution technique
reported by Rennard et al (1986). This technique involves concomitant quantification of
plasma and BALF urea, with the assumption that urea, a small and freely diffusible molecule
is present in equal concentrations in plasma and in PELF.
In addition to using the urea dilution technique, the variable dilution which occurs during
BAL was also corrected for by determining the albumen adjusted BALF histamine
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concentrations i.e. albumen adjusted BALF histamine concentration = BALF histamine
concentration x plasma albumen concentration / BALF albumen concentration. Plasma and
BALF albumen concentrations were determined as described in Chapter 7. These 2 dilution
techniques are discussed fully in Chapter 7.
BALF metachromatic cell ratios were determined using 2 techniques, namely by performing
differential counts of 1000 BALF cells on toluidine blue (Appendix 2.2) stained cytospin
preparations and of 300 cells on Lcishman's (Appendix 2.2) stained cytospin preparations.
The ratios of these cells in 51 BALF samples, collected from 8 control and 9 COPD affected
horses, before, and at 0.5 and 5h after NC, were compared.
The histamine content of metachromatic cells in BALF from 6 control and 5 COPD affected
horses was determined by quantification of histamine in BALF supernatants and in 'whole
BALF' which had been subjected to 3 freeze/thaw cycles (from room temperature to -2CPC) to
lyse cells and liberate intracellular histamine. The BALF supernatant histamine concentration
was subtracted from the 'whole BALF' histamine concentration, to yield the cellular histamine
concentration and then divided by the absolute metachromatic cell count to yield the
histamine content of BALF metachromatic cells.
STATISTICAL ANALYSES
Paired and unpaired data, which were shown to be non normally distributed, were compared
using the Wilcoxon Rank and Mann Whitney tests, respectively. Correlation was performed
using the Speannan Rank Correlation. All analyses were performed using Minitab (Minitab
Inc., Pennsylvania, USA), assuming a significance level of 5%.
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RESULTS
Intraassay coefficients of variation for histamine assay, calculated from 4 repeated duplicate
determinations on 2 plasma and 4 BALF samples with high and low histamine concentrations
were 10.5% and 13.9% for the plasma and 8.7%, 13.7%, 18.0% and 30.7% for BALF. Inter-
assay coefficients of variation, calculated from 4 duplicate repetitions using 2 plasma and 4
BALF samples, were 5.0 and 13.6% for plasma, and 1.0, 22.4, 25.4 and 30.4% for BALF.
Storage of whole BALF samples, from 3 control and 3 COPD affected horses, on ice for 15,
30, 45 or 60 min prior to collection of the supernatant resulted in a progressive decline in the
histamine concentrations of the supematants (Fig. 5.1). The half life of histamine in these
samples varied from 15-50min.
Fig. 5.1 The effect of delayed sample processing on the concentration of histamine (ng/ml) in
the supernatant of BALF from control (n=3) ( ) and COPD affected (n=3) horses ( ).
30 45
DELAY PRIOR TO CENTRIFUGATION (min)
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The stability of histamine was evaluated by performing BALs on 2 horses using, as the
lavaging fluid, PBS containing a known concentration of added histamine, and determining
the proportion of exogenous histamine in the recovered BALF. The data and calculations are
given in Appendix 5.2. The exogenous histamine was found to be stable during the collection,
processing and storage of the BALF, the percentage recoveries for the two horses being
and 115%.
There were only minor changes in histamine concentrations of 4 plasma and 4 BALF
supernatant samples during prolonged storage at -20°C (Fig. 5.2).
Fig. 5.2 The effect of prolonged storage, at -2(Pc, on the concentrations of histamine (ng/ml)
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NC had no significant effect on the concentrations of histamine in plasma (median = 0.24,
range 0.07-0.57 for control horses at baseline) (Table 5.1, Appendix 5.3) and BALF (median
= 1.78ng/ml, range 0.11-2.66 for control horses at baseline) (Table 5.2, Appendix 5.4) from
control and COPD affected horses.
Table 5.1. Plasma histamine concentrations (ng/ml) of control (n=8) and COPD (n=8) affected
horses before and at 1.5h and 5h after NC (median and range).
Time after Plasma histamine concentration
NC (h) Control horses COPD affected horses
0 0.24 (0.07-0.57) 0.16 (0.19-0.48)
1.5 0.36 (0.15-0.64) 0.18 (0.12-0.48)
5.0 0.23 (0.07-0.38) 0.17 (0.06-0.54)
Table 5.2. BALF histamine concentrations (ng/ml) of control (n=8) and COPD (n=9) affected
horses at baseline and at 0.5h and 5h after NC (median and range).
Time after BALF histamine concentration
NC (h) Control horses COPD affected horses
0 1.78 (0.11-2.66) 0.28 (0.01-3.93)
0.5 1.92 (0.00-3.05) 1.01 (0.10-2.37)
5.0 1.36 (0.13-2.37) 1.10 (0.02-6.38)
PELF histamine concentrations and albumen adjusted BALF histamine concentrations were
significantly higher in the COPD affected horses at 5h after NC (median PELF histamine
concentration = 246.0ng/ml, range 5.0-1087.0) than at baseline (35.2, 4.6-430.0) (p<0.05),
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although the values for control and COPD affected horses were not significantly different
(Table 5.3 & 5.4, Figs. 5.3 & 5.4, Appendices 5.5 - 5.8).
Table 5.3. PELF histamine concentrations (ng/ml), derived using the urea dilution technique,
for control (n=8) and COPD (n=9) affected horses before and at 0.5 and 5h after NC (median
and range).
Time after PELF histamine concentration
NC (h) Control horses COPD affected horses
0 189.3 (31.3-435.9) 35.2 (4.6-430.0)
0.5 243.9(1.1-651.4) 174.6 (11.1-777.3)
5.0 146.2 (64.9-658.2) *246.0(5.0-1087.0)
* significantly higher than for the COPD affected horses at baseline (p<0.05).
Table 5.4. Albumen adjusted BALF histamine concentrations (ng/ml) for control (n=8) and
COPD (n=9) affected horses before and at 0.5 and 5h after NC (median and range).
Time after Albumen adjusted BALF histamine concentration
NC (h) Control horses COPD affected horses
0 314.0(45.0-1178.0) 125.1 (16.4-925.3)
0.5 784.0 (8.0-1120.0) 400.3 (38.1-779.6)
5.0 706.0(49.0-1824.0) * 898.0 (93.0-2278.0)
* significantly higher than for the COPD horses at baseline (p<0.05).
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Fig. 5.3 Concentrations of histamine (ng/ml) in PELF of (A) control (n=8) and (B) COPD
affected (n=9) horses, before and at 0.5 and 5h after NC, as determined by the urea dilution
technique.













Fig. 5.4 Albumen adjusted BALF histamine concentrations (ng/ml) for (A) control (n=8) and
(B) COPD affected (n=9) horses, before and at 0.5 and 5h after NC, as determined by the
albumen dilution technique.







The concentration of histamine in PELF was on average 215 fold higher than that of BALF,
which in turn was on average 7 fold higher than that of plasma.
The BALF mast cell ratios, when determined using toluidine blue and Leishman's staining
techniques were not significantly different (p>0.05), the median difference between the counts
obtained using the two techniques being 0.0 (Ql=-0.9, Q3=0.9, range -8.8 to 3.9) (Fig. 5.5,
Appendix 5.4).
Fig. 5.5 Correlation between the BALF mast cell ratios obtained by performing differential
counts of 1000 BALF cells on toluidine blue stained preparations and of 300 BALF cells on
Leishman's stained preparations. The median difference of the ratios obtained using the 2
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The median histamine content of metachromatic cells was calculated to be 2.79 pg/cell (range
0.63-4.60). There was no significant difference in the histamine content of metachromatic
cells from control (median 2.86, range 1.54-4.60 pg/cell) and COPD affected (2.79, 0.63-3.12
pg/cell) horses (Appendix 5.9).
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Three rapid freeze thaw cycles did not affect the concentration of histamine within 4 BALF
supernatants (Table 5.5) and thus, by extrapolation, is unlikely to have affected the histamine
concentration of the 'whole BALF' samples, which were subjected to this procedure in order to
liberate the intracellular histamine.
Table 5.5 Histamine concentrations (ng/ml) of BALF supernatants (n=4) before and after
being subjected to 3 rapid freeze thaw cycles.
HORSE STATUS BEFORE FREEZE AFTER FREEZE
THAW THAW
1 COPD 0.64 0.64
2 COPD 0.43t 0.56
3 CONTROL 0.471 0.42
4 CONTROL 2.42 1 2.42
1 Mean of 4 paired determinations.
Histamine concentrations of plasma were not significantly correlated with those of BALF or
PELF (p>0.05). The BALF supernatant histamine concentrations were significantly correlated
with the absolute BALF metachromatic cell counts (rs=0.328, p<0.05) and the total BALF cell
counts (rs=0.873, p<0.01), but were not significantly correlated with the BALF
metachromatic cell ratios. The absolute BALF metachromatic cell counts were significantly
correlated with the whole BALF histamine concentrations (rs=0.675, p<0.05). The PELF
histamine concentrations were significantly correlated with the absolute BALF metachromatic
cell counts (rs=0.356 p<0.05), but not with the BALF metachromatic cell ratios.
There was no significant difference in the ratios of whole BALF histamine
concentration:BALF supernatant histamine concentration for control (median 43.6, range 6.4-
99.7) and COPD affected (23.3, 8.8-60.0) horses.
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DISCUSSION
Histamine concentrations of equine plasma and bronchoalveolar lavage fluid (BALF) were
satisfactorily determined using a commercial radioimmunoassay (RIA) kit which, being
relatively inexpensive, of suitable sensitivity and precision and not requiring the use of
specialist equipment, offers advantages over other histamine assay techniques.
The intraassay and interassay precisions for plasma histamine were, in most cases, higher
than those previously reported for man (Morel and Dclaagc 1988), possibly due to the smaller
number of repetitions performed in this study. BALF histamine concentrations showed more
variation than those of plasma. There are no previously reported precision data for histamine
determinations of BALF from any species using this RIA kit.
Exogenous histamine, instilled into the equine lung, was recovered by BAL without loss,
indicating that the techniques used to collect, process and store the BALF samples, in this
study, were unlikely to have affected the BALF histamine concentrations.
It was necessary to harvest the BALF supernatant immediately after collecting the BALF, as
the histamine concentrations of BALF supcrnatants were found to decrease significantly when
their separation from whole BALF was delayed. The half life of histamine in the supernatant
of whole BALF samples ranged from 15-50min. This was greater than the half life of lmin for
histamine in human plasma (Keyzer et al 1984), possibly because the whole BALF samples
were stored on ice immediately after collection, thereby reducing BALF histaminase activity.
In contrast, Soler et al (1987) found that histamine concentrations of whole BALF increased
when separation of the supernatant was delayed, and concluded that this was due to leakage of
histamine from BALF mast cells. Differences in the conditions used to store whole BALF
samples prior to collection of the supernatant may account for these contradictory findings, as
the conditions employed by Soler et al (1987) were not reported.
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Histamine in plasma and BALF was stable during prolonged storage at -2CPC, the minor
changes observed being considered to be within the limits of interassay variation. Similarly,
Rankin et al (1987) reported the coefficient of variance for human BALF histamine assay to
be only ±8% and ±10% in samples stored at -70°C for more than 8 weeks.
Plasma histamine concentrations of control horses prior to NC (median = 0.24ng/ml, range =
0.07-0.57), were similar to those reported in a previous study for horses (0.313 + 0.062ng/ml,
range 0.078-0.733, Hodson et al 1989), and for monkeys (Lorenz et al 1974) and humans
(Dyer et al 1982; Lorenz et al 1982; White et al 1987). The plasma histamine concentrations
reported for the dog show marked variation (from 0.2 + 0.3, Lorenz et al 1974 to 14.3 +
4.1ng/ml, Nimmo Wilkie et al 1990), making comparison difficult.
This is the first study to quantify histamine in equine BALF. The values for control horses at
baseline (median 1.78ng/ml, range 0.11-2.66) were similar to those reported for the dog
(Casolaro et al 1989). The wide range of BALF histamine concentrations reported for normal
humans (from 0.026 + 0.02ng/ml, Casale et al 1987 to 1.16 + 0.5, Haslam et al 1981) makes
comparison difficult, but in general values for man appear to be lower than for the other
species. Unexplainably high BALF histamine concentrations (6.4 ± 2.4ng/ml, Ingenito et al
1991) have been reported for the guinea pig.
As expected equine PELF histamine concentrations were considerably higher than those of
BALF, which in turn were higher than those of plasma. While there are apparently no reports
of PELF histamine determinations for other species, as human BALF and plasma histamine
concentrations are similar (Rankin et al 1987) and normal human PELF constitutes 1.0 +
0.1% of BALF (Rennard et al 1986), it can be estimated that the human PELF histamine
concentration is approximately 100 fold higher than that of plasma.
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Four possible explanations may account for the finding that PELF histamine concentrations
are markedly higher than those of plasma.
Firstly, PELF histamine concentrations may be markedly higher than those of plasma as a
result of local histamine release, i.e. from epithelial or luminal mast cells/basophils into the
PELF. The presence of mast cells in various stages of degranulation in normal human
pulmonary epithelia (Fox et al 1981; Lamb and Lumsden 1982) supports this theory.
Secondly, the high human PELF histamine concentrations may arise from the diffusion of
histamine from pulmonary tissues across the alveolar capillary membrane into the BALF
during BAL (Rankin et al 1987), as has been demonstrated for potassium (Davis et al 1982),
urea, albumen and glucose (Rennard et al 1986). However, this is unlikely in the present study
since equine BALF histamine concentrations were higher than those of plasma, and therefore
net diffusion of histamine from BALF into plasma would have been expected.
Thirdly, as equine whole BALF lysates contained, on average, 21.4 (range 6.4-99.7) fold
more histamine than BALF supernatants, artefactual release of histamine from mast
cells/basophils during BALF collection or processing could cause an overestimation of BALF
and PELF histamine concentrations. However there is considerable evidence from human
studies to suggest that this does not occur (Kaliner,M. pers obs. quoted Rankin et al 1987).
(a) artefactual histamine release was not induced by reaspiration of BALF through a
bronchoscope (Casale et al 1987),
(b) the fluid usually used in this study for lavage contained no calcium and was maintained
between 4-25°C making physiological release of histamine, which is calcium and temperature
dependent (Magro et al 1988), unlikely (Kalcnderian et al 1988),
(c) in man, BALF tryptase levels were on average 20 fold higher than those of histamine,
rather than being comparable to those of histamine, as would be expected with artefactual
mast cell degranulation (Kalenderian et al 1988).
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Fourthly, histamine produced by bacteria within the lung could account for the higher
histamine concentration of equine BALF compared with plasma. To minimise the errors
arising from the presence of bacterial derived histamine, Kalenderian et al (1988) suggested
discarding the first BALF aliquot, which was considered to contain bacterially derived
histamine. However, as Rankin et al (1987) found no significant difference in histamine
content of the first and pooled BALF samples, bacterially derived histamine would seem to
have little effect on BALF histamine concentrations.
The absolute BALF metachromatic cell counts were significantly correlated with the
concentrations of histamine in whole BALF lysates, consistent with the findings for man
(Rankin et al 1987) and dogs (Sommerhoff et al 1989). This finding suggests that BALF
histamine is derived from metachromatic cells which are recovered by BAL i.e. mast cell or
basophils within the epithelium, airway lumen or alveoli. In man, mast cells rather than
basophils were considered to be the source of BALF histamine, as the concentrations of
tryptase, which is abundant in human mast granules but is virtually absent from basophils
(Schwartz 1985), were considerably higher in human BALF than those of histamine
(Kalenderian et al 1988).
Equine BALF metachromatic cells were found to contain more histamine (median 2.86ug/cell
range 1.54-4.60) than was reported for dogs (1.80 ±0.1, Sommcrhoff 1989) and monkeys
(1.68 + 0.26, Patterson et al 1977). The values reported for normal human BALF mast cells
(from 7.1 ± 3.8, Miura et al 1989 to 15.3 ± 10.8, Tomioka et al 1984) show considerable
variation, possibly due to the different methods used to fix and stain mast cells (Overveld et al
1989).
While the validity of human BALF mast cell counts, based on examination of Wright's
stained cytospin preparations, has been questioned due to the small numbers of mast cells
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present in human BALF (Tomioka et al 1984; Rankin et al 1987), the accuracy of equine
BALF mast cell counts may be greater due to the comparatively higher ratios of BALF mast
cells in this species. It is possible that the absolute and differential BALF mast cell counts
reported for all species may underestimate the true counts, due to the presence of partially or
completely degranulated mast cells, which are not readily identified with light microscopy
(Fox et al 1981; Lamb and Lumsden 1982).
The histamine concentration of PELF from COPD affected horses was significantly increased
at 5h but not at 0.5h following NC, while that of controls was unaffected. This suggests that
mast cell and/or basophil degranulation occurs only during the antigen induced late phase
response (LPR) of COPD and that these cells may have a role in the pathogenesis of this
condition. Plasma and BALF histamine concentrations were unaffected by NC, the former
suggesting that peripheral blood basophils had not degranulated and that there was no
significant transfer of histamine from the PELF to the plasma.
In man, increased concentrations of histamine in BALF (Diaz et al 1989) and plasma
(Durham et al 1984) have been reported during LPRs to bronchial allergen challenges, and in
skin blister sites (Charlesworth et al 1989) and nasal lavage fluids (Naclerio 1990) during
LPRs to local allergen challenges.
The factors which induce histamine release during the LPR of equine COPD are not known,
but could include specific antigen, complement proteins, histamine releasing factors,
interleukins (reviewed by White 1990) or an antigen specific lymphokine which is produced
by T lymphocytes (Askenase and Van Loveren 1983; Ezeamuzie and Assem 1983).
Histamine releasing factors (HRF) and histamine releasing inhibitory factors (HRIF) are
recently described heterogeneous groups of cytokines which are believed to be involved in the
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local control of mast cell activation (Alam et al 1990) and which may be important in the
pathogenesis of antigen induced LPRs.
HRFs induce non cytotoxic release of histamine from mast cells and basophils in vitro, by
IgE dependent and independent mechanisms. They may be responsible for recruiting mast cell
or basophil participation in LPRs and possibly other chronic inflammatory conditions (Kaliner
1989; White 1990) and for inducing basophil degranulation during LPRs (Lichtenstein 1988).
These apparently low molecular weight (<15kDa) cytokines are produced largely by cells
with low affinity IgE receptors i.e. by mononuclear cells (Theuson et al 1979), T cells
(Sedgwick et al 1981), B cells (Alam et al 1989), neutrophils (White and Kaliner 1987) and
platelets (Orchard et al 1986).
As HRF and HRIF have been identified in BALF of normal humans (Alam et al 1989), it
appears that HRF production occurs in all individuals, including non atopics. However, only
mast cells and basophils from atopic individuals, which have a special form of IgE molecule,
designated IgE+, appear to be able to respond to HRF (Lichtenstein 1988). Alternatively, the
increased amounts of HRF demonstrated in lavage fluids from humans with idiopathic
pulmonary fibrosis (Broide et al 1990), asthma and allergic rhinitis (Wasserman 1990), may
account for the increased BALF histamine noted in patients suffering from these conditions.
It is possible that HRFs, so far unidentified in the horse, could induce the antigen induced
LPR histamine release demonstrated in horses with COPD.
Recently the duration of the allergen challenge has been shown to have an important effect on
the pattern of allergen induced histamine release.
Classically, in vivo allergic responses to single or short term antigenic challenges, and in vitro
stimulation of mast cells/basophils with immunological or non immunological agents
suggested that allergens induced a very intense and rapid mast cell/basophil degranulation,
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with almost complete release of preformed mediators within 30min (Lichtenstein and Oster
1964). These short term antigen challenges rarely induce LPRs (Shalit et al 1988).
In contrast, prolonged intradermal allergen challenges elicited release of histamine which
peaked at lh and which continued at a constant level for at least 9h (Shalit et al 1988).
It is possible that prolonged antigen challenge, as would occur during naturally occurring
equine COPD and during NCs, may have induced a prolonged pattern of histamine release
which differed from that induced by the short duration AF, TV and MF antigen inhalation
challenges described in Chapter 2.
In addition, the pattern of histamine release appears to be affected by the concentration of
allergen (Peters et al 1982).
While it is unclear whether histamine released during the LPR in equine COPD arises from
basophils or mast cells, there is increasing evidence to implicate basophils in human nasal,
bronchial and dermal late phase responses to allergen (Okuda et al 1978; Nagy et al 1982;
Mitchell et al 1986; Bascom et al 1988; Shalit et al 1988; Naclerio 1990; Kay et al 1991).
Histamine may have numerous roles in the pathogenesis of equine COPD, as it can induce
bronchoconstriction, airway mucosal oedema and mucus secretion and increase pulmonary
vascular permeability in several species (reviewed by White et al 1987). Histamine may also
induce production of a CD4+ T cell chcmoattractant lymphokine, termed lymphocyte
chemoattractant factor (Center et al 1983; Berman et al 1984), which may induce pulmonary
recruitment of selective lymphocyte phenotypes, as has been shown to occur in horses with
COPD (Chapter 4). Other mediators which arc released from mast cells and basophils
concomitantly with histamine may also have roles in the pathogenesis of equine COPD.
In conclusion, the findings of this study are consistent with the hypothesis that a late phase,




ATTEMPTED QUANTIFICATION OF TRYPTASE IN EQUINE SERUM AND
BRONCHOALVEOLAR LAVAGE FLUID
SUMMARY
A commercial radioimmunoassay kit for human tryptase was found to be unsuitable for the
quantification of tryptase in equine serum and bronchoalveolar lavage fluid (BALF) samples.
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INTRODUCTION
Tryptase is a neutral protease, comprised of four 35-37Kd chains, which constitutes
approximately 30% of the protein content of human mast cells (Schwartz et al 1981).
In man, tryptase, which is secreted from degranulating mast cells, has been used as a specific
indicator of mast cell involvement in anaphylaxis (Schwartz et al 1987B), allergen induced
early and late phase nasal responses (Castells and Schwartz 1988), allergen induced early
cutaneous responses (Shalit et al 1988) and in local endobronchial allergen challenge
responses (Wenzel et al 1988).
Tryptase offers several advantages over histamine as an indicator of mast cell dcgranulation.
(a) Tryptase has a half life in body tissues and body fluids of approximately 2h, which is
considerably longer the 1 minute half life of histamine (Keyzer et al 1984).
(b) Tryptase is a more specific indicator of mast cell degranulation than histamine, as its
concentration is 250-900 fold higher in human mast cells than in basophils, while mast cell
histamine concentration is only 1-2 fold higher than that of basophils (MacGlashan and
Lichtenstein 1980; Schwartz et al 1987A). No other cell type, including those from normal
lung, skin, peripheral blood and small intestine contain appreciable amounts of tryptasc
(Schwartz 1985; Craig et al 1986; Castells et al 1987).
(c) Tryptase may be assayed at lower concentrations than histamine (Wenzel et al 1988).
There are apparently no reports describing or quantifying tryptase in the horse.
A commercial radioimmunoassay (RIA) kit for quantification of human tryptase which




SAMPLE COLLECTION AND PREPARATION
Sera and bronchoalveolar lavage fluid (BALF) samples were collected from control and
COPD affected horses as described in Chapter 2. The samples were processed and stored
according to the recommendations of the manufacturers of the RIA kit (Pharmacia, Milton
Keynes).
Tryptase was assayed in 5 samples, as follows;
1. Serum collected from a COPD affected horse at 0.5h after 'natural challenge' (NC).
2. Serum collected from a control horse at 0.5h after NC.
3. BALF supernatant collected from a COPD affected horse at ().5h after NC.
4. A whole BALF lysate. Whole BALF, with a high mast cell ratio (22%), which had been
collected from a control horse, was subjected to three rapid freeze thaw cycles (from -2CP C to
room temperature) to rupture the cells and liberate intracellular enzymes.
5. A BALF cell pellet lysate. 100ml BALF, with a high mast cell ratio (22%), which had been
collected from a control horse, was centrifuged at 500g for 5min at 4°C and the resultant
pellet subjected to three freeze thaw cycles to liberate intracellular enzymes.
TRYPTASE ASSAY
A commercial human tryptase RIA kit, capable of measuring tryptase within the range 2-
50U/1 (Pharmacia Tryptase RIACT, Pharmacia, Uppsala, Sweden), was used according to the
manufacturers' instructions. The 5 samples were assayed in duplicate.




While a satisfactory standard curve was obtained using the human tryptase standards
provided in the RIA kit, assay of the equine samples yielded negative results.
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DISCUSSION
Attempted assay of human tryptase using a commercial RIA kit was unsuccessful. This was
likely to be due to lack of antigenic cross reactivity between equine tryptase and the 2 anti
human tryptase monoclonal antibodies employed in the kit. Alternatively the negative results
could indicate that the horse does not possess a homologue of human tryptase.
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CHAPTER 7
EVALUATION OF UREA AND ALBUMEN AS ENDOGENOUS MARKERS OF
DILUTION OF EQUINE BRONCHOALVEOLAR LAVAGE FLUID
SUMMARY
Bronchoalveolar lavage fluid (BALF) is comprised of lavage fluid and pulmonary epithelial
lining fluid (PELF) in variable proportions. Quantitative comparisons of the cellular and
molecular components in different BALF samples are thus valid only if the proportions of
PELF in the BALF samples are standardised. Two BALF standardisation techniques, namely
the urea and albumen dilution techniques, were evaluated in the horse.
Four BALF samples, from the left and right diaphragmatic lobes, the accessory lobe of the
right lung and the apical lobe of the left lung, and plasma were collected from 7 control
horses. The concentrations of urea and albumen in these samples were determined and the
plasma:BALF urea and albumen ratios calculated. The products of these ratios and the BALF
cell counts yielded the urea adjusted BALF cell counts, which were taken to be the PELF cell
counts, and the albumen adjusted BALF cell counts, respectively.
The PELF cell counts calculated for the 4 lung lobes of individual horse showed less
variation than the albumen adjusted BALF cell total counts. Assuming that PELF cell counts
are uniform throughout the lung, the urea dilution technique appears to be the more accurate
BALF standardisation technique.
BALF contained 0.4% PELF (range 0.1-1.0%), as determined by the urea dilution technique.
Albumen adjusted BALF cell counts were significantly higher than PELF cell counts.
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INTRODUCTION
Bronchoalveolar lavage (BAL), a simple and safe technique for collecting cellular and
molecular components from the lung, facilitates qualitative studies of these components.
However, quantitative comparison of cellular and molecular components in different
bronchoalveolar lavage (BALF) samples may not be valid, as the concentration of these
components in BALF depends not only on their concentrations in pulmonary epithelial lining
fluid (PELF), but also on the proportion of PELF in each BALF sample. The latter is variable
and may be affected by the composition and volume of the lavage fluid, the dwell time (i.e.
the time the BAL fluid is in contact with the pulmonary epithelium), the site of the lavage and
the presence of disease (Brain and Frank 1973; Pinsker et al 1980: Davis et al 1982; Pingleton
et al 1983; Dohn and Baughman 1985; Yam et al 1985; Rennard et al 1986; Pringle et al
1988; Sweeney et al In Press A).
To overcome the problem of variable PELF recovery which occurs during BAL, the
concentrations of BALF components are commonly compared to endogenous reference
substances, usually urea or albumen (Rennard et al 1986). Assuming that the plasma:PELF
ratios of urea and albumen are uniform throughout the lung and are identical in different
individuals, simultaneous determinations of either of these markers in plasma and in BALF
permit standardisation of the concentrations of PELF within BALF samples.
There are important differences between the 'urea and albumen dilution techniques'. Urea,
being a small molecule which diffuses readily throughout body fluids, is in equilibrium in
PELF and plasma (Rennard et al 1986). Thus, in addition to permitting standardisation of the
variable concentrations of PELF in BALF, the urea dilution technique can also be used to
determine the concentration of PELF in BALF samples, and hence to determine the
concentration of cells and molecules in PELF. As the alveolar membrane has reduced
permeability to the large albumen molecules, plasma albumen concentrations exceed those of
PELF (Rennard et al 1986). Thus, while the albumen dilution technique can be used to
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standardise the variable concentrations of PELF in BALF samples, it cannot be used to
determine the concentration of PELF in BALF samples.





Seven control (median age 16years, range 10-25; median body weight 593kg, range 500-652)
horses were used (Appendix 7.1).
SAMPLE COLLECTION AND PROCESSING
BALF samples, from the left and right diaphragmatic lobes, the accessory lobe of the right
lung and the apical lobe of the left lung and plasma samples were collected during a single
bronchoscopy session.
The samples were collected, processed and stored prior to assay as described in Chapter 2.
The total and differential BALF cell counts were determined as described in Chapter 2. The
plasma and BALF albumen and urea concentrations were determined as described below.
PLASMA AND BALF ALBUMEN DETERMINATIONS
The albumen concentrations of plasma and BALF supernatants were kindly determined,
using a radioimmunodiffusion (RID) assay, by Ms.P.Irving, Department of Veterinary
Clinical Studies, R(D)SVS.
Ten ul sample or purified equine albumen standard (Cohn Fraction V, Sigma, Poole, which
had been purified through Sephacryl S300, Pharmacia, Milton Keynes) was placed in 4mm
diameter wells in 3% agar (Difco, Detroit, USA) containing 0.06M barbital buffer pH 8.6
(Appendix 7.2) and the optimised concentration of anti-equine albumen (purified rabbit anti
equine albumen, prepared by Prof.R.E.W. Halliwell) and incubated at room temperature for
48h. The agar plates were then washed in phosphate buffered saline (pH 7.2) (PBS) for 48h
and in distilled water for 48h. After drying, the agar plates were stained with amido blue-black
(Appendix 7.2) until dark blue, then decolourised with 4 washes in 2% glacial acetic acid. The
diameters of the precipitin rings were determined using a magnifying lens and graticule
(Graticules Ltd., Tonbridge). The albumen concentrations of samples were determined using a
Page - 191
standard curve, plotted for each plate, which related the square of the precipitin diameter to
the albumen concentration of the standards. Samples were assayed in duplicate, using
different plates for each assay. Duplicates which varied by >10% were repeated.
PLASMA AND BALF UREA DETERMINATIONS
BALF supernatant urea concentrations were determined using a commercial enzymatic assay
kit (BUN Endpoint, Sigma, Poole), employing a modification of the technique of Rennard et
al (1986). Samples were processed and assayed immediately after thawing to room
temperature, to minimise bacterial degradation of urea. Prior to assay, BALF supernatants
were ultracentrifuged at 12000g for 5min (Maxifuge, Whitelcafe Scientific, Dulverton) to
remove precipitated matter which could affect optical density measurements. Reaction
mixtures of 2.08ml freshly prepared reagent and 0.42ml BALF supernatant or urea standard
were mixed by gentle inversion of the cuvette (Semi micro, BDH, Poole) and incubated at
room temperature for 5min. The absorbance was determined spectrophotometrically (CE 292,
Cecil Instruments, Cambridge) at 340nm using a 0.5cm light path. The mean absorbances of
duplicate samples were subtracted from the sum of the absorbance of a reagent blank (2.08ml
reagent and 0.42ml PBS) and that of a BALF supernatant blank (2.08ml PBS and 0.42ml
BALF supernatant) to yield the change in absorbance.
The urea concentration was determined from a standard curve prepared using a glucose/urea
nitrogen standard solution (Sigma, Poole).
Plasma urea concentrations were kindly determined by the Clinical Diagnostic Laboratory,
R(D)SVS using a Technicon RAXT (Technicon, Dublin).
DETERMINATION OF PELF CONCENTRATION OF BALF SAMPLES
Assuming that urea, being a small freely diffusible molecule, is present in equal
concentrations in plasma and in PELF, the concentration of PELF in BALF samples can be
determined by the 'urea dilution technique' (Rennard et al 1986);
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PELF concentration of BALF (%) = 100 x BALF urea concentration (mg/dl) / plasma
urea concentration (mg/dl)
DETERMINATION OF TOTAL AND ABSOLUTE PELF CELL COUNTS
These were calculated by the urea dilution technique;
Total PELF cell count (xltP/ul) = Total BALF cell count (xltP/ul) x plasma urea
concentration / BALF urea concentration.
Absolute PELF cell count (xlO^/ul) = Absolute BALF cell count (xHp/ul) x plasma urea
concentration / BALF urea concentration.
DETERMINATION OF ALBUMEN ADJUSTED TOTAL AND ABSOLUTE BALF CELL
COUNTS
As the PELF and plasma albumen concentrations are not equal (Rennard et al 1986), the
albumen dilution technique cannot be used directly to determine PELF cell counts. However
the variable dilution of BALF samples may be standardised by determining the 'albumen
adjusted BALF cell count', using the albumen dilution technique;
Albumen adjusted total BALF cell count (xl(P/ul) = Total BALF cell count (xHp/ul) x
plasma albumen concentration / BALF albumen concentration.
Albumen adjusted absolute BALF cell count (xl(P/ul) = Absolute BALF cell count
(xlO^/ul) x plasma albumen concentration / BALF albumen concentration.
STATISTICAL ANALYSIS
Plasma and BALF urea and albumen concentrations, which were not normally distributed,
were analysed by non parametric techniques. Paired and unpaired data were compared using
the Wilcoxon Rank and Mann Whitney tests respectively.
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RESULTS
Plasma urea (median 23.6mg/dl, range 18.2-31.8; Table 7.1, Appendix 7.3) and albumen
concentrations (median 22.8mg/ml, range 20.4-25.7; Table 7.1, Appendix 7.4) were within the
working ranges of the assays.
Table 7.1. Concentrations of albumen (mg/ml) and urea (mg/dl) in plasma and in BALF,
recovered from the diaphragmatic lobe of the right (RD) and left (LD) lungs, the accessory
lobe of the right lung (RA) and the apical lobe of the left lung (LA), of 7 control horses
(median and range).
UREA ALBUMEN
PLASMA 23.6(18.2-31.8) 22.8 (20.4-25.7)
RD 0.105 (0.042-0.147) 0.0675 (0.0429-0.1047)
RA 0.170 (0.058-0.246) 0.0970 (0.0747-0.1620)
LD 0.089 (0.056-0.333) 0.0834 (0.0562-0.1216)
LA 0.106 (0.024-0.330) 0.0803 (0.0029-0.0097)
All BALF samples contained urea concentrations (median 0.109mg/dl, range 0.024-0.333;
Table 7.1, Appendix 7.3) within the linear range of the assay (0.04-1 mg/dl). Interassay
coefficients of variation for urea determination of BALF samples with low (median 0.079
mg/dl) and high (median 0.581 mg/dl) urea concentrations, based on 5 repeated duplicate
assays, were 6.1% and 12.8% respectively. Intraassay coefficient of variation for urea
determination in BALF, based on 10 repeated duplicate assays, was 1.6%.
All BALF samples contained albumen concentrations (median 82.3ug/ml, range 29.0-162.0;
Table 7.1, Appendix 7.4) within the working range of the assay. Duplicate determinations did
not vary by >10%.
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BALF samples were shown, by the urea dilution technique, to contain on average 0.4% PELF
(range 0.1-1.0%).
The total and differential BALF cell counts, which were used to calculate the total and
absolute PELF cell counts and the albumen adjusted total and absolute BALF cell counts, are
given in Table 7.2 and Appendices 7.5 and 7.6.
The total PELF cell counts (Table 7.3, Appendix 7.7) were significantly lower (p<0.01) than
the albumen adjusted total BALF cell counts (Table 7.4, Appendix 7.8), on average by 1.2
fold (range 0.6-2.7).
The total and absolute (Appendix 7.9) PELF cell counts calculated for the 4 lung segments of
individual horses showed less variation than the albumen adjusted total and absolute
(Appendix 7.10) BALF cell total counts.
Table 7.2 Total BALF cell counts (/ul) and BALF cell ratios for the diaphragmatic lobe of the
right (RD) and left (LD) lungs, the accessory lobe of the right lung (RA) and the apical lobe of
the left lung (LA) of control (n=7) horses (median and range).
CELL RD RA LD LA
TOTAL 90 150 80 105
(50-140) (65-280) (35-200) (25-130)
NEUT 1.0 1.3 1.3 3.0
(0.7-4.0) (0.7-4.0) (0.0-2.3) (0.7-4.3)
LYM 39.7 23.0 24.3 28.7
(20.0-51.3) (16.0-47.0) (17.0-56.7) (16.3-52.7)
MAC 49.7 63.3 61.7 60.7
(36.0-74.3) (42.7-73.7) (29.3-75.7) (35.7-78.0)
EOS 0.0 0.0 0.0 0.0
(0.0-0.7) (0.0-0.7) (0.0-0.7) (0.0-2.3)
MAST 9.3 6.3 8.0 4.0
(0.3-10.7) (2.0-18.7) (3.3-13.7) (1.0-13.7)
BAS 0.3 0.3 0.0 0.3
(0.0-2.3) (0.0-1.3) (0.0-1.0) (0.0-4.0)
TOTBAS 9.3 6.3 8.0 5.7
(0.7-12.3) (2.3-19.0) (4.3-13.7) (2.0-14.0)
EP 0.3 0.7 1.0 0.7
(0.0-1.7) (0.0-2.7) (0.0-3.3) (0.0-2.0)
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Table 7.3 Total and absolute PELF cell counts (xl(P/ul) for the diaphragmatic lobe of the
right (RD) and left (LD) lungs, the accessory lobe of the right lung (RA) and the apical lobe of
the left lung (LA) of control (n=7) horses (median and range).
CELL RD RA LD LA
TOTAL 18.9 26.5 19.1 24.9
(14.2-36.8) (12.7-36.2) (14.0-27.1) (12.5-30.3)
NEUT 0.2 0.4 0.2 0.4
(0.1-1.5) (0.1-1.0) (0.0-0.5) (0.1-1.3)
LYM 7.3 5.8 6.3 7.6
(4.3-12.9) (3.5-12.4) (3.1-13.5) (2.0-13.2)
MAC 12.8 13.9 13.8 9.8
(5.4-27.3) (6.5-26.5) (5.1-16.7) (5.7-20.0)
EOS 0.0 0.0 0.0 0.0
(0.0-0.2) (0.0-0.2) (0.0-0.1) (0.0-0.6)
MAST 1.5 1.3 1.1 0.7
(0.1-3.0) (0.4-4.1) (0.7-3.3) (0.1-2.1)
BAS 0.1 0.1 0.0 0.0
(0.0-0.3) (0.0-0.3) (0.0-0.2) (0.0-1.1)
TOTBAS 1.8 1.7 1.1 1.7
(0.3-3.0) (0.4-4.2) (1.0-3.3) (0.3-2.2)
EP 0.1 0.2 0.2 0.1
(0.0-0.3) (0.0-0.8) (0.0-0.8) (0.0-0.6)
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Table 7.4 Albumen adjusted total and absolute BALF cell counts (xlO^/ul) for the
diaphragmatic lobe of the right (RD) and left (LD) lungs, the accessory lobe of the right lung
(RA) and the apical lobe of the left lung (LA) of control (n=7) horses.
CELL RD RA LD LA
TOTAL 26.6 34.3 23.5 39.5
(21.7-38.0) (19.0-51.8) (15.7-52.4) (17.6-35.8)
NEUT 0.3 0.5 0.3 0.9
(0.2-1.5) (0.2-1.4) (0.0-1.2) (0.2-1.5)
LYM 10.8 8.3 7.0 8.3
(4.4-13.6) (6.1-10.3) (2.7-17.5) (4.8-18.5)
MAC 13.8 23.3 11.9 16.2
(7.8-28.2) (8.1-32.8) (8.2-38.1) (7.9-23.6)
EOS 0.0 0.0 0.0 0.0
(0.0-0.2) (0.0-0.2) (0.0-0.2) (0.0-0.8)
MAST 2.1 1.6 1.9 1.3
(0.1-3.4) (0.7-9.7) (0.7-4.2) (0.3-3.1)
BAS 0.1 0.1 0.0 0.7
(0.0-0.5) (0.0-0.2) (0.0-0.4) (0.0-0.7)
TOTBAS 2.1 1.6 1.9 1.3
(0.3-3.9) (0.8-9.8) (0.9-4.2) (0.6-0.7)
EP 0.1 0.3 0.2 0.2
(0.0-0.5) (0.0-0.9) (0.0-0.9) (0.0-0.4)
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DISCUSSION
As BALF comprises variable proportions of lavage fluid and PELF, comparison of the
concentrations of molecules and cells in different BALF samples is only valid if the
concentrations of PELF in the samples are standardised. Two techniques to standardise the
concentration of PELF within BALF samples, namely the urea and albumen dilution
techniques (Rennard et al 1986), were evaluated in the horse.
Both the urea and albumen dilution techniques were shown to be suitable for standardising
the concentration of PELF within equine BALF samples. These techniques assume that the
plasma:PELF ratios of urea and albumen are uniform throughout the lung and are identical in
different horses.
Both techniques were employed to standardise the concentration of PELF within equine
BALF samples in other aspects of this study (Chapters 2, 5, 8 and 9). In all cases, within and
between group statistical comparisons of the BALF cellular and molecular components
yielded identical results, irregardless of whether the data were standardised using the urea or
albumen dilution techniques.
However, assuming that there is no regional inhomogcneity in the PELF cell counts of
individual horses, as the PELF cell counts calculated for the 4 lung lobes of individual horse
showed less variation than the albumen adjusted BALF cell total counts, the urea dilution
technique appears to be the more accurate technique for standardising the variable PELF
recovery in BALF samples.
The urea dilution technique was used to calculate the proportion of PELF in BALF samples
from control horses. This technique assumes that urea, being a small molecule (60 Daltons),
which diffuses readily throughout body fluids, is in equilibrium in equine PELF and plasma.
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This assumption has been confirmed by direct measurements of PELF urea concentrations in
foetal sheep (Adams et al 1963; Strang 1968). Equine BALF was shown to comprise 0.4%
PELF (range 0.1-1.0%). The proportions of PELF in human BALF have been determined
using the urea dilution technique (1.0+0.1%; Rennard et al 1986), using methylene blue as an
exogenous {vide infra) marker of dilution (10.7+6.8, range 2.3-21.1%; Baughman et al 1983)
and by a technique combining the use of urea as an endogenous marker of dilution and
methylene blue and technetium as exogenous markers of dilution (2.2%, range 0.7-2.5%;
Kelly et al 1988). The reason for the variation in these reported values is not known.
The albumen dilution technique may be used to standardise the variable concentration of
PELF in BALF, however, as plasma and PELF albumen concentrations are not in equilibrium
(Rennard et al 1986), it cannot be used to determine the concentrations of molecules and cells
in PELF. The alveolar membrane is considered to have properties similar to cell membranes
(Taylor et al 1965), with reduced permeability to larger molecules such as albumen
(60kDaltons) and plasma albumen concentrations exceed those of PELF. Albumen
concentrations of PELF obtained by direct collection from foetal lambs (Strang 1968) and
from rats (Reifenrath 1973) were, respectively, 3% and 13% that of plasma albumen
concentrations. In man the albumen concentration of PELF was calculated to be 8.8% that of
the plasma albumen concentrations. In contrast, in this study, the albumen adjusted total
BALF cell counts were on average 1.2 fold higher than the total PELF cell counts, suggesting
that in the horse the concentration of albumen in plasma is, only, on average 1.2 fold higher
than that in PELF. As it is unlikely that the permeability of the alveolar membrane of normal
horses to albumen differs considerably from that reported for man (Rennard et al 1986), foetal
lambs (Strang 1968) and rats (Reifenrath 1973), it is likely that the BALF albumen
concentrations reported in the present study are overestimations. The finding that the median
BALF albumen concentration of control horses (82.3ug/ml, range 29.0-162.0) was higher than
those reported previously for the horse (64.5+ 8.3ug/ml; Robinson et al 1986) and for man
(34+2ug/ml; Rennard et al 1986) is consistent with this possibility. If this is the case, the
albumen adjusted total and absolute BALF cell counts reported are underestimations of their
actual values, although the magnitude of this error is likely to be uniform throughout the
study.
Unfortunately, potential problems limit the accuracy of both the albumen and the urea
dilution techniques.
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During BAL, large volumes of fluid rapidly cross the alveolar membrane, both from the
lavage fluid into the pulmonary interstitium and vice versa (Kelly et al 1988), with a net
movement of fluid from the pulmonary interstitium into the BALF. During human BAL,
approximately 60ml of the 180ml instilled fluid passed into the pulmonary circulation, while
approximately 105ml fluid passed from the circulation into BALF (Kelly et al 1988).
The rate of fluid transfer is related to the transmembrane differences in hydrostatic pressure,
which vary markedly during the injection and suction phases of BAL, and to the
transmembrane diffusion gradient, which is likely to be minimal when isotonic lavage fluids
are used (Kelly et al 1988).
Similarly, both urea and albumen diffuse passively from the pulmonary interstitium into
BALF during the BAL procedure (Rennard et al 1986; Marcy et al 1987). Consequently,
BALF contains urea and albumen derived from PELF and from the pulmonary interstitium,
the latter leading to overestimation of the volume of PELF recovered. The magnitude of this
error is greater for urea than for albumen, as the rate of diffusion is inversely proportional to
the molecular size. The magnitude of this error is also proportional to the duration the BALF
remains in contact with the pulmonary tissues, termed the 'dwell time'. In man, dwell times
lasting several minutes may result in equilibration of interstitial and BALF urea
concentrations (Sietsema et al 1986), while equilibration of the larger albumen molecules
would take considerably longer.
In this study, to minimise the diffusion of urea and albumen from the pulmonary interstitium
into the BALF, BALF was aspirated immediately after instillation, thus the dwell time was
always less than 45s. In man, BALF which was recovered immediately after instillation
contained urea which was derived mainly (>80%) from the PELF, rather than from the
pulmonary interstitium (Rennard et al 1986).
Further inaccuracies in the albumen dilution technique may follow alterations in the
plasma:PELF albumen ratio, a feature of lung diseases which are associated with increased
lung permeability (Rennard et aI 1986).
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Other endogenous markers of BALF dilution, including potassium and calcium, have been
used in man, but are generally considered to be less useful than the albumen and urea dilution
techniques (Davis et al 1982; Lam et al 1984).
Several exogenous markers of dilution, i.e. markers which are added to the lavage fluid prior
to BAL, have been used, but are not considered to be as useful as the urea and albumen
dilution techniques (Rennard et al 1986). The most commonly employed exogenous marker
technique, the methylene blue dilution technique, results in a greater overestimation in PELF
recovery than the urea technique, possibly due to loss of the dye by diffusion into the
pulmonary interstitium or by binding to cells within the lung (Baughman et al 1983).
Recently, a new 'rewash' lavage procedure, incorporating a radioactive tracer, was reported to
give more accurate estimations of PELF volume than the urea dilution technique (Peterson et
al 1990). However, as this technique utilises radioactive materials it was considered
unsuitable for the present study.
The median equine BALF urea concentration of 0.109mg/dl (range 0.024-0.333) was similar
to that reported for man (0.120+ lOmg/dl) (Rennard et al 1986). The median BALF albumen
concentration of control horses (82.3ug/ml, range 29.0-162.0) was unaccountably higher than
those reported previously for the horse (64.5+ 8.3ug/ml; Robinson et al 1986) and for man
(34+2ug/ml; Rennard et al 1986).
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CHAPTERS
COMPARISON OF CELLULAR AND MOLECULAR COMPONENTS OF
BRONCHOALVEOLAR LAVAGE FLUID (BALF) HARVESTED FROM
DIFFERENT SEGMENTS OF THE EQUINE LUNG
SUMMARY
A comparison was made of the cellular and molecular components of bronchoalveolar lavage
fluid (BALF) harvested from four different lung segments, namely the left and right
diaphragmatic lobes, the accessory lobe of the right lung and the apical lobe of the left lung,
of 7 control horses and 6 horses with symptomatic chronic obstructive pulmonary disease
(COPD).
Neither control nor symptomatic COPD affected horses showed significant regional
differences in BALF recovery volumes, total and differential BALF cell counts, albumen
adjusted total and absolute BALF cell counts, total and absolute pulmonary epithelial lining
fluid (PELF) cell counts, and BALF albumen and urea concentrations. This suggests that the
composition of PELF is uniform throughout the lungs of normal horses and horses with




Bronchoalveolar lavage (BAL) is a safe and relatively simple technique for harvesting
molecules and cells from the distal airways and alveoli. It has proved invaluable in the
investigation of equine pulmonary disease.
However, numerous different BAL techniques are currently being used in the horse, and
variations in methodology may affect the cellular and molecular components of the recovered
bronchoalveolar lavage fluid (BALF) (Sweeney and Beech 1991). Identification and
standardisation of the factors which affect BALF composition are thus prerequisites to
accurate comparison of BALF data from different laboratories.
In other species, BALF composition is affected by the type, pH and volume of the lavage
fluid (Brain and Frank 1973; Pinsker et al 1980: Davis et al 1982; Pingleton et al 1983; Dohn
and Baughman 1985; Yam et al 1985), the diameter of the collection instrument (Pringle et al
1988), the processing technique (Mordelet-Dambrine et al 1984) and the duration of storage
of BALF prior to processing (Costabcl et al 1988).
The site of BAL also affected the BALF volume and total BALF cell counts of healthy
humans (Pingleton et al 1983) and dogs (Carre et al 1985), although no regional differences in
their BALF cell ratios were demonstrated. Furthermore, humans with interstitial pulmonary
disease showed marked interlobar variation in their BALF cell counts (Nugent et al 1984;
Garcia et al 1986). These findings cast doubt on the common assumption that the cellular and
molecular components of a single BALF sample are always representative of those throughout
the lung.
In healthy calves, no significant difference was demonstrated in the cellular and protein
components of BALF harvested from the cranial and caudal lobes, although there was
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considerable variation in the concentrations of these parameters in BALF collected from the 2
lobes of individual calves (Pringle et al 1988).
In the normal horse, the volume of fluid used for BALs affected the total, absolute and
differential BALF cell counts (Sweeney et al In Press A). A large lavage volume (300ml)
yielded lower total BALF cell counts and lower BALF neutrophil, macrophage and
lymphocyte ratios than a small lavage volume (50ml).
No difference was demonstrated in the cell populations in BALF collected from the right and
left lungs of normal horses, with the exception of an unaccountably higher number of mast
cells in BALF collected from the left lung (Sweeney et al In Press A). In contrast, horses with
localised pulmonary diseases, including pneumonia and pleuropneumonia, may show regional
variations in BALF cytology (Rossier et al 1991). This regional variation may have clinical
diagnostic significance, as 'normal' BALF may be harvested for these horses if BAL is
inadvertently performed in a lung segment unaffected by the inflammatory process.
Consequently, BALF examination is of limited value in the diagnosis of localised pulmonary
conditions.
This study investigated whether there are regional differences in the cellular and molecular





Seven control (median age 16years, range 10-25; median body weight 593kg, range 500-652)
and 6 symptomatic COPD affected (median age 18.5years, range 6-25; median body weight
482kg, range 371-546) horses were used (Appendix 8.1). The criteria used to define control
and symptomatic COPD affected horses arc described in Chapter 2.
SAMPLE COLLECTION AND PROCESSING
Venous blood was collected by jugular venupuncturc, and the plasma harvested as described
in Chapter 2. BALF samples were collected, at a single bronchoscopy session, from the
diaphragmatic lobes of the right and left lungs, the accessory lobe of the right lung and the
apical lobe of the left lung, as described in Chapter 2.
Blood and BALF samples were processed, and the plasma and BALF urea and albumen
concentrations determined, as described in Chapters 2 and 7. Total and differential BALF cell
counts, albumen adjusted total and absolute BALF cell counts and total and absolute
pulmonary epithelial lining fluid (PELF) cell counts were determined as described in Chapters
2 and 7.
STATISTICAL ANALYSIS
The data, for the 4 lung segments, which were not normally distributed, were compared using
the Kruskal-Wallis test, performed using Minitab (Minitab Inc., Pennsylvania, USA). The
data for the control and the COPD affected horses were analysed separately.
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RESULTS
There were no significant regional differences in volume recovery (Table 8.1, Appendix 8.2),
total (Table 8.2, Appendix 8.3) and differential BALF cell counts (Table 8.3, Appendix 8.4),
albumen adjusted total (Table 8.4, Appendix 8.5) and absolute BALF cell counts (Table 8.5,
Appendix 8.6), total (Table 8.6, Appendix 8.7) and absolute PELF cell counts (Table 8.7,
Appendix 8.8), and albumen (Table 8.8, Appendix 8.9) and urea (Table 8.9, Appendix 8.10)
concentrations of BALF collected from the 4 different lung segments of either control or
COPD affected horses (p<0.05).
PELF total cell counts of control horses were significantly lower than albumen adjusted total
BALF cell counts (p<0.01), by on average by 1.2 fold (range 0.6-2.7). The 4 PELF cell counts
of individual horses showed less variation than the albumen adjusted total BALF cell counts.
Table 8.1. Volume (ml) of BALF recovered from the diaphragmatic lobe of the right (RD) and
left (LD) lungs, the accessory lobe of the right lung (RA) and the apical lobe of the left lung
(LA) of control (n=7) and COPD affected (n=6) horses (median and range).










Tabic 8.2. Total cell counts (/ul) of BALF recovered from the diaphragmatic lobe of the right
(RD) and left (LD) lungs, the accessory lobe of the right lung (RA) and the apical lobe of the
left lung (LA) of control (n=7) and COPD affected (n=6) horses (median and range).









Table 8.3 Cell ratios of BALF collected from the diaphragmatic lobe of the right (RD) and
left (LD) lungs, the accessory lobe of the right lung (RA) and the apical lobe of the left lung
(LA) of (A) control (n=7) and (B) COPD affected (n=6) horses (median and range).
(A) Control horses.
CELL RD RA LD LA
NEUT 1.0 1.3 1.3 3.0
(0.7-4.0) (0.7-4.0) (0.0-2.3) (0.7-4.3)
LYM 39.7 23.0 24.3 28.7
(20.0-51.3) (16.0-47.0) (17.0-56.7) (16.3-52.7)
MAC 49.7 63.3 61.7 60.7
(36.0-74.3) (42.7-73.7) (29.3-75.7) (35.7-78.0)
EOS 0.0 0.0 0.0 0.0
(0.0-0.7) (0.0-0.7) (0.0-0.7) (0.0-2.3)
MAST 9.3 6.3 8.0 4.0
(0.3-10.7) (2.0-18.7) (3.3-13.7) (1.0-13.7)
BAS 0.3 0.3 0.0 0.3
(0.0-2.3) (0.0-1.3) (0.0-1.0) (0.0-4.0)
TOTBAS 9.3 6.3 8.0 5.7
(0.7-12.3) (2.3-19.0) (4.3-13.7) (2.0-14.0)
EP 0.3 0.7 1.0 0.7
(0.0-1.7) (0.0-2.7) (0.0-3.3) (0.0-2.0)
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Table 8.3 (B) COPD affected horses.
CELL RD RA LD LA
NEUT 64.2 59.0 62.2 64.5
(5.7-94.3) (5.3-94.0) (5.0-89.3) (4.7-95.3)
LYM 22.2 15.9 6.9 14.0
(3.7-36.3) (5.3-41.3) (4.0-40.7) (2.7-26.7)
MAC 11.9 14.5 12.7 15.0
(1.7-57.3) (0.3-60.7) (3.0-82.3) (1.7-71.0)
EOS 0.0 0.3 0.0 0.0
(0.0-0.7) (0.0-0.7) (0.0-1.0) (0.0-1.0)
MAST 1.8 0.9 2.0 1.7
(0.0-4.3) (0.0-4.0) (0.3-4.0) (0.3-5.0)
BAS 0.0 0.0 0.0 0.0
(0.0-0.7) 90.0-0.3) (0.0-0.7) (0.0-1.3)
TOTBAS 2.2 1.0 8.0 1.7
(0.0-4.3) (0.0-4.0) (4.3-13.7) (0.3-5.0)
EP 0.0 0.0 1.0 0.2
(0.0-1.0) (0.0-1.3) (0.0-3.3) (0.0-1.3)
Table 8.4 Albumen adjusted total BALF cell counts (xlCp/ul) for the diaphragmatic lobe of
the right (RD) and left (LD) lungs, the accessory lobe of the right lung (RA) and the apical
lobe of the left lung (LA) of control (n=7) and COPD affected (n=6) horses.










Table 8.5 Albumen adjusted absolute BALF cell counts (xlO^/ul) for the diaphragmatic lobe
of the right (RD) and left (LD) lungs, the accessory lobe of the right lung (RA) and the apical
lobe of the left lung (LA) of (A) control (n=7) and (B) COPD affected (n=6) horses.
(A) Control horses.
CELL RD RA LD LA
NEUT 0.3 0.5 0.3 0.9
(0.2-1.5) (0.2-1.4) (0.0-1.2) (0.2-1.5)
LYM 10.8 8.3 7.0 8.3
(4.4-13.6) (6.1-10.3) (2.7-17.5) (4.8-18.5)
MAC 13.8 23.3 11.9 16.2
(7.8-28.2) (8.1-32.8) (8.2-38.1) (7.9-23.6)
EOS 0.0 0.0 0.0 0.0
(0.0-0.2) (0.0-0.2) (0.0-0.2) (0.0-0.8)
MAST 2.1 1.6 1.9 1.3
(0.1-3.4) (0.7-9.7) (0.7-4.2) (0.3-3.1)
BAS 0.1 0.1 0.0 0.7
(0.0-0.5) (0.0-0.2) (0.0-0.4) (0.0-0.7)
TOTBAS 2.1 1.6 1.9 1.3
(0.3-3.9) (0.8-9.8) (0.9-4.2) (0.6-0.7)
EP 0.1 0.3 0.2 0.2
(0.0-0.5) (0.0-0.9) (0.0-0.9) (0.0-0.4)
Table 8.5 (B) COPD affected horses.
CELL RD RA LD LA
NEUT 18.8 16.3 24.2 22.6
(3.0-40.0) (3.4-41.9) (1.7-52.0) (3.0-81.6)
LYM 6.4 5.4 4.0 9.8
(1.3-19.3) (1.5-23.6) (1.5-1919) (0.6-24.4)
MAC 2.9 3.5 5.8 9.6
(0.6-28.3) (0.1-36.1) (0.1-51.8) (0.4-44.6)
EOS 0.0 0.1 0.0 0.0
(0.0-0.1) (0.0-0.3) (0.2-0.3) (0.0-1.0)
MAST 0.4 0.4 0.7 0.9
(0.0-2.0) (0.0-0.8) (0.0-2.5) (0.1-3.0)
BAS 0.0 0.0 0.0 0.0
(0.0-0.4) (0.0-0.1) (0.2-0.3) (0.0-1.2)
TOTBAS 0.5 0.5 0.8 1.5
(0.0-2.0) (0.0-0.8) (0.2-2.8) (0.1-4.0)
EP 0.0 0.0 0.0 0.1
(0.0-0.5) (0.0-0.6) (0.0-0.2) (0.0-0.7)
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Table 8.6 Total PELF cell counts (xlO^/ul) for the diaphragmatic lobe of the right (RD) and
left (LD) lungs, the accessory lobe of the right lung (RA) and the apical lobe of the left lung
(LA) of control (n=7) and COPD affected (n=6) horses (median and range).










Table 8.7 PELF cell counts (xl(P/ul) for the diaphragmatic lobe of the right (RD) and left
(LD) lungs, the accessory lobe of the right lung (RA) and the apical lobe of the left lung (LA)
of (A) control (n=7) and (B) COPD affected (n=6) horses (median and range).
(A) Control horses.
CELL RD RA LD LA
NEUT 0.2 0.4 0.2 0.4
(0.1-1.5) (0.1-1.0) (0.0-0.5) (0.1-1.3)
LYM 7.3 5.8 6.3 7.6
(4.3-12.9) (3.5-12.4) (3.1-13.5) (2.0-13.2)
MAC 12.8 13.9 13.8 9.8
(5.4-27.3) (6.5-26.5) (5.1-16.7) (5.7-20.0)
EOS 0.0 0.0 0.0 0.0
(0.0-0.2) (0.0-0.2) (0.0-0.1) (0.0-0.6)
MAST 1.5 1.3 1.1 0.7
(0.1-3.0) (0.4-4.1) (0.7-3.3) (0.1-2.1)
BAS 0.1 0.1 0.0 0.0
(0.0-0.3) (0.0-0.3) (0.0-0.2) (0.0-1.1)
TOTBAS 1.8 1.7 1.1 1.7
(0.3-3.0) (0.4-4.2) (1.0-3.3) (0.3-2.2)
EP 0.1 0.2 0.2 0.1
(0.0-0.3) (0.0-0.8) (0.0-0.8) (0.0-0.6)
Table 8.7 (B) COPD affected horses.
CELL RD RA LD LA
NEUT 7.7 7.2 8.6 8.3
(1.7-16.4) (1.6-18.3) (1.0-15.0) (1.2-19.1)
LYM 3.5 2.5 1.6 0.1
(0.5-10.6) (0.6-11.0) (0.5-7.4) (0.3-5.7)
MAC 1.7 2.0 2.1 2.0
(0.3-15.6) (0.0-16.8) (0.5-23.6) (0.2-18.5)
EOS 0.0 0.0 0.0 0.0
(0.0-0.1) (0.0-0.1) (0.0-0.2) (0.0-0.2)
MAST 0.2 0.2 0.3 0.4
(0.0-1.1) (0.0-0.4) (0.0-1.1) (0.0-0.7)
BAS 0.0 0.0 0.0 0.0
(0.0-0.1) (0.0-0.0) (0.0-0.1) (0.0-0.3)
TOTBAS 0.3 0.2 0.4 0.4
(0.0-1.1) (0.0-0.4) (0.0-1.1) (0.0-0.9)
EP 0.0 0.0 0.0 0.0
(0.0-0.3) (0.0-0.3) (0.0-0.1) (0.0-0.2)
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Table 8.8 Albumen concentrations (ug/ml) of BALF recovered from the diaphragmatic lobe
of the right (RD) and left (LD) lungs, the accessory lobe of the right lung (RA) and the apical
lobe of the left lung (LA) of control (n=7) and COPD affected (n=6) horses (median and
range).









Table 8.9 Urea concentrations (ug/dl) of BALF recovered from the diaphragmatic lobe of the
right (RD) and left (LD) lungs, the accessory lobe of the right lung (RA) and the apical lobe of
the left lung (LA) of control (n==7) and COPD affected (n=6) horses (median and range).











This study tested the assumptions that (a) cellular and molecular components of PELF are
uniformly distributed throughout the lungs of healthy and symptomatic COPD affected horses
and (b) that a single BALF sample, collected from any lung segment, is representative of the
entire lung in these horses.
No significant regional variation was demonstrated in BALF and PELF cytology, or in BALF
albumen and urea concentrations of control and symptomatic COPD affected horses. Thus a
single BALF sample is representative of the entire lung of normal and symptomatic COPD
affected horses, and analysis of a single BALF sample, harvested from any lung segment,
appears to be adequate for the diagnosis and monitoring of equine COPD. These findings are
consistent with the observation that COPD is a generalised pulmonary condition (Nicholls
1978).
However, while no significant regional variation was demonstrated in the BALF and PELF
cytology of symptomatic COPD affected horses, considerable variation was noted in the
neutrophil ratios of the 4 BALF samples from individual symptomatic COPD affected horses.
Indeed, in 3 of the 6 symptomatic COPD affected horses, the maximum and minimum BALF
neutrophil ratios differed by more than 10%. This variation should be taken into consideration
when performing quantitative studies of BALF cytology in horses with symptomatic COPD.
The 4 total PELF cell counts of individual horses showed less variation than their 4 albumen
adjusted BALF total cell counts. Thus, assuming that the total PELF cell counts of individual
horses show regional homogeneity, the urea dilution technique would appear to be more
accurate than the albumen dilution technique for correcting for the variable PELF recovery
which occurs during BAL.
Page - 213
PELF cell counts were significantly lower than albumen adjusted BALF cell counts,
consistent with the finding that the plasma:PELF ratio for albumen is greater than that for urea
(Rennard et al 1986). This topic is discussed fully in Chapter 7.
Total and absolute PELF cell counts of control horses were similar to those reported
previously for normal horses (Robinson et al 1986) and for healthy humans (Rennard et al
1986) (Table 8.10). However, the PELF neutrophil ratio reported for 'normal horses' by
Robinson et al (1986), of approximately 12%, appears to be excessively high when compared
those reported for normal horses by the present study (median BALF neutrophil ratio 1.5%,
range 0.0-4.3%) and previous equine studies (4.7+1.16%, Viel, 1983; 6.2+5.0%, Mair et al
1987; 8.9+1.2%, Derksen et al 1989; 1.2+1.2% - 5.4+3.2%, Sweeney et al In Press A). It is
possible that some of the horses studied by Robinson et al (1986) suffered from COPD.
Table 8.10 PELF cell counts (xl0^/ul) reported for normal horses and humans (median and
range or mean+SE).
EQUINE EQUINE HUMAN
ROBINSON ET AL PRESENT STUDY RENNARD ET AL
CELL (1986) (1986)
TOTAL 15.5±2.7 21.7(12.5-36.8) 21.0±0.3
NEUT 1.8+1.4 0.3 (0.0-1.5) 0.2+0.0
MAC 6.8+0.9 12.7 (5.1-27.3) 17.0+0.3
LYM 5.0+1.1 6.9 (2.0-13.5) 4.0+0.4
EOS 0.5+0.5 0.0 (0.0-0.6) NR
MAST 0.7+0.3 1.2 (0.1-4.1) NR
BASO NR 0.1 (0.0-1.1) NR
TOTBAS NR 1.6 (0.3-4.2) NR
EP 0.8+0.2 0.1 (0.0-0.8) NR
NR = Not reported.
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CHAPTER 9
EVALUATION OF LOCAL ENDOBRONCHIAL ANTIGEN CHALLENGES IN THE
INVESTIGATION OF EQUINE CHRONIC OBSTRUCTIVE PULMONARY
DISEASE (COPD)
SUMMARY
Local transendoscopic endobronchial antigen challenge, which has proved to be a valuable
clinical and research technique in the study of human pulmonary hypersensitivity, was
evaluated in normal and asymptomatic chronic obstructive pulmonary disease (COPD)
affected horses.
Transendoscopic endobronchial challenges with phosphate buffered saline (PBS), 60ug/ml
and 600ug/ml Micropolyspora faeni extract (MF) and mouldy hay extract elicited neutrophilic
airway inflammatory responses in both control and asymptomatic COPD affected horses, as
determined by cytological examinations of bronchoalveolar lavage fluid (BALF) harvested
from the challenged lung segments.
Endobronchial challenges with 6()0ug/ml MF induced a significant BALF neutrophilia only
in horses with asymptomatic COPD, when compared with PBS challenges. However, as the
BALF neutrophil ratios of COPD affected horses after this MF challenge did not differ
significantly from those of control horses, this finding has little clinical diagnostic value. The
BALF neutrophilia induced in control and asymptomatic COPD affected horses by 60ug/ml
MF and mouldy hay extract challenges was not significantly different from that induced by
PBS challenge.
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Endoscopically visible bronchial changes were observed in a proportion of both control and
COPD affected horses within 5min and at 5h after PBS, MF and mouldy hay extract
challenges.
As local endobronchial challenges induced a non specific pulmonary neutrophilia in both
control and COPD affected horses and elicited endoscopically visible responses in a
proportion of horses from both groups, this technique is considered to be of limited value in
the investigation of equine COPD.
Page - 216
INTRODUCTION
Local endobronchial antigen challenge, a technique introduced by Metzger et al (1985A), has
yielded valuable information on the pathogenesis of human asthma (Metzger et al 1985B;
Metzger et al 1985C; Fick et al 1987; Metzger et al 1987; Casale et al 1987; Wenzel et al
1988). Transendoscopic instillation of minute quantities of appropriate allergens onto the
bronchial mucosa of human asthmatics was shown to induce, within several minutes,
endoscopically visible bronchial pallor, followed by hyperaemia, oedema and bronchial
narrowing (Casale et al 1987). Despite using 100 fold higher allergen concentrations, no
visible response was elicited in control subjects. Bronchoalveolar lavage (BAL) was then
performed at the challenge sites at various times post challenge, to harvest cellular and
molecular components of the inflammatory response for further characterisation.
This technique offers three potential advantages over conventional antigen inhalation
challenges, namely (a) a rapid visual response is obtained, (b) the presence of numerous
challenge sites within the lung permits challenge with several antigens or different
concentrations of antigen and the inclusion of simultaneous control challenges during a single
bronchoscopy, and (c) minute quantities of antigen, approximating those required for
intradermal antigen testing, are required, which is advantageous when challenge substances
are scarce, expensive or potentially toxic.
We report here an evaluation of local endobronchial antigen challenge as a tool for the




Seven control (median age lOyears, range 6-20; median body weight 531kg, range 500-652)
and 7 fully asymptomatic COPD affected (median age 20years, range 13-30; median body
weight 497kg, range 371-546) horses (Appendix 9.1), which had no evidence of pulmonary
disease according to criteria previously described (Chapter 2), were used. All horses were
maintained in a 'controlled environment' (Chapter 2), prior to and during all challenges.
ENDOBRONCHIAL CHALLENGE WITH HISTAMINE
One control horse and one asymptomatic COPD horse were given endobronchial challenges
with histamine under general anaesthesia which was induced by 10 mg/kg intravenous
thiopentone sodium (Intraval, RMB Animal Health, Dagenham) and maintained with a
halothane (Halothane M&B, RMB Animal Health, Dagenham) and oxygen mixture. During
bronchoscopy, gaseous anaesthesia was administered via a permanent tracheostomy in one
horse and via a nasal catheter in the other.
Horses were given incremental challenges with 5ml of solutions containing 10^ to lCT*
mg/ml histamine acid phosphate (BDH, Poole) in PBS pH 7.4 (Sigma, Poole) at 37°C,
administered transendoscopically (CF-1T10L, Olympus Optical Co., Japan) via an endoscopic
catheter (OD=2mm, ID=lmm; Lectrocath, Vygon, Ecoucn, France), each challenge being
performed in a different second or third generation bronchus. The challenge solution was
instilled with the catheter approximately 15cm beyond the tip of the endoscope. Care was
taken to avoid touching the challenge site with the endoscope or catheter, although this was
occasionally unavoidable. The bronchial response was visualised endoscopically for lOmin
and sequential photographs taken for later comparisons. Direct visualisation of the bronchi via
the eyepiece of the endoscope was found to be more useful than using the videoendoscope
monitor. Comparison of the subtle colour changes of bronchi at the challenge site with those
of unchallenged sites was useful.
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ENDOBRONCHIAL CHALLENGE WITH PBS AND M.FAENI EXTRACT
Control (n=7) and asymptomatic COPD affected (n-7) horses were given endobronchial
challenges under standing sedation (lOug/kg i/v detomidine, Domosedan, SmithKline
Beecham Animal Health, Tadworth and lOug/kg i/v butorphanol, Torbugesic, C-Vet, Bury
St.Edmunds). 10ml 0.2% xylocaine (Astra, King's Langley) was sprayed onto the tracheal
carina and major bronchi to minimise coughing.
Control endobronchial challenges, with 5ml PBS at 37°C, were performed in the right
diaphragmatic lobe bronchus and the challenge site was examined endoscopically for visible
changes for lOmin. A control bronchoalveolar lavage was then performed in the accessory
lobe of the right lung, as previously described (Chapter 2). Five hours later the horses were
sedated and the PBS challenge site was examined endoscopically, photographed, and
transendoscopically lavaged.
Three days later, under sedation, the horses were given endobronchial antigen challenges
with 5ml PBS containing 60ug/ml and 600ug/ml M.faeni extract (Greer Laboratories, Lenoir,
North Carolina, USA), instilled into the left diaphragmatic lobe bronchus and left apical lobe
bronchus respectively. Five hours later the horses were sedated and the challenge sites were
examined endoscopically, photographed and lavaged.
BALF was processed as described previously (Chapter 2) and the total and differential BALF
cell counts determined.
LOCAL ENDOBRONCHIAL CHALLENGE WITH MOULDY HAY EXTRACT
The hay used to prepare the mouldy hay extract had visible mould contamination, a mouldy
smell and contained large quantities of mould spores, forage mites and mite faeces, as
assessed microscopically. The hay was from a batch which had induced COPD in
asymptomatic COPD affected horses (Chapter 2). Thirteen grammes hay was incubated in
300ml PBS at room temperature for 12h with constant stirring, the resultant suspension then
being filtered through a 5um membrane (Metricel GA-1, Gelman Instruments, Ann Arbor,
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USA) and stored at -20°C. The protein nitrogen concentration of the extract, kindly
determined by Ms.R.Muirhead, R(D)SVS, using the Kjcldahl technique (Ministry of
Agriculture, Fisheries and Food 1973), was 1.5x1 (P PNU/ml.
Five control and fully 5 asymptomatic COPD affected horses, sedated with 200mg i/v
xylazine (Rompun, Bayer UK, Bury St.Edmunds), were given endobronchial challenges with
lml hay extract at 37°C, in a third generation bronchus in the accessory lobe of the right lung.
The challenge site was visualised endoscopically for 5min post challenge and photographed.
Five hours later the horses were sedated and the challenge site was examined endoscopically
and BALs were performed in the left diaphragmatic lobe bronchus and at the challenged site.
The total and differential BALF cell counts were determined.
STATISTICAL ANALYSES
As data were not normally distributed, paired and unpaired data were analysed using the
Wilcoxon Rank and the Mann Whitney tests respectively, with a 5% significance level.
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RESULTS
ENDOBRONCHIAL CHALLENGE WITH HISTAMINE
Local endobronchial challenge with 10"^ mg/ml histamine acid phosphate induced
endoscopically visible erythema and mild bronchial narrowing within 3min in both horses.
One minute after challenge with 10"^ mg/ml both horses had visible bronchial narrowing, by
2min the bronchi were diffusely erythematous, with obvious annular rugae and had froth
bubbling through their almost totally occluded lumina. These changes were localised to the
challenge sites. No visible responses were elicited by challenge with more dilute histamine
solutions.
Attempts to quantify the degree of bronchial constriction using a transendoscopic pressure
balloon and by measuring bronchial diameter using a transendoscopic telescopic umbrella
device were unsuccessful.
ENDOBRONCHIAL CHALLENGES WITH PBS AND M.FAENI EXTRACT
PBS challenge significantly increased (p<0.05) BALF neutrophil ratios from the prechallenge
values, in both control and COPD affected horses (median values 1.0% and 3.3% respectively,
to 11.0% and 8.0%, respectively) (Table 9.1, Appendix 9.2). In the COPD affected group,
BALF neutrophil ratios were significantly increased by challenge with 600ug/ml MF (median
36.0%), when compared with the PBS challenge (median 8.0%) (p<0.05). The BALF cell
ratios and total BALF cell counts of controls were not significantly different from those of
COPD affected horses before or after the challenges (Table 9.1, Appendix 9.3).
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Local hyperaemia was observed in one control horse at 4min after PBS challenge and in
another at 5min after challenges with 60ug/ml and 600ug/ml MF. Three COPD affected
horses had immediate local bronchial blanching followed by hyperaemia after 60ug/ml MF
challenge, with one of these also having visible luminal frothing within 4min of the 600ug/ml
MF challenge (Fig 9.1).
While no endoscopically visible bronchial changes were apparent at the sites of PBS or MF
challenges at 5h post challenge, all horses had marked local inflammation of the mucosa
which had been in contact with the endoscope.
ENDOBRONCHIAL CHALLENGE WITH MOULDY HAY EXTRACT
Five hours after mouldy hay challenge all control and COPD affected horses showed non
significantly increased BALF neutrophil ratios in the challenged segment (median 19.7% and
30.7%, respectively) when compared with the control segment in the contralateral lung
(median 7.7% and 8.3%, respectively) (Table 9.2, Appendix 9.4). BALF neutrophil ratios
were also non significantly higher in both the control and challenged sites when compared
with the prechallenge ratios (0.7% and 2.3%, respectively). The total BALF cell counts were
not significantly affected by the mouldy hay challenge (Table 9.2, Appendix 9.5).
While no endoscopically visible changes were observed within 5min of the challenges, 1
control and 3 COPD affected horses showed obvious inflammatory changes at 5h post
challenge, including bronchial narrowing, hyperacmia and accumulation of froth on the
bronchial walls. In one horse marked bronchial narrowing prevented passage of the endoscope
during the postchallenge BAL, which was consequently performed in an adjacent bronchus.
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Fig 9.1 Endoscopic photograph of third generation bronchus of an asymptomatic COPD
affected horse (A) before and (B) at 4min after endobronchial challenge with 5ml 600ug/ml
MF antigen extract. After challenge, the bronchus is markedly narrowed and blanched and has




Endobronchial challenges with PBS, MF extract and mouldy hay extract elicited a
neutrophilic pulmonary inflammatory response in both control and COPD affected horses, as
determined by cytological examination of BALF collected from the challenged segments. The
mouldy hay extract also induced a neutrophilic inflammatory response in the contralateral
lung.
Only horses with asymptomatic COPD showed a significant BALF neutrophilia after
challenges with 600ug/ml MF, when compared with PBS challenges. However, as the BALF
neutrophil ratios of COPD affected horses after this MF challenge were not significantly
different from those of control horses, this finding has little clinical diagnostic value.
These findings contrast with the nebulised PBS inhalation challenges, which were shown to
have no significant effect on the BALF cytology of control or COPD affected horses (Chapter
2). The findings also differ from the nebulised MF extract inhalation challenges and natural
exposure to hay and straw, which induced a statistically significant BALF neutrophilia in
horses with asymptomatic COPD, but not in controls (Chapter 2). Endobronchial challenges
with 5ml 600ug/ml MF (6x10'^ w/v) would have produced higher local bronchial antigen
concentrations than the previous MF inhalation challenges with 20ml 2.5x1 (C* w/v MF.
Antigen administered during endobronchial challenges is likely to have remained at the
challenge site or be transported proximally within the tracheobronchial tree by the
mucociliary clearance mechanisms, while the inhalation challenges, performed by
administering nebulised MF antigen via a face mask, would have produced a more uniform
pattern of antigen deposition throughout the entire respiratory tract.
As antigen inhalation challenges with excessive antigen concentrations (i.e. >10"^ w/v;
Spector 1989) induce false positive bronchial responses in normal humans (Townley et al
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1965; Cavanaugh et al 1977), endobronchial challenge with concentrations of MF greater than
6x10"^ w/v were not performed in this study.
Metzger et al (1987) elicited positive bronchial inflammatory responses in asthmatic humans
by endobronchial challenges with approximately 100 fold more dilute antigen preparations
than were required to elicit positive intradermal challenge responses. In the present study
endobronchial antigen challenges were performed using 6x10^ and 6x10^ w/v MF, while
the median minimal intradermal end point titres for MF for these horses were 1x10"^ w/v
(range 1/10*6 - 1x10*3) and 1x10*6 w/v (range 1x10*6 w/v - 1x10*3), for early and late phase
responses, respectively (Chapter 3).
Bacterial growth and subsequent endotoxin production, which could have occurred during the
preparation of the mouldy hay extract, may have affected the results of the mouldy hay extract
challenges, as endotoxins have been shown to elicit pulmonary disease in man and animals
(Pemis et al 1967; Cavagna et al 1969). However, it is likely that the mouldy hay contained
endotoxin prior to the preparation of the extract, due to bacterial growth which occurs after
baling and during storage (Lacey 1971). Endotoxins have been demonstrated in airborne dust
in stable environments which contain poorly saved hay and straw (Robinson,N.E., pers comm.)
and it is possible that they may also have a role in the aetiology of equine COPD.
It was concluded that, in the horse, local endobronchial challenges, even with PBS, induce a
non specific pulmonary neutrophilia. This is consistent with the finding that BAL, and in
some instances bronchoscopy alone, may elicit a transient pulmonary neutrophil influx in
horses (Sweeney et al In Press B), humans (von Essen et al 1991), monkeys (Kazmierowski et
al 1977; Krombach et al 1985; Haley et al 1989), dogs (Cohen and Batra 1980; Damiano et al
1980) and sheep (Weiss et al 1983). The extent of pulmonary neutrophilia observed in these
previous studies varied, being either diffuse or localised to the lavaged segment. In contrast to
these findings, Derksen et al (1987) demonstrated that three repeated BALs, performed in
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different segments within a 29h period, did not significantly affect BALF cytology of 3
ponies.
The pulmonary neutrophil influx induced in control and COPD affected horses by
endobronchial challenges greatly limits the use of this technique in the study of equine COPD,
a disease which is also characterised by pulmonary neutrophilia (Nicholls 1978; Derksen et al
1985B).
Endoscopically visible local bronchial changes were observed in a proportion of control and
COPD affected horses within 5min of challenge with PBS and MF and at 5h after challenge
with hay extract. Initial pallor, followed by hyperacmia, bronchial narrowing and an
accumulation of froth on the bronchial walls were noted. However, as these changes were not
observed consistently in COPD affected horses and were observed in a proportion of control
horses, the visible bronchial response appears to have little clinical diagnostic value.
Most subjects had endoscopically visible hyperacmia, pctcchiation and fibrin like exudation
in the trachea and major bronchi at 5h post challenge. As this was confined to the larger
airways which had been in contact with the endoscope, iatrogenic trauma was the likely cause.
Similar tracheal inflammation has been reported as a sequel to routine endotracheal intubation
in normal horses (Heath et al 1989).
While sedation and local anaesthesia of the carina and major bronchi minimised the marked
cough response, which would otherwise have been elicited by bronchoscopy and which would
have precluded the use of this technique, occasional coughing did occur during the
bronchoscopy.
In conclusion, local endobronchial challenges, as performed in this study, were associated
with several problems and appear to offer no advantage over conventional antigen inhalation
challenges in the investigation of equine pulmonary hypersensitivity.
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CHAPTER 10
PRELIMINARY OBSERVATIONS ON INHALATION AND INTRADERMAL
CHALLENGES OF NORMAL AND CHRONIC OBSTRUCTIVE PULMONARY
DISEASE (COPD) AFFECTED HORSES WITH OIL SEED RAPE
SUMMARY
Three different pulmonary challenges with oil seed rape (OSR), namely (a) exposure to a
field of flowering Brassica campestrus for 6 days, (b) inhalation challenge with freshly
collected Brassica napus pollens and (c) nebulised inhalation challenge with a commercial
B.napus pollen extract, were performed on asymptomatic and symptomatic chronic
obstructive pulmonary disease (COPD) affected horses and on control horses.
The challenges did not induce detectable pulmonary disease in control or asymptomatic
COPD affected horses, as determined by clinical and bronchoscopic examinations, and did not
significantly affect their pulmonary mechanics, arterial blood gas tensions, arterial pH and
bronchoalveolar lavage fluid (BALF) cytology.
However, inhalation challenges with fresh B.napus pollen and commercial B.napus pollen
extract exacerbated the pulmonary disease in some symptomatic COPD affected horses,
possibly due to non specific toxicity/bronchial hyperresponsiveness.
Intradermal testing using a commercial B.napus pollen extract suggested that none of the
horses was hypersensitive to this agent.
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INTRODUCTION
Over the last two decades there has been a massive EEC supported increase in the growing of
oil seed rape (OSR) in Britain, with the acreage increasing from 6,500 ha in 1968 to 300,000
ha in 1989. In Scotland the acreage has increased from 1,600 ha in 1982 to 42,000 ha in 1988
and subsequently remained at that level. Approximately 90% is winter sown Brassica napus
which flowers in the spring while the remainder is B. campestrus, sown in spring and
flowering in mid-summer.
Simultaneously there have been numerous reports in all branches of the media alleging a
relationship between the growing of OSR and diseases affecting man, including hay fever,
asthma, allergic rhinitis, headaches and dermatitis and affecting the horse, including
pulmonary dysfunction, dermatitis, parotid salivary gland swelling and the so called 'poor
performance syndrome'.
Mair and Lane (1990) also suggested that seasonal headshaking in horses, which is probably
a rhinitis, may be associated with OSR exposure. In addition, some clinical cases of summer
pasture associated obstructive pulmonary disease (SPAOPD) in Northern England and
Scotland have been found in proximity to OSR fields (Dixon and McGorum 1990A and
1990B). However, in view of the very widespread distribution of OSR throughout these areas,
i.e. covering 6% of arable land in Scotland, this observation is perhaps not surprising.
A large increase in the incidence of human asthma has been recorded in the last 15 years,
with inhalation of newly introduced pollens being one of the causal factors implicated (Hide
1990; Layzell 1991).
Colldahl (1954) reported the first case of human OSR hypersensitivity, manifested as
conjunctivitis, rhinitis and asthma, with positive responses to intradermal and nasal
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provocation testing with an OSR pollen extract. Satisfactory control was achieved with
hyposensitisation.
Bucur and Arner (1978) showed that 23% of 366 patients in southern Sweden suffering
bronchial asthma and other allergies had positive intradermal tests to OSR pollens, with 81%
of 54 of these patients showing positive conjunctival provocation tests with OSR pollens.
Meding (1985) reported a case of human contact dermatitis to mustard seed (B.nigra) which
also reacted to prick testing with B. napus.
Parrat et al (1990) demonstrated IgE antibodies to OSR in human sera. While 26.3% of sera
from patients, suffering mainly from atopy, in a rural area of central Scotland (Tayside) were
positive, only 7.8% of sera from patients in an urban area (Strathclyde) were positive. These
authors concluded that OSR was a new antigenic hazard to man and that it was one of the
most potent antigens described to date. However, the relationship between the noted OSR
sensitisation and clinical disease was not determined.
In contrast, Ninian et al (1990) studied 81 children from Northern Scotland with hay fever,
allergic rhinitis or asthma suspected by the referring general practitioners to be due to OSR,
and found that only 9% were mildly positive on intradermal testing to OSR antigen, whilst
over 50% were positive to the usual antigens implicated in these diseases, i.e. grass and tree
pollens, house dust, house dust mite and cat and dog hair. These authors concluded that OSR
was not a potent antigen in man, causing only mild and infrequent sensitisation.
OSR related disease could potentially arise from hypersensitivity and/or non specific toxic
responses to OSR pollens (pollenosis), volatile substances released from the crop, fungi
growing on the crop or to some of the numerous chemical insecticides and fungicides that are
sprayed on these crops.
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It is generally considered that OSR pollenosis is unlikely to account for the alleged OSR
related symptoms (Hannant 1988) as OSR is primarily a self pollinating plant producing small
numbers of large sticky pollens (Olsson 1960), which would be expected to travel only short
distances. Seaton, A. et al (pers comm. 1991) found only small numbers of airborne OSR
pollens adjacent to fields of OSR, in contrast to large numbers of fungal spores. Furthermore
the OSR pollen season is relatively short and does not appear to coincide with all the alleged
OSR related disease in the horse. However under certain circumstances the distribution of
OSR pollens may be more widespread. Parrat, D. et al (pers comm 1990), using portable
continuous pollens monitors worn by human volunteers, demonstrated that OSR pollens and
OSR pollen fragments were frequently isolated up to 1.7 km from OSR fields. Likewise OSR
pollens have been detected in pollen traps 15 km from the nearest known OSR fields,
(Caulton, E,,pers comm 1990).
It is possible that inhalation of smaller airborne grass pollens or fungal spores, which have a
more widespread distribution and arc produced over a longer period of time than OSR pollens,
may have caused the alleged OSR diseases in the horse and man.
Despite repeated fungicide applications, OSR plants are subject to fungal infection during the
flowering season, particularly by Alternaria brassicae and Botrytis cinerea and these fungi
have also been suggested as a possible cause of OSR related disease (Wilson, R., pers comm
1990).
It is possible that symptoms may result from exposure to one of the many volatile organic
compounds released from OSR (Seaton, A. et al, pers comm 1991). Tollsen and Bergstrom
(1988) identified, respectively, 21 and 16 volatile compounds in the headspaces of B.napus
and B.campestrus plants.
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Despite the anecdotal evidence, it is unclear if OSR causes any disease in the equine, either
by non specific toxic or hypersensitivity mechanisms. This study was performed to determine
whether OSR respiratory challenge, using a variety of antigens and challenge techniques,
caused respiratory changes in normal and in asymptomatic and symptomatic chronic
obstructive pulmonary disease (COPD) affected horses, as assessed by clinical,
bronchoscopic, pulmonary function and bronchoalveolar lavage fluid (BALF) cytological
examinations.
Symptomatic COPD affected horses were utilised to determine whether OSR could
exacerbate respiratory disease in horses with preexisting pulmonary inflammation.





Seven control (median age 15years, range 7-25; median body weight 593kg, range 212-652)
and 6 COPD affected (median age 18.5ycars, range 13-25; median body weight 469kg, range
371-546) horses were used (Appendix 10.1). The criteria used to define control and
symptomatic COPD affected horses are described in Chapter 2.
CHALLENGE PROCEDURE
All horses were maintained in a 'controlled environment' throughout the duration of the
challenges.
Horses were given three different OSR inhalation challenges according to the protocol
outlined in Fig. 10.1.
OSR FIELD CHALLENGE
The horses were confined in a 4 ha paddock directly adjacent to a 9 ha flowering B.
campestrus field for 6 days.
OSR POLLEN INHALATION CHALLENGE
B.napus pollens, laboriously collected within the previous 24h at the Scottish Crop Research
Institute, Invergowrie, were found to be too large to nebulise as a saline suspension. However
O.lg of pollen was effectively administered using a modified 'spinhaler' (Fisons,
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NEBULISED B.NAPUS POLLEN EXTRACT INHALATION CHALLENGE
Horses received nebulised (Ultra Neb 99, DeVilbliss Co., Somerset, USA) inhalation
challenges with 20ml phosphate buffered saline (PBS), containing lOmg commercial B.napus
pollen extract (Solupric, ALK, Denmark) which had been dialysed (dialysis tubing, Medicell,
London) twice, in 50ml and 100ml PBS, for 24h at 4°C and sterile filtered through a 0.8um
filter (Millipore, Buc, France). The aerosol was delivered via a face mask incorporating a one
way valve system to minimise aerosol loss during expiration (Fig. 2.1).
Previous control challenges with nebulised PBS had not induced clinical, bronchoscopic,
pulmonary mechanic, arterial blood gas or BALF cytological changes in these horses (Chapter
2).
ARTERIAL BLOOD GAS and pH ANALYSES
Carotid arterial blood samples were collected and analysed as previously described (Chapter
2).
PULMONARY MECHANICS TESTING
Respiratory rate, tidal volume, minute volume, mean maximum transthoracic pressure
change, dynamic compliance and total pulmonary resistance were determined immediately
before and after each challenge, as described in Chapter 2.
All horses were familiar with the pulmonary mechanics testing procedure.
COLLECTION OF BRONCHOALVEOLAR LAVAGE FLUID (BALF)
BALF was collected from all horses before and after the challenges, according to the protocol
outlined in Fig 10.1. Bronchoalveolar lavage (BAL) and BALF processing were performed as
previously described (Chapter 2). Differential cell count of 300 cells were performed on
Leishman's stained cytospin preparations (Chapter 2).
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INTRADERMAL TESTING
Twenty horses, including 8 which had been given experimental OSR inhalation challenges, as
described above, and 12 which had no known exposure to OSR, were intradermally tested
with a commercial extract of B.napus pollens (lOmg dry matter/ml in a solvent containing
50% glycerol, 2.5% NaCl and 1.25% NaHCOg; Solupric, ALK, Denmark), undiluted and
diluted to 10"*, 10"^ and 10"^ in sterile PBS diluent (Greer Laboratories, Lenoir, North
Carolina, USA). The positive and negative controls were, respectively, 0.01% histamine
phosphate in sterile PBS and PBS. Intradermal injections were administered and interpreted as
described previously (Chapter 3).
Ten horses, all of which had no known exposure to OSR, were also intradermally tested with
undiluted and 10"^, 10"^ and 10"^ dilutions of the same B.napus pollen extract, which had
been dialysed, as previously described, to remove low molecular weight irritants including
glycerol.
STATISTICAL ANALYSIS
The data for all three challenges was pooled for each group and the prechallenge and
postchallenge data for each group were compared. Arterial blood gas tensions and pH data
were normally distributed and were analysed by the paired T-test, while the other data, which
were not normally distributed, were analysed using the Wilcoxon Rank Test, with a
significance level of 5%.
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RESULTS
The challenges had no significant effect on any of the groups (Table 10.1, Appendix 10.2)
and none of the horses showed any other clinical signs such as headshaking, dermatitis or
parotid swelling.
No individual control or asymptomatic COPD affected horses developed any evidence of
respiratory disease following the challenges (Appendix 10.2).
Following the field challenge two symptomatic COPD affected horses showed improvements
in all parameters examined, while the other horse showed no improvement in BALF
neutrophil ratio (Fig. 10.2) or pulmonary mechanics.
With the fresh pollen challenge, while two of the three symptomatic COPD affected horses
showed reduced BALF neutrophil ratios (Fig. 10.2), one horse showed a markedly increased
BALF neutrophil ratio without concomitant deterioration in its pulmonary function.
Following B.napus pollen extract inhalation challenge all three symptomatic horses showed
increased BALF neutrophil ratios (Fig. 10.2) without detectable deterioration of their
pulmonary function.
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Fig. 10.2 BALF neutrophil ratios of (A) control horses, (B) asymptomatic COPD horses and
(C) symptomatic COPD affected horses, before (PRE) and after (POST) OSR challenges.
= OSR field challenge.
= fresh B.napus pollen challenge.
= B.napus pollen extract challenge.
INTRADERMAL TESTS
The intradermal test results obtained are presented in Table 10.2 and Appendix 10.3.
TABLE 10.2 The percentages of horses showing positive dermal reactions at 1.5 and 5h
following intradermal testing with dialysed and undialysed B.napus pollen extracts at Kp, 10"




10° 10"1 10"2 10"3
5 HOURS





85 80 10 0
0 0 0 0
90 75 10 0
80 10 0 0
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DISCUSSION
The field challenge was performed to reproduce exposure to OSR as occurs naturally. The
field used, however, contained B.campestrus which has been shown to release a slightly
different range of volatile substances than the more commonly encountered B.napus (Tollsten
and Bergstrom 1988). The significance of this difference on the outcome of the field challenge
is not known.
Freshly harvested B.napus pollens were used for the pollen inhalation challenge to minimise
potential losses of any volatile or unstable compounds associated with the pollens. Deposition
of pollen in the nasal cavity was observed, but the extent and depth of pulmonary deposition
was not determined. While the vast majority of panicles of this size arc deposited by
impaction within the nasal cavities and upper respiratory tract (Swift 1980), it is probable that
small numbers of whole pollens, pollen fragments or volatile or soluble OSR components
penetrated to the distal airways (Particle dynamics arc discussed further in Chapter 2).
It is likely that the field and fresh pollen inhalation challenges exposed the horses to the
volatile compounds released from OSR. while it is possible that they were absent from the
commercial OSR preparation. No details of its production were available.
For the B.napus pollen extract inhalation challenge 5x10"^ w/v antigen was used. In human
studies allergens are commonly administered in incremental doses from 10"° to lCT^ w/v
(Anon. 1980), challenge with the higher concentration being usually required to exclude
hypersensitivity (Salvaggio and Hcndrick 1989). In this study the possibility of positive
reactions being elicited by higher antigen concentrations cannot be ruled out.
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The OSR challenges did not elicit detectable non specific toxic or hypersensitivity pulmonary
responses in any control or asymptomatic COPD affected horses, suggesting that OSR is
unlikely to be a major cause of equine pulmonary disease.
As antigen challenges will only induce hypersensitivity phenomena in individuals previously
sensitised to that antigen, the absence of OSR hypersensitivity in these horses could indicate
either that they had no prior exposure to OSR, or that prior exposure had not induced
sensitisation. While the horses used had no known close contact with OSR fields during the
two years before the field challenge, exposure prior to this period could not be ruled out.
Indeed, as OSR cultivation is so widespread in central Scotland, all of these animals may have
been previously exposed to OSR antigens. The horses had their first known exposure to OSR
antigens during the field challenge and consequently may have become sensitised prior to the
two subsequent inhalation challenges.
While the challenges had no significant effect on symptomatic COPD affected horses, some
individual horses did show responses.
Exposure to a field of flowering B.campestrus for 6 days did not induce any detectable
exacerbation of pulmonary disease in the symptomatic COPD affected horses. Indeed partial
improvement in all clinical and laboratory parameters were noted in 2 of these 3 horses,
consistent with the improvement shown by symptomatic COPD affected horses when moved
to a hay and straw free environment (Thomson and McPherson 1983). Whilst the absence of
expected improvement in BALF cytology and pulmonary mechanics noted in the other horse
suggests it may have undergone pulmonary toxicity, individual variations in the rate of
remission could provide an alternative explanation.
Following fresh B.napus pollen inhalation, one symptomatic COPD affected horse showed a
marked increase in its BALF neutrophil ratio without a concomitant deterioration of its
pulmonary function. This response was considered to be due to non specific pulmonary
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toxicity/bronchial hyperresponsiveness rather than to hypersensitivity as this horse showed no
response to this challenge when asymptomatic. The other two symptomatic COPD affected
horses showed improvements which would be expected following housing in a hay and straw
free environment for 4 days prior to the challenge.
Following the nebulised B.napus extract challenge, all three symptomatic COPD affected
horses showed mildly increased BALF neutrophil ratios, without concomitant increased
pulmonary dysfunction. As two of these horses were unaffected by this challenge when
performed while they were asymptomatic, this response was considered to be due to non
specific pulmonary toxicity/bronchial hypcrresponsiveness rather than hypersensitivity.
Undialysed commercial B.napus pollen extract, undiluted and at 10"', induced numerous
positive early and late phase intradermal responses. These were considered to be false positive
responses due to non specific toxicity by glycerol (Slavin 1974) as they were markedly
reduced by double dialysis of the pollen extract.
The B.napus pollen extract used was formulated for human epicutaneous prick testing
(Nelson 1981), which is the preferred method of skin testing in man and which involves
making a needle prick or scratch in the skin to permit passive diffusion of topically applied
antigen into the superficial dermis. However, differences in the sensitivity of epicutaneous
and intradermal skin testing techniques render this OSR extract, which contains 50% glycerol
to stabilise the antigens, unsuitable for equine intradermal testing without prior dialysis. While
extracts containing 50% glycerol can be employed for epicutaneous testing in man, even 6%
glycerol causes a high incidence of false positive reactions when used intradermally (Lindblad
and Farr 1961).
Intradermal tests are more sensitive than epicutancous tests, but studies in man show that the
two techniques produce similar skin reactions only if the intradermal preparation is 1000
times more dilute (Voorhorst and van Kriekcn 1973). Thus intradermal testing using
preparations formulated for epicutancous testing which have been diluted to less than 10"^
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have been associated with positive reactions in humans with no history of allergic disease
(Lindblad and Farr 1961). It would thus be prudent to consider only the results obtained
following intradermal testing with the 10"^ dilution of the dialysed preparation. At this
concentration no positive responses were obtained, suggesting the horses were not
hypersensitive to the antigens present in this extract. Furthermore, as immediate cutaneous
responses have been shown in man to be correlated with in vitro measurement of allergen
specific IgE (Norman et al 1973; Lessof et al 1980), it could be concluded that sera from
these horses does not contain B.napus specific IgE.
These findings suggest that, while OSR exposure docs not appear to be a major cause of
equine respiratory disease, it appears to exacerbate pulmonary disease in some horses with
preexisting pulmonary disease such as COPD. No evidence of pulmonary or dermal
hypersensitivity to OSR was demonstrated, although as only a limited number of horses,
without histories suggestive of OSR related disease, were investigated in relatively short term
studies, the existence of individual horses with pulmonary hypersensitivity to OSR cannot be
ruled out. Performing similar challenges on horses with a history suggestive of alleged OSR
related diseases e.g. SPAOPD is thus warranted.
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APPENDIX 2.1 Description of horses used for antigen inhalation challenge study.
HORSE GROUP TYPE SEX AGE (y) WEIGHT (kg)
1 CONTROL CROSS MN 15 593
2 tt SHETLAND F 7 212
3 tt TB MN 19 643
4 tt CROSS F 16 561
5 tt CROSS F 10 515
6 tt TB MN 13 652
7
tt
TB MN 25 609
8 tt CROSS MN 20 500
9 COPD CROSS F 20 371
10 tt CROSS F 20 488
11 tt CROSS MN 13 501
12 tt CROSS MN 25 422
13 tt CROSS F 17 546
14 tt TB MN 13 537
15 ft TB MN 6 475
16 tt CROSS MN 14 450
F^female, MN= gelding, cross=crossbrcd, TB=Thoroughbred.
APPENDIX 2.2 Histochemical staining techniques employed.
TOLU1DINE BLUE STAIN
Cytospin preparations, prepared and fixed as described previously (Chapter 2), were stained
overnight in 0.5% toluidine blue (Sigma, Poole) in 0.7N HC1 at room temperature, washed
quickly in distilled water and air dried.
LEISHMAN'S STAIN
Cytospin preparations, prepared and fixed as described previously (Chapter 2), were covered
with one volume of Leishman's stain (Leishman's staining solution, BDH, Poole) and
incubated at room temperature for 4min. Two volumes of phosphate buffered saline (pH 6.8)
were then added and left for 12min. The preparations were washed well with tap water and air
dried.
GIEMSA STAIN
Cytospin preparations, prepared and fixed as described previously (Chapter 2), were stained
in 1:10 Giemsa stain (BDH, Poole), differentiated in distilled water for 5min, dehydrated in
isopropyl alcohol, cleared and mounted in neutral mountant.
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APPENDIX 2.4 Volume (ml) of BALF recovered by BAL from control (n=8) and COPD
affected (n=8) horses at 5h after inhalation challenges with PBS, AF, TV and MF and after
NCs.
CONTROL COPD
PBS AF TV MF NC PBS AF TV MF NC
1 114 130 48 75 145 52 78 92 68 120
2 67 72 135 80 122 63 98 130 113 180
3 105 100 114 53 129 44 88 84 76 43
4 83 104 124 106 79 71 40 73 54 44
5 37 135 125 85 38 29 112 144 91 140
6 162 41 64 103 150 103 71 69 85 39
7 91 95 89 98 141 27 160 132 109 132
8 147 104 135 127 150 106 102 91 102 110
APPENDIX 2.5 Total BALF cell counts (/ul) for control (n=8) and COPD affected (n=8)
horses at 5h following inhalation challenges with PBS, AF, TV and MF and after NC.
CONTROL COPD
PBS AF TV MF NC PBS AF TV MF NC
1 300 250 287 200 675 45 212 187 305 222
2 98 240 200 312 175 200 360 130 113 280
3 362 250 640 320 362 132 73 75 120 251
4 1125 212 112 200 212 175 80 220 250 520
5 237 387 262 400 787 75 275 240 290 2750
6 220 60 147 120 308 190 240 95 680 3737
8 168 270 220 143 425 138 133 230 123 463
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APPENDIX 2.8 Total PELF cell counts (xlO^/ul) for control (CONT) (n=8) and COPD
affected (n=8) horses after inhalation challenges with PBS, AF, TV and MF and after NC.
HORSE PBS AF TV MF NC
1 CONT 55.4 31.6 99.5 89.3 90.5
2 10.0 83.4 39.1 29.8 14.1
3 89.4 21.1 174.9 86.2 40.3
4 168.5 83.0 76.0 31.8 58.9
5 97.9 51.3 74.4 46.7 119.8
6 137.5 22.7 46.2 53.0 45.0
7 71.1 34.9 61.0 30.0 22.0
8 52.8 28.4 12.3 23.5 236.4
1 COPD 20.6 40.2 27.7 94.6 27.1
2 110.0 118.8 10.9 23.7 23.0
3 37.8 36.2 19.3 67.3 181.0
4 23.1 45.3 58.7 90.3 178.5
5 25.7 31.6 89.9 39.1 404.9
6 67.6 55.9 81.9 279.3 21.3
7 4.9 5.9 1.3 61.3 637.2
8 47.2 28.4 62.0 30.2 58.6
APPENDIX 2.9 Albumen adjusted total BALF cell counts (xlCp/ul) for control (CONT)
(n=8) and COPD affected (n=8) horses after inhalation challenges with PBS, AF, TV and MF
and after NC.
HORSE PBS AF TV MF NC
1 CONT 81.1 87.3 449.3 79.7 276.7
2 36.0 151.1 273.0 157.5 44.9
3 309.1 86.2 185.2 111.0 287.1
4 621.9 97.8 47.5 59.7 59.4
5 67.9 152.8 100.6 64.9 650.3
6 97.7 52.6 94.5 40.9 156.4
7 309.3 32.4 205.2 118.8 280.7
8 151.5 51.7 68.8 25.6 155.4
1 COPD 23.7 52.4 180.2 285.2 74.2
2 66.4 597.2 94.6 86.2 69.9
3 102.9 88.1 319.6 69.6 404.1
4 180.7 128.5 162.5 197.0 210.2
5 48.7 99.1 84.5 78.2 2125.3
6 219.3 60.0 70.3 92.2 1022.2
7 40.2 19.7 6.5 71.5 2059.0
8 132.6 55.0 126.9 79.9 397.2
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APPENDIX 2.10 BALF cell ratios for control horses (n=8) and COPD affected (n=8) horses
at 5h after inhalation challenges with PBS, AF, TV and MF and after NC.
(A) Control horses.
AIC NEUT LYM MAC EOS MAST BASO TOTBAS EP
1 PBS 0.0 22.3 70.3 0.0 6.3 0.3 6.7 0.7
2 II 0.0 48.0 42.3 1.3 6.7 0.0 6.7 1.7
3 »1 1.0 15.3 71.7 0.3 9.3 2.3 11.7 0.0
4 tl 1.3 26.0 66.0 0.0 6.7 0.0 6.7 0.0
5 It 4.3 20.7 63.3 0.7 11.0 0.0 11.0 0.0
6 t» 0.0 62.3 37.7 0.0 0.0 0.0 0.0 0.0
7 II 2.7 35.3 51.3 0.0 4.7 4.0 8.7 2.0
8 It 2.0 15.7 65.3 0.0 14.7 0.3 15.0 2.0
1 AF 1.3 30.0 60.7 0.0 8.0 0.0 8.0 0.0
2 it 1.0 25.3 68.0 0.3 4.3 1.0 5.3 0.0
3 it 4.0 34.0 53.3 2.3 6.3 0.0 6.3 0.0
4 it 3.0 20.0 72.0 0.0 3.0 0.0 3.0 2.0
5 it 5.0 52.0 34.0 0.0 6.0 3.0 9.0 0.0
6 tt 2.0 66.0 29.3 0.0 2.7 0.0 2.7 0.0
7 it 5.7 37.3 49.0 0.7 6.7 0.7 7.3 0.0
8 n 0.0 43.0 52.0 0.0 3.0 0.0 3.0 2.0
1 TV 11.3 32.0 48.0 0.7 8.0 0.0 8.0 0.0
2 ti 0.3 59.7 30.0 5.0 5.0 0.0 5.0 0.0
3 it 2.3 50.0 40.3 0.0 5.0 1.7 6.7 0.7
4 n 3.3 36.3 47.7 0.0 11.0 0.7 11.7 1.0
5 n 1.0 15.3 77.0 0.0 6.0 0.7 6.7 0.0
6 tt 33.7 35.3 27.3 0.0 1.7 0.0 1.7 2.0
7 it 4.3 20.3 70.7 0.0 4.3 0.3 4.7 0.3
8 II 0.7 24.0 51.7 0.0 21.0 0.3 21.3 2.3
1 MF 0.7 37.3 45.7 0.0 11.3 0.0 11.3 5.0
2 tt 0.3 60.0 30.0 4.3 5.0 0.3 5.3 0.0
3 ti 3.0 16.3 75.3 0.0 3.7 1.0 4.7 0.7
4 it 1.5 16.7 79.3 0.0 2.3 0.3 2.7 0.0
5 it 0.7 58.3 31.0 0.3 8.0 0.7 8.7 1.0
6 ti 0.3 43.0 51.0 0.0 4.0 0.0 4.0 1.7
7 ii 4.0 23.3 64.7 0.0 6.0 0.0 6.0 2.0
8 ii 1.3 19.3 57.7 0.0 20.7 0.3 21.0 0.7
1 NC 3.0 49.0 45.0 0.0 2.3 0.7 3.0 0.0
2 it 4.0 34.3 40.7 12.3 6.7 1.3 8.0 0.7
3 it 1.3 17.0 71.3 0.0 8.7 0.7 9.3 1.0
4 it 2.7 35.0 56.3 0.7 4.3 1.0 5.3 0.0
5 ti 3.0 32.7 58.7 0.3 4.3 1.0 5.3 0.0
6 it 0.3 48.7 47.7 1.0 2.3 0.0 2.3 0.0
7 it 3.0 33.3 56.0 0.0 7.7 0.0 7.7 0.0
8 ii 2.7 28.0 53.7 0.3 14.3 0.7 15.0 0.3
NEUT = neutrophils, LYM = lymphocytes, MAC = macrophages, EOS = eosinophils, MAST




(B) COPD affected horses.
AIC NEUT LYM MAC EOS MAST BASO TOTBAS EP
1 PBS 0.0 17.0 68.0 0.0 5.0 0.0 5.0 10.0
2 II 2.0 15.7 65.3 0.0 14.7 0.3 15.0 2.0
3 II 4.7 45.3 38.3 0.0 9.3 1.0 10.3 1.3
4 II 4.0 58.7 33.3 0.0 3.7 0.0 3.7 0.3
5 II 4.3 51.0 35.0 0.0 9.0 0.0 9.0 0.7
6 II 5.0 23.0 69.0 1.0 0.7 0.0 0.7 1.3
7 II 4.0 54.3 36.7 0.7 3.7 0.3 4.0 0.3
8 It 2.0 58.0 25.0 15.0 0.0 0.0 0.0 0.0
1 AF 2.0 47.3 47.0 0.0 3.7 0.0 3.7 0.0
2 it 29.3 28.7 38.3 0.0 3.7 0.0 3.7 0.0
3 n 6.3 38.0 44.7 0.0 9.3 0.0 9.3 1.7
4 II 7.3 41.7 34.3 0.0 6.3 0.7 7.0 9.7
5 n 6.3 50.3 34.0 0.0 7.7 0.3 8.0 1.3
6 it 14.7 21.3 62.7 0.0 1.3 0.0 1.3 0.0
7 it 36.0 27.0 34.0 0.0 3.0 0.0 3.0 0.0
8 n 7.0 51.7 35.7 0.0 5.7 0.0 5.7 0.0
1 TV 1.7 68.3 25.3 0.0 3.3 1.3 4.7 0.0
2 ii 9.7 33.3 48.0 0.0 9.0 0.0 9.0 0.0
3 ii 9.0 46.0 36.7 0.0 7.3 0.7 8.0 0.3
4 ti 1.7 67.3 25.0 0.3 4.0 1.7 5.7 0.7
5 ii 3.7 60.3 31.0 0.0 3.3 1.3 4.7 0.3
6 ii 9.0 42.0 43.7 0.0 3.0 0.0 3.0 2.3
7 ti 1.0 17.0 80.0 0.0 0.0 2.0 2.0 0.0
8 ii 19.0 46.0 31.3 0.3 2.0 0.0 2.0 1.3
1 MF 10.7 42.0 43.0 1.0 2.7 0.0 2.7 0.7
2 it 9.0 47.0 37.0 0.0 7.0 0.0 7.0 0.0
3 ii 27.7 29.0 33.3 0.0 0.0 7.0 7.0 3.0
4 n 4.0 48.7 34.7 1.0 6.0 1.0 7.0 4.7
5 ii 11.0 45.7 28.7 5.0 5.3 2.7 8.0 1.7
6 ti 18.0 38.0 43.3 0.0 0.7 0.0 0.7 0.0
7 ti 14.7 35.7 46.0 1.0 2.0 0.3 2.3 0.3
8 n 24.0 34.0 34.7 0.3 3.7 0.0 3.7 3.3
1 NC 10.3 38.7 44.3 1.3 3.7 0.0 3.7 1.7
2 19.0 30.0 45.3 0.0 5.3 0.0 5.3 0.3
3 n 36.0 30.0 29.7 0.0 3.3 0.3 3.7 0.7
4 ii 87.3 7.3 4.3 0.0 0.7 0.0 0.7 0.3
5 It 97.7 2.0 0.3 0.0 0.0 0.0 0.0 0.0
6 ii 54.7 22.0 23.3 0.0 0.0 0.0 0.0 0.0
7 it 93.0 4.7 1.7 0.0 0.3 0.3 0.7 0.0
8 ti 86.7 9.3 2.7 0.0 1.3 0.0 0.3 0.0
NEUT = neutrophils, LYM = lymphocytes, MAC = macrophages, EOS = eosinophils, MAST
= mast cells, BASO = basophiloid cells, TOTBAS = total basophilic cells, EP = epithelial
cells.
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APPENDIX 2.11 Absolute PELF cell counts (xltP/ul) for (A) control horses (n=8) and (B)
COPD affected (n-8) horses after inhalation challenges with PBS, AF, TV and MF and after
(A) Control horses.
AIC NEUT LYM MAC EOS MAST BASO TOTBAS EP
1 PBS 0.0 12.4 39.0 0.0 3.5 0.2 3.7 0.4
2 tt 0.0 4.8 4.2 0.1 0.7 0.0 0.7 0.2
3 tt 0.9 13.7 64.1 0.3 8.3 2.1 10.5 0.0
4 tt 2.2 43.8 111.2 0.0 11.3 0.0 11.3 0.0
5 tt 4.2 20.3 62.0 0.7 10.8 0.0 10.8 0.0
6 ft 0.0 85.7 51.8 0.0 0.0 0.0 0.0 0.0
7 tt 1.9 25.1 36.5 0.0 3.3 2.8 6.2 1.4
8 tt 1.1 8.3 34.5 0.0 7.8 0.2 7.9 1.1
1 AF 0.4 9.5 19.2 0.0 2.5 0.0 2.5 0.0
2 tt 0.8 21.1 56.7 0.3 3.6 0.8 4.4 0.0
3 tt 0.8 7.2 11.2 0.5 1.3 0.0 1.3 0.0
4 tt 2.5 16.6 59.8 0.0 2.5 0.0 2.5 1.7
5 tt 2.6 26.7 17.5 0.0 3.1 1.5 4.6 0.0
6 tt 0.5 15.0 6.7 0.0 0.6 0.0 0.6 0.0
7 tt 2.0 13.0 17.1 0.2 2.3 0.2 2.6 0.0
8 ft 0.0 12.2 14.7 0.0 0.9 0.0 0.9 0.6
1 TV 11.2 31.8 47.7 0.7 8.0 0.0 8.0 0.0
^
2 tt 0.1 23.3 11.7 2.0 2.0 0.0 2.0 0.0
3 tt 4.0 87.5 70.5 0.0 8.7 3.0 11.7 1.2
4 tt 2.5 27.6 36.3 0.0 8.4 0.5 8.9 0.8
5 tt 0.7 11.4 57.3 0.0 4.5 0.5 5.0 0.0
6 tt 15.6 16.3 12.6 0.0 0.8 0.0 0.8 0.9
7 tt 2.6 12.4 43.1 0.0 2.6 0.2 2.8 0.2
8 tt 0.1 2.9 6.3 0.0 2.6 0.0 2.6 0.3
1 MF 0.6 33.3 40.8 0.0 10.1 0.0 10.1 4.5
2 tt 0.1 17.9 8.9 1.3 1.5 0.1 1.6 0.0
3 tt 2.6 14.1 64.9 0.0 3.2 0.9 4.1 0.6
4 tt 0.5 5.3 25.2 0.0 0.7 0.1 0.8 0.0
5 tt 0.3 27.2 14.5 0.1 3.7 0.3 4.1 0.5
6 tt 0.2 22.8 27.0 0.0 2.1 0.0 2.1 0.9
7 tt 1.2 7.0 19.4 0.0 1.8 0.0 1.8 0.6
8 tt 0.3 4.5 13.5 0.0 4.9 0.1 4.9 0.2
1 NC 2.7 44.3 40.7 0.0 2.1 0.6 2.7 0.0
2 tt 0.6 4.8 5.7 1.7 0.9 0.2 1.1 0.1
3 tt 0.5 6.9 28.8 0.0 3.5 0.3 3.8 0.4
4 tt 1.6 20.6 33.2 0.4 2.5 0.6 3.1 0.0
5 tt 3.6 39.2 70.3 0.4 5.2 1.2 6.4 0.0
6 tt 0.1 21.9 21.5 0.5 1.0 0.0 1.0 0.0
7 tt 0.7 7.3 12.3 0.0 1.7 0.0 1.7 0.0
8 tt 6.4 66.2 127.0 0.7 33.8 1.7 35.5 0.7
NEUT = neutrophils, LYM = lymphocytes, MAC = macrophages, EOS = eosinophils, MAST




(B) COPD affected horses.
AIC NEUT LYM MAC EOS MAST BASO TOTBAS EP
1 PBS 0.0 3.5 14.0 0.0 1.0 0.0 1.0 2.1
2 it 2.2 17.3 71.8 0.0 16.2 0.3 16.5 2.2
3 tt 1.8 17.1 14.5 0.0 3.5 0.4 3.9 0.5
4
tt 0.9 13.5 7.7 0.0 0.9 0.0 0.9 0.1
5 tt 1.1 13.1 9.0 0.0 2.3 0.0 2.3 0.2
6
tt 3.4 15.6 46.7 0.7 0.5 0.0 0.5 0.9
7
tt 0.2 2.7 1.8 0.0 0.2 0.0 0.2 0.0
8 tt 0.9 27.4 11.8 7.1 0.0 0.0 0.0 0.0
1 AF 0.8 19.0 18.9 0.0 1.5 0.0 1.5 0.0
2
tt 34.8 34.1 45.5 0.0 4.4 0.0 4.4 0.0
3 tt 2.3 13.8 16.2 0.0 3.4 0.0 3.4 0.6
4
tt 3.3 18.9 15.5 0.0 2.9 0.3 3.2 4.4
5 tt 2.0 15.9 10.7 0.0 2.4 0.1 2.5 0.4
6
tt 8.2 11.9 35.1 0.0 0.7 0.0 0.7 0.0
7
tt 2.1 1.6 2.0 0.0 0.2 0.0 0.2 0.0
8 tt 2.0 14.7 10.1 0.0 1.6 0.0 1.6 0.0
1 TV 0.5 18.9 7.0 0.0 0.9 0.4 1.3 0.0
2 1.1 3.6 5.2 0.0 1.0 0.0 1.0 0.0
3 1.7 8.9 7.1 0.0 1.4 0.1 1.5 0.1
4 1.0 39.5 14.7 0.2 2.3 1.0 3.3 0.0
5 3.3 54.2 27.9 0.0 3.0 1.2 4.1 0.3
6 7.4 34.4 35.8 0.0 2.5 0.0 2.5 1.9
7 0.0 0.2 1.0 0.0 0.0 0.0 0.0 0.0
8 11.8 28.5 19.4 0.2 1.2 0.0 1.2 0.8
1 MF 10.1 39.7 40.7 0.9 2.6 0.0 2.6 0.7
2 tt 2.1 11.1 8.8 0.0 1.7 0.0 1.7 0.0
3 tt 18.5 19.5 22.5 0.0 0.0 4.7 4.7 2.0
4 tt 3.6 44.0 31.3 0.9 5.4 0.9 6.3 4.2
5 tt 4.3 17.9 11.2 2.0 2.1 1.1 3.1 0.7
6 tt 50.3 106.1 120.9 0.0 2.0 0.0 2.0 0.0
7
tt 9.0 21.9 28.2 0.6 1.2 0.2 1.4 0.2
8 tt 7.2 10.3 10.5 0.1 1.1 0.0 1.1 1.0
1 NC 2.8 10.5 12.0 0.4 1.0 0.0 1.0 0.5
2 tt 4.4 6.9 10.4 0.0 1.2 0.0 1.2 0.1
3
tt 65.1 54.3 53.7 0.0 6.0 0.5 6.5 1.3
4 tt 155.9 13.0 7.7 0.0 1.2 0.0 1.2 0.5
5 tt 395.5 8.1 1.2 0.0 0.0 0.0 0.0 0.0
6 tt 11.6 4.7 5.0 0.0 0.0 0.0 0.0 0.0
7
tt 592.6 29.9 10.8 0.0 1.9 1.9 3.8 0.0
8 tt 50.8 5.5 1.6 0.0 0.8 0.0 0.8 0.0
NEUT = neutrophils, LYM = lymphocytes, MAC = macrophages, EOS = eosinophils, MAST
= mast cells, BASO = basophiloid cells, TOTBAS = total basophilic cells, EP = epithelial
cells.
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APPENDIX 2.12 Albumen adjusted absolute BALF cell counts (xlCp/ul) for (A) control
horses (n=8) and (B) COPD affected (n=8) horses after inhalation challenges with PBS, AF
TV and MF and after NC.
(A) Control horses.
AIC NEUT LYM MAC EOS MAST BASO TOTBAS EP
1 PBS 0.0 18.1 57.0 0.0 5.1 0.2 5.4 0.6
2 0.0 17.3 15.2 0.5 2.4 0.0 2.4 0.6
3 3.1 47.3 221.6 0.9 28.7 7.1 36.2 0.0
4 ft 8.1 161.7 410.5 0.0 41.7 0.0 41.7 0.0
5 tt 2.9 14.1 43.0 0.5 7.5 0.0 7.5 0.0
6 ft 0.0 60.9 36.8 0.0 0.0 0.0 0.0 0.0
7 tt 8.4 109.2 158.7 0.0 14.5 12.4 26.9 6.2
8 tt 3.0 23.8 98.9 0.0 22.3 0.5 22.7 3.0
1 AF 1.1 26.2 53.0 0.0 7.0 0.0 7.0 0.0
2 tt 1.5 38.2 102.8 0.5 6.5 1.5 8.0 0.0
! 3 tt 3.4 29.3 46.0 2.0 5.4 0.0 5.4 0.0
5 4 tt 2.9 19.6 70.4 0.0 2.9 0.0 2.9 0.0
5 tt 7.6 79.5 52.0 0.0 9.2 4.6 13.8 0.0
6 tt 1.1 34.7 15.4 0.0 1.4 0.0 1.4 0.0
7 tt 1.8 12.1 15.9 0.2 2.2 0.2 2.4 0.0
8 tt 0.0 22.2 26.9 0.0 1.6 0.0 1.5 1.0
1 TV 50.8 143.8 215.7 3.1 35.9 0.0 35.9 0.0
2 tt 0.8 163.0 81.9 13.7 13.7 0.0 13.7 0.0
3 tt 4.3 92.6 74.6 0.0 9.3 3.1 12.4 1.3
4 tt 1.6 17.2 22.6 0.0 5.2 0.3 5.6 0.5
5 tt 1.0 15.4 77.5 0.0 6.0 0.7 6.7 0.0
6 tt 31.8 33.3 25.8 0.0 1.6 0.0 1.6 1.9
7 tt 8.8 41.7 145.1 0.0 8.8 0.6 9.4 0.6
8 tt 0.5 16.5 35.6 0.0 14.4 0.2 14.7 1.6
1 MF 0.6 29.7 36.4 0.0 9.0 0.0 9.0 4.0
2 tt 0.5 94.5 47.2 6.8 7.9 0.5 8.3 0.0
3 tt 3.3 18.1 83.6 0.0 4.1 1.1 4.2 0.8
4 tt 0.9 10.0 47.3 0.0 1.4 0.2 1.6 0.0
5 tt 0.5 37.8 20.1 0.2 5.2 0.5 5.6 0.6
6 tt 0.1 17.6 20.8 0.0 1.6 0.0 1.6 0.7
7 ft 4.8 27.7 76.8 0.0 7.1 0.0 7.1 2.4
8 tt 0.3 4.9 14.8 0.0 5.3 0.1 5.4 0.2
1 NC 8.3 135.6 124.5 0.0 6.4 1.9 8.3 0.0
2 " 1.8 15.4 18.3 5.5 3.0 0.6 3.6 0.4
3 " 3.7 48.8 204.7 0.0 25.0 2.0 26.7 2.9
4 " 1.6 20.8 33.4 0.4 2.6 0.6 3.1 0.0
5 " 19.5 212.7 381.7 2.0 28.0 6.5 34.5 0.0
6 tt 0.5 76.2 74.6 1.6 3.6 0.0 3.6 0.0
7 " 8.4 93.5 157.2 0.0 21.6 0.0 21.6 0.0
8 tt 4.2 43.5 83.5 0.5 22.2 1.1 23.3 0.5
NEUT = neutrophils, LYM = lymphocytes, MAC = macrophages, EOS = eosinophils, MAST




(B) COPD affected horses.
AIC NEUT LYM MAC EOS MAST BASO TOTBAS EP
1 PBS 0.0 4.0 16.1 0.0 1.2 0.0 1.2 2.4
2 f i 1.3 10.4 43.4 0.0 9.8 0.2 10.0 1.3
3 tt 1.8 46.6 39.4 0.0 9.6 1.0 10.6 1.3
4 H 7.2 106.1 60.2 0.0 6.7 0.0 6.7 0.5
5 tt 2.1 24.9 17.1 0.0 4.4 0.0 4.4 0.3
6 tt 11.0 50.4 151.3 2.2 1.5 0.0 1.5 2.9
7 It 1.6 21.8 14.7 0.3 1.5 0.1 1.6 0.1
8 tt 2.7 76.9 33.2 19.9 0.0 0.0 0.0 0.0
1 AF 1.0 24.8 24.6 0.0 1.9 0.0 1.9 0.0
2 tt 175.0 171.4 228.7 0.0 22.1 0.0 22.1 0.0
3 tt 5.5 33.5 39.4 0.0 8.2 0.0 8.2 1.5
4 tt 9.4 53.6 44.1 0.0 8.1 0.9 9.0 12.5
5 tt 6.2 49.9 33.7 0.0 7.6 0.3 7.9 1.3
6 tt 8.8 12.8 37.6 0.0 0.8 0.0 0.8 0.0
7 tt 7.1 5.3 6.7 0.0 0.6 0.0 0.6 0.8
8 tt 3.9 28.5 19.6 0.0 3.1 0.0 3.1 0.0
1 TV 3.1 123.1 45.6 0.0 5.9 2.3 8.3 0.0
2 tt 9.2 31.5 45.4 0.0 8.5 0.0 8.5 0.0
3 tt 8.8 147.0 117.3 0.0 23.3 2.2 25.6 1.0
4 tt 2.8 109.4 40.6 0.5 6.5 2.8 9.3 0.0
5 tt 3.1 50.9 26.2 0.0 2.8 1.1 3.9 0.3
6 tt 6.3 29.5 30.7 0.0 2.1 0.0 2.1 1.6
7 tt 0.1 1.1 5.2 0.0 0.0 0.1 0.1 0.0
8 tt 24.1 58.4 39.7 0.4 2.5 0.0 2.5 1.6
1 MF 30.5 119.8 122.6 2.9 7.7 0.0 7.7 2.0
2 tt 7.8 40.5 31.9 0.0 6.0 0.0 6.0 0.0
3 tt 19.1 20.2 23.3 0.0 0.0 4.9 4.9 2.1
4 tt 7.9 95.9 68.4 2.0 1.8 2.0 13.8 9.3
5 tt 8.6 35.7 22.4 3.9 4.1 2.1 6.3 1.3
6 tt 16.6 35.0 39.9 0.0 0.6 0.0 0.6 0.0
7 tt 10.5 25.5 32.9 0.7 1.4 0.2 1.6 0.2
8 tt 19.2 27.2 27.7 0.2 3.0 0.0 3.0 2.6
1 NC 7.6 28.7 32.9 1.0 2.7 0.0 2.7 1.3
2 tt 13.3 21.0 31.7 0.0 3.7 0.0 3.7 0.2
3 tt 145.5 121.2 120.0 0.0 13.3 1.2 14.5 2.8
4 tt 183.5 15.3 9.0 0.0 1.5 0.0 1.5 0.6
5 tt 2076.4 42.5 6.4 0.0 0.0 0.0 0.0 0.0
6 tt 557.1 224.9 240.2 0.0 0.0 0.0 0.0 0.0
7 tt 1914.8 96.8 35.0 0.0 6.2 6.2 12.4 0.0
8 tt 344.4 36.9 10.7 0.0 5.2 0.0 5.2 0.0
NEUT = neutrophils, LYM = lymphocytes, MAC = macrophages, EOS = eosinophils, MAST
= mast cells, BASO = basophiloid cells, TOTBAS = total basophilic cells, EP = epithelial
cells.
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APPENDIX2.18Totalpulmonaryresistances(cmH20/l/ )for( )control(n=8andB)COPDaffect(n=8hors s,be ore(Oh)a dt








































































































































































































































































































APPENDIX2.19ArterialbloodC>2tensi ns(T r)for)co tr l(n=8)a dB)COPDaffecte(n=8hors ,before(Oh)a d1.5







































































































































































































































































































APPENDIX2.20ArterialbloodCO2tensions(T rr)fo )co tr l(n=8andB)COPDaffecte(n=8hors s,before(Oh)andt1.5














































































































































































































































































































































































































































































































































































































APPENDIX 4.1 Description of horses used for lymphocyte study.
HORSE GROUP TYPE SEX AGE (y) WEIGHT (kg)
1 CONTROL TB MN 24 615
2 tt CROSS MN 15 593
3 »t SHETLAND F 7 212
4 it TB MN 19 643
5 n TB MN 13 652
6 " CROSS F 20 500
1 COPD CROSS F 20 371
2 t! CROSS F 20 488
3 IT CROSS MN 13 501
4 It CROSS MN 25 422
5 It TB MN 13 537
6 II TB M 30 504
F=female, M=male, MN= gelding, Cross=crossbred, TB=Thoroughbred.
APPENDIX 4.2 Ratios of positively fluorescent gated PBL cells from (a) control (n=6) and
(b) COPD affected (n=6) horses, after control labelling with phosphate buffered saline (PBS),
normal mouse serum (NMS) and normal rat serum (NratS) and ratios of CD5+, CD8+, equine
class 1+ (CL1), MAC284+ (284+) and B cells, before (PRE) and at 72h after (POST) NC.
(a) Control horses.
PBA NMS CD5+ CD8+ NratS CL1+ 284+ B
1 PRE 2.0 2.9 69.3 33.8 2.3 90.5 68.8 34.0
2 2.9 2.5 70.1 29.1 3.2 96.6 77.5 14.6
3 1.8 4.3 59.5 19.6 1.0 87.8 43.8 36.0
4 2.0 1.9 56.1 24.3 2.3 98.9 53.7 21.1
5 1.3 1.6 70.0 41.1 1.7 91.3 85.8 40.9
6 0.9 2.2 81.8 23.8 0.7 94.6 68.0 22.4
1 POST 0.8 2.3 87.2 37.5 1.1 99.7 96.3 19.8
2 0.4 0.5 86.8 30.5 3.4 99.9 96.9 15.2
3 0.7 1.3 67.9 29.6 2.4 99.4 89.4 22.9
4 1.1 2.4 72.8 25.5 1.8 98.1 89.2 27.6
5 0.5 2.5 68.5 33.7 2.7 98.0 67.9 38.4
6 2.1 3.1 67.2 22.8 2.4 95.9 60.7 37.5
(b) COPD affected horses.
PBA NMS CD5+ CD8+ NratS CL1 + 284+ B
1 PRE 0.6 4.2 73.7 26.9 1.1 97.0 69.8 18.7
! 2 3.3 3.1 73.7 14.8 2.3 95.6 78.0 41.0
j 3 2.0 3.5 77.2 30.6 2.5 98.6 80.8 10.9
4 1.5 2.7 80.7 20.2 1.5 98.3 80.3 18.5
5 0.9 3.1 73.1 38.5 2.9 98.7 87.5 29.5
6 4.0 3.4 67.7 24.6 4.4 98.3 71.4 28.4
1 POST 0.2 0.9 76.3 20.3 1.2 95.7 58.9 19.6
2 0.4 1.6 82.9 18.7 3.8 94.3 77.1 11.8
3 3.7 2.5 59.0 29.4 3.6 93.4 52.8 39.7
4 0.4 0.7 76.7 43.0 0.8 99.1 95.9 25.3
5 0.5 3.1 68.2 40.1 4.7 90.3 77.7 28.8
6 0.9 2.3 89.0 41.3 3.9 86.2 73.5 5.6
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APPENDIX 4.3 Ratios of positively fluorescent gated BALF cells from (a) control (n=6)
and (b) COPD affected (n=6) horses after control labelling with phosphate buffered saline
(PBS), normal mouse serum (NMS) and normal rat serum (NratS) and ratios of CD5+, CD8+,
equine class 1+ (CL1), MAC284+ (284+) and B cells, before (PRE) and at 72h after (POST)
NC.
(a) Control horses.
PBA NMS CD5+ CD8+ NratS CL1+ 284+ B
1 PRE 0.4 5.1 59.5 33.0 1.3 64.7 59.3 3.5
2 tf 4.0 4.5 91.1 59.9 5.1 90.7 82.3 4.0
3 If 3.1 5.0 74.6 40.2 1.9 54.5 46.3 4.2
4 If 0.6 4.7 83.0 43.5 0.9 93.0 86.9 2.5
5 It 4.1 4.7 77.2 42.2 6.1 81.1 78.1 4.2
6 II 0.6 2.6 91.0 44.7 5.2 72.6 65.3 2.2
1 POST 1.1 1.8 89.2 42.4 1.9 96.7 91.5 3.9
2 " 1.2 1.1 88.0 45.5 5.1 96.7 93.6 1.9
3 it 0.2 1.1 83.8 45.2 3.5 97.6 91.4 5.3
4 ii 0.8 2.5 87.3 43.9 2.4 90.3 80.8 2.9
5 " 0.9 1.8 91.4 40.9 2.8 92.0 74.4 2.4
6 1.8 2.2 65.5 34.5 1.9 30.3 25.0 4.5
(b) COPD affected horses.
PBA NMS CD5+ CD8+ NratS CL1 + 284+ B
1 PRE 0.2 4.8 70.0 42.4 0.9 67.9 71.0 11.1
2 II 1.5 4.7 78.1 42.2 2.4 65.6 56.3 10.0
3 ti 1.2 0.1 62.3 41.3 1.6 47.6 56.3 7.3
4 II 1.8 3.4 66.6 43.7 3.7 48.5 32.0 9.8
5 II 2.8 0.6 76.6 45.6 4.6 94.7 83.4 12.7
6 n 3.6 4.5 57.1 43.1 5.1 47.6 47.5 8.9
1 POST 3.4 5.7 65.0 27.7 1.9 71.4 64.7 1.4
2 " 1.7 4.7 64.0 31.3 1.7 45.7 42.2 1.4
3 it 4.0 7.2 32.2 19.5 4.1 30.5 17.3 6.3
4 it 1.8 3.4 66.6 41.7 2.8 48.5 32.0 9.8
5 ti 1.5 5.7 29.3 15.1 3.3 48.3 48.0 3.6
6 n 1.3 1.2 84.7 42.6 1.9 87.5 72.3 3.4
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APPENDIX 4.4 Ratios of CD5+, CD8+, CD5+CD8- and B lymphocytes, expressed as ratios
of the total gated lymphocytes, in PB of control (CONT) (n=6) and COPD affected (n=6)
horses before (PRE) and at 72h post (POST) NC.
CONT CONT COPD COPD
mAb PRE POST PRE POST
1 CD5+ 67.1 81.5 79.8 79.6
2 tt 82.8 85.1 64.3 87.5
3 »» 62.3 74.8 87.6 59.8
4 tt 52.3 72.5 81.4 75.2
5 tt 63.1 64.1 71.2 70.3
6 tt 78.5 64.2 70.4 94.1
1 CD8+ 32.7 35.0 29.1 21.2
2 it 34.4 29.9 12.9 19.7
3 tt 20.5 32.6 34.7 29.8
4 tt 31.5 25.4 20.4 42.2
5 tt 37.1 31.5 37.5 41.3
6 tt 22.8 21.8 25.6 43.7
1 CD5+CD8- 34.4 46.4 50.6 58.4
2 tt 48.4 55.2 51.4 67.8
3 tt 41.8 42.2 52.9 30.0
4 tt 41.2 47.1 61.0 33.0
5 tt 26.1 32.6 33.7 29.0
6 tt 55.7 42.4 44.8 50.4
1 B CELL 32.9 18.5 20.2 20.4
2 tt 17.2 14.9 35.7 12.5
3 tt 37.7 25.2 12.4 40.2
4 tt 27.3 27.5 18.6 24.8
5 tt 36.9 35.9 28.8 29.7
6 tt 21.5 35.8 29.6 5.9
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APPENDIX 4.5 Ratios of CD5+, CD8+, CD5+CD8- and B lymphocytes, expressed as ratios
of the total gated lymphocytes, in BALF of control (CONT) (n=6) and COPD affected (n=6)
horses, before (PRE) and at 72h post (POST) NC.
CONT CONT COPD COPD
mAb PRE POST PRE POST
1 CD5+ 94.4 95.8 86.3 97.9
2 f ! 95.8 97.9 90.7 97.9
3 1! 94.7 94.1 89.5 83.6
4 " 97.1 96.8 87.2 87.2
5 II 94.8 97.4 85.8 89.1
6 97.6 93.6 86.5 96.1
1 CD8+ 52.4 45.5 52.3 41.7
2 ti 63.0 50.6 47.9 47.9
3 II 51.0 50.7 59.3 50.6
4 n 50.9 48.7 57.2 54.6
5 n 51.8 43.6 51.1 45.9
6 ♦i 48.0 49.3 65.3 48.4
1 CD5+CD8- 42.1 50.3 34.0 56.2
2 ii 32.8 47.3 40.7 50.0
3 ii 43.7 43.3 30.2 33.0
4 it 46.2 48.1 30.0 32.6
5 ii 43.0 53.8 34.7 43.2
6 n 49.7 44.3 21.2 47.8
1 B CELL 5.6 4.2 13.7 2.1
2 ii 4.2 2.1 11.4 2.1
3 ii 5.3 5.9 10.5 16.4
4 ii 2.9 3.2 12.8 12.8
5 " 5.2 2.6 14.2 10.9
6 ii 2.4 6.4 13.5 3.9
APPENDIX 5.1 Description of horses used for histamine study.
HORSE GROUP TYPE SEX AGE (y) WEIGHT (kg)
1 CONTROL CROSS MN 15 593
2 ii SHETLAND F 7 212
3 ii TB MN 19 643
4
ii CROSS F 16 561
5 ii CROSS F 10 515
6 " TB MN 13 652
7
ii
TB MN 25 609
8 ii CROSS MN 20 500
9 COPD CROSS F 20 371
10 ii CROSS F 20 488
11
n CROSS MN 13 501
12 ii CROSS MN 25 422
13 ii CROSS F 17 546
14 ii TB MN 13 537
15 n TB MN 6 475
16 ii CROSS MN 14 450
17
it DUTCH MN 8 642
F=female, MN= gelding, cross=crossbrcd, TB=Thoroughbred, DUTCH= Dutch Warmblood.
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APPENDIX 5.2 INVESTIGATION OF THE STABILITY OF EXOGENOUS HISTAMINE
DURING THE COLLECTION, PROCESSING AND STORAGE OF BALF
The stability of exogenous histamine during the collection, processing and storage of BALF
was investigated. Exogenous histamine, which had been instilled into the apical lobes of the
left lungs of 2 horses, was recovered by BAL, and the proportions remaining after collection,
processing and storage were determined.
BALF, recovered from the apical lobe following instillation of the exogenous histamine,
contained both the exogenous histamine which was instilled into the lung and 'endogenous,
PELF derived' histamine. Thus, to determine the proportion of exogenous histamine recovered
by BAL, the concentration of 'endogenous, PELF derived' histamine within the BALF had to
be calculated.
Assuming that the PELF histamine concentration in the left and right equine lungs are
identical, as has been reported for man (Rankin et al 1987), the 'endogenous, PELF derived'
histamine concentration of BALF recovered from the 'test site' can be determined by
quantifying histamine in BALF harvested from the opposite lung ('control site');
[Endogenous histamine] = [BALF urea (test site)] x [BALF histamine (control site)]
[BALF urea (control site)]
Subtraction of the 'endogenous, PELF derived histamine' concentration from the BALF
histamine concentration yielded the exogenous histamine concentration. This value was then
compared with the concentration of exogenous histamine present within the fluid which was
instilled into the lung to determine the proportion of histamine remaining after the collection,
processing and storage of BALF.
The calculation steps are shown on page 323.
REFERENCE
RANKIN,J.A., KALINER,M. and REYNOLDS,H.Y. (1987) Histamine levels in
bronchoalveolar lavage from patients with asthma, sarcoidosis and idiopathic pulmonary
fibrosis. J.Allergy Clin.Immunol. 79 371-377.
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APPENDIX 53 Plasma histamine concentrations (ng/ml) for control (n=8) and COPD
affected (n=8) horses at 0, 1.5 and 5h after NC.
CONTROL COPD AFFECTED
HORSE 0 1.5 5 0 1.5 5
1 0.27 0.38 0.29 0.26 0.39 0.54
2 0.11 0.15 0.27 0.23 0.48 0.26
3 0.24 0.48 0.18 0.11 0.13 0.10
4 0.34 0.27 0.35 0.16 0.38 0.26
5 0.57 0.64 0.07 0.18 0.16 0.16
6 0.21 0.33 0.38 0.10 0.20 0.19
7 0.07 0.19 0.08 0.17 0.17 0.12
8 0.24 0.48 0.18 0.11 0.12 0.06
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APPENDIX5.4Differentialandabsolu emetachr maticc l(MET)countsinBALFsamplefro( )8c trola d( )9COPDaffectehorses









































































































































































































































































































































































































































































































APPENDIX 5.5 PELF histamine concentrations (ng/ml) for control (n=8) and COPD
affected (n=9) horses at 0, 0.5 and 5h after NC.
CONTROL COPD AFFECTED
HORSE 0 0.5 5 0 0.5 5
1 31.27 651.35 64.87 187.73 174.63 104.93
2 40.42 353.36 81.25 7.00 118.12 441.03
3 202.18 103.23 105.10 35.16 385.63 794.97
4 435.86 150.61 658.16 95.48 256.31 245.59
5 424.08 244.53 336.07 90.44 62.84 171.10
6 105.96 1.14 250.78 4.63 777.27 4.88
7 305.36 515.93 187.21 430.05 143.52 1087.36
8 176.51 243.30 74.16 29.10 273.21 336.21
9 - - - 11.50 11.10 34.15
APPENDIX 5.6 Albumen adjusted B ALF histamine concentrations (ng/ml) for control
(n=8) and COPD affected (n=9) horses at 0, 0.5 and 5h after NC.
CONTROL COPD AFFECTED
HORSE 0 0.5 5 0 0.5 5
1 45.48 702.69 198.35 238.56 400.32 287.52
2 112.11 1119.76 259.36 16.44 322.29 1339.94
3 737.35 886.90 747.99 178.39 514.32 1775.35
4 1177.65 865.58 663.42 118.27 265.77 289.11
5 362.18 619.17 1823.92 64.64 241.04 898.16
6 107.65 7.52 871.68 62.73 779.60 115.94
7 703.02 1095.38 806.85 925.28 423.84 1996.08
8 265.21 315.35 48.75 125.07 598.75 2277.74
9 - - - 161.20 38.10 92.81
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APPENDIX 5.7 Concentrations of urea (mg/dl) in plasma and BALF from (A) 8 control
horses and (B) 9 COPD affected horses at 0, 0.5 and 5h after NC.
(A) CONTROL HORSES
PLASMA UREA BALF UREA
HORSE 0 0.5 5 0 0.5 5
1 24.8 36.1 29.9 0.076 0.144 0.223
2 25.9 30.1 33.6 0.071 0.260 0.418
3 29.1 22.0 23.4 0.236 0.096 0.210
4 24.1 30.3 22.5 0.147 0.315 0.081
5 26.8 19.8 30.3 0.101 0.175 0.199
6 19.8 18.6 33.9 0.067 0.044 0.232
7 32.5 21.5 29.7 0.205 0.088 0.320
8 42.2 30.4 35.6 0.557 0.215 0.064
(B) COPD AFFECTED HORSES
PLASMA UREA BALF UREA
HORSE 0 0.5 5 0 0.5 5
1 35.7 20.5 26.1 0.319 0.101 0.214
2 28.7 27.7 23.1 0.048 0.150 0.281
3 19.9 25.1 31.0 0.206 0.112 0.043
4 31.2 35.5 30.9 0.199 0.140 0.090
5 37.4 19.9 26.5 0.076 0.202 0.180
6 24.7 26.9 29.5 0.101 0.082 0.098
7 22.2 30.1 34.1 0.203 0.212 0.200
8 19.9 18.4 27.1 0.069 0.108 0.214
9 22.2 8.1 23.4 0.532 0.163 0.100
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APPENDIX 5.8 Concentrations of albumen in plasma (mg/ml) and BALF (ug/ml) from (A)
8 control and (B) 9 COPD affected horses at 0, 0.5 and 5h after NC.
(A) CONTROL HORSES
PLASMA ALBUMEN BALF ALBUMEN
HORSE 0 0.5 5 0 0.5 5
1 22.1 28.1 32.8 59.1 103.9 80.0
2 25.8 24.8 22.4 25.5 67.6 87.3
3 38.0 38.0 27.2 84.5 19.3 34.3
4 23.3 40.3 21.0 52.6 72.9 75.0
5 23.5 21.2 27.6 103.7 74.0 33.4
6 27.8 41.8 28.9 92.6 15.0 56.9
7 26.9 38.8 30.2 73.7 74.8 75.5
8 25.5 23.0 23.0 224.0 125.5 62.9
(B) COPD AFFECTED HORSES
PLASMA ALBUMEN BALF ALBUMEN
HORSE 0 0.5 5 0 0.5 5
1 15.8 18.1 26.0 111.1 38.9 77.8
2 30.6 26.1 26.2 21.8 51.8 104.9
3 29.8 21.7 32.2 60.8 72.6 20.0
4 20.1 23.9 29.1 103.5 90.9 72.0
5 19.1 19.5 33.0 54.3 51.6 42.7
6 18.9 20.4 38.6 5.7 62.0 5.4
7 30.4 30.4 40.0 129.2 72.5 127.8
8 20.7 23.0 31.4 16.7 61.6 36.6
9 34.5 36.5 37.2 59.0 95.8 58.5
t>Q























































































































APPENDIX 7.1 Description of horses used in evaluation of urea and albumen as
endogenous markers of dilution for equine BALF.
HORSE TYPE SEX AGE (y) WEIGHT (kg)
1 CROSS MN 15 593
2 TB MN 19 643
3 CROSS F 16 561
4 CROSS F 10 515
5 TB MN 13 652
6 TB MN 25 609
7 CROSS MN 20 500
F=female, MN= gelding, Cross=crossbred, TB=Thoroughbred.
APPENDIX 12 Solutions used in the albumen radial immunodiffusion assay.
Amido blue-black stain
500mg Amido blue-black stain
225ml 0.1M Na acetate
225ml 1M acetic acid
Barbital buffer (pH 8.61
Nabarbitone 10.3g
Barbituric acid 1.84g
HC1 to pH 8.6
NaN3 0.2g
APPENDIX 73 Urea concentrations (mg/dl) of plasma and of BALF, recovered from the
diaphragmatic lobes of the right (RD) and left (LD) lungs, the accessory lobe of the right lung
(RA) and the apical lobe of the left lung (LA), of control (n=7) horses.
HORSE PLASMA RD RA LD LA
1 30.1 0.125 0.108 0.089 0.106
2 22.1 0.105 0.120 0.172 0.162
3 23.6 0.086 0.058 0.071 0.109
4 27.3 0.147 0.204 0.274 0.024
5 31.8 0.121 0.246 0.333 0.330
6 20.7 0.073 0.176 0.056 0.075
7 18.2 0.042 0.170 0.080 0.063
APPENDIX 7.4 Albumen concentrations of plasma (mg/ml) and of BALF (ug/ml),
recovered from the diaphragmatic lobe of the right (RD) and left (LD) lungs, the accessory
lobe of the right lung (RA) and the apical lobe of the left lung (LA), of control (n=7) horses.
HORSE PLASMA RD RA LD LA
1 21.4 87.4 74.7 56.7 84.0
2 25.2 104.7 101.9 56.2 80.3
3 25.7 65.0 88.1 89.4 84.2
4 20.4 58.2 75.0 121.6 29.0
5 22.0 81.1 62.0 84.0 97.0
6 22.8 42.9 99.7 63.2 67.6
7 24.5 67.5 97.0 83.4 59.7
PofTO _ 1
APPENDIX 7.5 Total cell counts (/ul) of BALF recovered from the diaphragmatic lobe of
the right (RD) and left (LD) lungs, the accessory lobe of the right lung (RA) and the apical
lobe of the left lung (LA) of control (n=7) horses.
RD RA LD LA
1 90 95 80 105
2 90 165 35 100
3 55 65 55 115
4 90 95 140 25
5 140 280 200 130
6 50 150 60 110
7 75 205 105 55
APPENDIX 7.6 BALF cell ratios for the diaphragmatic lobe of the right (RD) and left (LD)
lungs, the accessory lobe of the right lung (RA) and the apical lobe of the left lung (LA) of
control (n=7) horses.
N° SITE NEUT LYM MAC EOS MAST BAS TOTBAS EP
1 RD 0.7 20.0 68.7 0.7 9.7 0.0 9.7 0.3
2 " 1.0 25.3 67.3 0.0 5.3 0.0 5.3 1.0
3 »t 1.7 50.3 36.0 0.0 9.7 2.3 12.0 0.0
4 tt 1.7 40.3 43.7 0.0 10.7 1.7 12.3 1.7
5 11 4.0 20.7 74.3 0.0 0.3 0.3 0.7 0.3
6 tl 1.0 51.3 42.3 0.0 4.0 1.3 5.3 0.0
7
tt 0.7 39.7 49.7 0.3 9.3 0.0 9.3 0.3
1 RA 0.7 26.3 63.3 0.7 8.3 0.7 9.0 0.0
2 it 1.3 22.7 73.7 0.0 2.3 0.0 2.3 0.0
3 it 4.0 47.0 42.7 0.0 5.0 1.3 6.3 0.0
4 tt 1.0 40.0 51.0 0.3 6.3 0.0 6.3 1.3
5 n 1.7 16.0 73.3 0.0 6.7 0.0 6.7 2.3
6 it 4.0 23.0 68.0 0.0 2.0 0.3 2.3 2.7
7 it 0.7 16.0 63.3 0.3 18.7 0.3 19.0 0.7
1 LD 1.7 23.3 61.7 0.0 10.0 0.3 10.3 3.0
2 it 0.7 17.0 75.7 0.0 6.0 0.0 6.0 0.7
3 ii 1.0 38.3 51.7 0.0 8.0 0.0 8.0 1.0
4 it 1.3 52.0 36.3 0.7 8.0 0.0 8.0 1.7
5 ii 2.3 19.7 72.7 0.0 4.3 0.7 5.0 0.3
6 it 2.0 24.3 65.7 0.3 3.3 1.0 4.3 3.3
7
it 0.0 56.7 29.3 0.3 13.7 0.0 13.7 0.0
1 LA 2.0 28.7 60.7 0.3 6.3 1.0 7.3 1.0
2 ii 3.0 26.3 66.3 0.0 4.0 0.0 4.0 0.3
3 3.7 52.7 38.3 2.3 2.7 0.0 2.7 0.3
4 tt 1.0 46.3 44.7 0.0 2.0 4.0 6.0 2.0
5 it 3.0 16.3 78.0 0.0 1.0 1.0 2.0 0.7
6 it 4.3 24.0 66.0 0.0 5.7 0.0 5.7 0.0
7
ii 0.7 47.7 35.7 0.3 13.7 0.3 14.0 1.7
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APPENDIX 7.7 Total PELF cell counts (xlO^/ul) for the diaphragmatic lobe of the right
(RD) and left (LD) lungs, the accessory lobe of the right lung (RA) and the apical lobe of the
left lung (LA) of control (n=7) horses.
RD RA LD LA
1 21.7 26.5 27.1 29.8
2 18.9 30.4 18.2 13.6
3 15.1 26.4 18.3 24.9
4 16.7 12.7 13.9 28.4
5 36.8 36.2 19.1 12.5
6 14.2 17.6 22.2 30.3
7 32.5 21.9 23.9 15.9
APPENDIX 7.8 Albumen adjusted total BALF cell counts (xl(P/ul) for the diaphragmatic
lobe of the right (RD) and left (LD) lungs, the accessory lobe of the right lung (RA) and the
apical lobe of the left lung (LA) of control (n=7) horses.
RD RA LD LA
1 22.0 27.2 30.2 26.8
2 21.7 40.4 15.7 31.4
3 21.7 19.0 15.8 35.1
4 31.5 25.8 23.5 17.6
5 38.0 38.0 52.4 29.5
6 26.6 34.3 21.6 35.8
7 27.2 51.8 30.8 22.6
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APPENDIX 7.9 PELF cell counts (xlCp/ul) for the diaphragmatic lobe of the right (RD) and
left (LD) lungs, the accessory lobe of the right lung (RA) and the apical lobe of the left lung
(LA) of control (n=7) horses.
N° SITE NEUT LYM MAC EOS MAST BAS TOTBAS EP
1 RD 0.2 4.3 14.9 0.2 2.1 0.0 2.1 0.1
2 !t 0.2 4.8 12.7 0.0 1.0 0.0 1.0 0.2
3 M 0.3 7.6 5.4 0.0 1.5 0.3 1.8 0.0
4 It 0.3 6.7 7.3 0.0 1.8 0.3 2.1 0.3
5
It 1.5 7.6 27.3 0.0 0.1 0.1 0.3 0.1
6 It 0.1 7.3 6.0 0.0 0.6 0.2 0.8 0.0
7
It 0.2 12.9 16.2 0.1 3.0 0.0 3.0 0.1
1 RA 0.2 7.0 16.8 0.2 2.2 0.2 2.4 0.0
2 It 0.4 6.9 22.4 0.0 0.7 0.0 0.7 0.0
3 it 1.1 12.4 11.3 0.0 1.3 0.3 1.7 0.0
4 ti 0.1 5.1 6.5 0.0 0.8 0.0 0.8 0.2
5 tt 0.6 5.8 26.5 0.0 2.4 0.0 2.4 0.8
6 tt 0.7 4.1 12.0 0.0 0.4 0.1 0.4 0.5
7 it 0.2 3.5 13.9 0.1 4.1 0.1 4.2 0.2
1 LD 0.5 6.3 16.7 0.0 2.7 0.1 2.8 0.8
2 it 0.1 3.1 13.8 0.0 1.1 0.0 1.1 0.1
3 ti 0.2 7.0 9.5 0.0 1.5 0.0 1.5 0.2
4
ti 0.2 7.3 5.1 0.1 1.1 0.0 1.1 0.2
5
it 0.4 3.8 13.9 0.0 0.8 0.1 1.0 0.1
6 ti 0.4 5.4 14.6 0.1 0.7 0.2 1.0 0.7
7
it 0.0 13.5 7.0 0.1 3.3 0.0 3.3 0.0
1 LA 0.6 8.6 18.1 0.1 1.9 0.3 2.2 0.3
2 ti 0.4 3.6 9.0 0.0 0.5 0.0 0.5 0.0
3 tt 0.9 13.1 9.5 0.6 0.7 0.0 0.7 0.1
4 tt 0.3 13.2 12.7 0.0 0.6 1.1 1.7 0.6
5 tt 0.4 2.0 9.8 0.0 0.1 0.1 0.3 0.1
6 tt 1.3 7.3 20.0 0.0 1.7 0.0 1.7 0.3
7
tt 0.1 7.6 5.7 0.0 2.2 0.0 2.2 0.3
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APPENDIX 7.10 Albumen adjusted absolute BALF cell counts (xl(P/ul) for the
diaphragmatic lobe of the right (RD) and left (LD) lungs, the accessory lobe of the right lung
(RA) and the apical lobe of the left lung of control (n=7) horses.
N° SITE NEUT LYM MAC EOS MAST BAS TOTBAS EP
1 RD 0.2 4.4 15.1 0.2 2.1 0.0 2.1 0.1
2 tt 0.2 5.5 14.6 0.0 1.1 0.0 1.1 0.2
3 tt 0.4 10.9 7.8 0.0 2.1 0.5 2.6 0.0
4 it 0.5 12.7 13.8 0.0 3.4 0.5 3.9 0.5
5 if 1.5 7.9 28.2 0.0 0.1 0.1 0.3 0.1
6 it 0.3 13.6 11.2 0.0 1.1 0.3 1.4 0.0
7 IT 0.2 10.8 13.5 0.1 2.5 0.0 2.5 0.1
1 RA 0.2 7.2 17.2 0.2 2.3 0.2 2.4 0.0
2 tt 0.5 9.3 30.1 0.0 0.9 0.0 0.9 0.0
3 tt 0.8 8.9 8.1 0.0 0.9 0.2 1.2 0.0
4 tt 0.3 10.3 13.2 0.1 1.6 0.0 1.6 0.3
5 tt 0.6 6.1 27.9 0.0 2.5 0.0 2.5 0.9
6 it 1.4 7.9 23.3 0.0 0.7 0.1 0.8 0.9
7 tt 0.4 8.3 32.8 0.2 9.7 0.2 9.8 0.4
1 LD 0.5 7.0 18.6 0.0 3.0 0.1 3.1 0.9
2 it 0.1 2.7 11.9 0.0 0.9 0.0 0.9 0.1
3 tt 0.2 6.1 8.2 0.0 1.3 0.0 1.3 0.2
4 tt 0.3 12.2 8.5 0.2 1.9 0.0 1.9 0.4
5 tt 1.2 10.3 38.1 0.0 2.3 0.4 2.6 0.2
6 tt 0.4 5.3 14.2 0.1 0.7 0.2 0.9 0.7
7 tt 0.0 17.5 9.0 0.1 4.2 0.0 4.2 0.0
1 LA 0.5 7.7 16.2 0.1 1.7 0.3 2.0 0.3
2 tt 0.9 8.3 20.8 0.0 1.3 0.0 1.3 0.1
3 tt 1.3 18.5 13.4 0.8 0.9 0.0 0.9 0.1
4 tt 0.2 8.1 7.9 0.0 0.4 0.7 1.1 0.4
5 tt 0.9 4.8 23.0 0.0 0.3 0.3 0.6 0.2
6 tt 1.5 8.6 23.6 0.0 2.0 0.0 2.0 0.0
7 tt 0.2 10.8 8.1 0.1 3.1 0.1 3.2 0.4
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APPENDIX 8.1 Description of horses used in the investigation of regional variation in the
cellular and molecular components of equine B ALF.
HORSE GROUP TYPE SEX AGE (y) WEIGHT (kg)
1 CONTROL CROSS MN 15 593
2 tt TB MN 19 643
3 »t CROSS F 16 561
4 ft CROSS F 10 515
5 tt TB MN 13 652
6 t! TB MN 25 609
7 tt CROSS MN 20 500
8 COPD CROSS F 20 371
9 tt CROSS F 20 488
10 tt CROSS MN 13 501
11 tt CROSS MN 25 422
12 tt CROSS F 17 546
13 tt TB MN 6 475
MN=gelding, F=female, Cross=crossbred, TB=Thoroughbred.
APPENDIX 8.2 Volume (ml) of BALF recovered from the diaphragmatic lobe of the right
(RD) and left (LD) lungs, the accessory lobe of the right lung (RA) and the apical lobe of the
left lung (LA) of control (n=7) and COPD affected (n=6) horses.
CONTROL COPD
RD RA LD LA RD RA LD LA
1 116 113 89 98 95 85 45 26
2 105 94 67 112 103 124 98 84
3 61 70 142 90 79 139 145 182
4 130 76 122 10 103 86 67 105
5 111 79 65 101 98 111 98 123
6 65 56 104 86 155 24 95 27
7 109 91 67 104
APPENDIX 8.3 Total cell counts (/ul) of BALF recovered from the diaphragmatic lobe of
the right (RD) and left (LD) lungs, the accessory lobe of the right lung (RA) and the apical
lobe of the left lung (LA) of control (n=7) and COPD affected (n=6) horses.
CONTROL COPD
RD RA LD LA RD RA LD LA
1 90 95 80 105 90 95 140 250
2 90 165 35 100 110 155 65 160
3 55 65 55 115 70 250 300 200
4 90 95 140 25 240 130 169 190
5 140 280 200 130 180 95 115 45
6 50 150 60 110 100 100 110 110
7 75 205 105 55
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APPENDIX 8.4 BALF cell ratios for the diaphragmatic lobe of the right (RD) and left (LD)
lungs, the accessory lobe of the right lung (RA) and the apical lobe of the left lung (LA) of
(A) control horses (n=7) and (B) COPD affected (n=6) horses.
(A) Control horses.
N° SITE NEUT LYM MAC EOS MAST BAS TOTBAS EP
1 RD 0.7 20.0 68.7 0.7 9.7 0.0 9.7 0.3
2 it 1.0 25.3 67.3 0.0 5.3 0.0 5.3 1.0
3 ii 1.7 50.3 36.0 0.0 9.7 2.3 12.0 0.0
4 ii 1.7 40.3 43.7 0.0 10.7 1.7 12.3 1.7
5 ii 4.0 20.7 74.3 0.0 0.3 0.3 0.7 0.3
6 it 1.0 51.3 42.3 0.0 4.0 1.3 5.3 0.0
7 ti 0.7 39.7 49.7 0.3 9.3 0.0 9.3 0.3
1 RA 0.7 26.3 63.3 0.7 8.3 0.7 9.0 0.0
2 ti 1.3 22.7 73.7 0.0 2.3 0.0 2.3 0.0
3 ii 4.0 47.0 42.7 0.0 5.0 1.3 6.3 0.0
4 it 1.0 40.0 51.0 0.3 6.3 0.0 6.3 1.3
5 ii 1.7 16.0 73.3 0.0 6.7 0.0 6.7 2.3
6 ii 4.0 23.0 68.0 0.0 2.0 0.3 2.3 2.7
7 it 0.7 16.0 63.3 0.3 18.7 0.3 19.0 0.7
1 LD 1.7 23.3 61.7 0.0 10.0 0.3 10.3 3.0
2 it 0.7 17.0 75.7 0.0 6.0 0.0 6.0 0.7
3 it 1.0 38.3 51.7 0.0 8.0 0.0 8.0 1.0
4 ii 1.3 52.0 36.3 0.7 8.0 0.0 8.0 1.7
5
• t 2.3 19.7 72.7 0.0 4.3 0.7 5.0 0.3
6 n 2.0 24.3 65.7 0.3 3.3 1.0 4.3 3.3
7 ii 0.0 56.7 29.3 0.3 13.7 0.0 13.7 0.0
1 LA 2.0 28.7 60.7 0.3 6.3 1.0 7.3 1.0
2 ii 3.0 26.3 66.3 0.0 4.0 0.0 4.0 0.3
3 it 3.7 52.7 38.3 2.3 2.7 0.0 2.7 0.3
4
ti 1.0 46.3 44.7 0.0 2.0 4.0 6.0 2.0
5
ii 3.0 16.3 78.0 0.0 1.0 1.0 2.0 0.7
6 it 4.3 24.0 66.0 0.0 5.7 0.0 5.7 0.0
7
it 0.7 47.7 35.7 0.3 13.7 0.3 14.0 1.7
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APPENDIX 8.4 (B) COPD affected horses.
N° SITE NEUT LYM MAC EOS MAST BAS TOTBAS EP
1 RD 49.0 30.0 17.0 0.7 2.3 0.7 3.0 0.3
2 ti 86.3 5.7 6.7 0.0 1.3 0.0 1.3 0.0
3 tt 5.7 36.3 53.3 0.0 3.7 0.0 3.7 1.0
4 tt 79.3 14.3 5.3 0.0 0.3 0.7 1.0 0.0
5 it 16.3 35.7 43.7 0.0 4.3 0.0 4.3 0.0
6 II 94.3 3.7 1.7 0.3 0.0 0.0 0.0 0.0
1 RA 33.0 41.3 21.7 0.0 4.0 0.0 4.0 0.0
2 it 85.0 5.3 7.3 0.0 1.0 0.0 1.0 1.3
3 ti 5.3 36.7 56.3 0.3 1.3 0.0 1.3 0.0
4 tt 85.0 9.0 3.3 0.3 0.7 0.3 1.0 1.3
5 ii 15.0 22.7 60.7 0.7 0.7 0.3 1.0 0.0
6 ti 94.0 5.3 0.3 0.3 0.0 0.0 0.0 0.0
1 LD 37.7 40.7 17.7 0.0 3.0 0.7 3.7 0.0
2 ti 86.7 4.0 7.7 0.0 1.7 0.0 1.7 0.0
3 tt 6.3 7.0 82.3 0.0 4.0 0.0 4.0 0.3
4 ii 88.0 6.7 3.0 1.0 1.3 0.0 1.3 0.0
5 n 5.0 28.3 63.7 0.3 2.3 0.3 2.7 0.0
6 ii 89.3 6.3 4.0 0.0 0.3 0.0 0.3 0.0
1 LA 43.3 25.7 24.3 0.3 5.0 0.0 5.0 1.3
2 ti 85.7 6.0 6.0 0.0 0.7 1.3 2.0 0.3
3 it 4.7 22.0 71.0 0.0 1.7 0.0 1.7 0.7
4 it 93.7 3.0 1.7 0.0 1.7 0.0 1.7 0.0
5 it 19.7 26.7 48.7 1.0 3.3 1.0 4.3 0.0
6 ti 95.3 2.7 1.7 0.0 0.3 0.0 0.3 0.0
APPENDIX 8.5 Albumen adjusted total BALF cell counts (xl(P/ul) for the diaphragmatic
lobe of the right (RD) and left (LD) lungs, the accessory lobe of the right lung (RA) and the
apical lobe of the left lung (LA) of control (n=7) and COPD affected (n=6) horses.
CONTROL COPD
RD RA LD LA RD RA LD LA
1 22.0 27.2 30.2 26.8 18.6 15.9 48.8 55.5
2 21.7 40.4 15.7 31.4 32.9 49.3 37.8 95.3
3 21.7 19.0 15.8 35.1 53.2 64.2 62.9 62.8
4 31.5 25.8 23.5 17.6 50.0 47.8 34.4 38.7
5 38.0 38.0 52.4 29.5 37.4 38.7 33.0 91.5
6 26.6 34.3 21.6 35.8 34.3 28.7 58.3 22.3
7 27.2 51.8 30.8 22.6 - - - -
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APPENDIX 8.6 Albumen adjusted absolute BALF cell counts (xlO^/ul) for the
diaphragmatic lobe of the right (RD) and left (LD) lungs, the accessory lobe of the right lung
(RA) and the apical lobe of the left lung of (A) control (CONT) (n=7) and (B) COPD affected
(n=6) horses.
(A) Control horses.
N° SITE NEUT LYM MAC EOS MAST BAS TOTBAS EP
1 RD 0.2 4.4 15.1 0.2 2.1 0.0 2.1 0.1
2 tt 0.2 5.5 14.6 0.0 1.1 0.0 1.1 0.2
3 ft 0.4 10.9 7.8 0.0 2.1 0.5 2.6 0.0
4 tt 0.5 12.7 13.8 0.0 3.4 0.5 3.9 0.5
5 tt 1.5 7.9 28.2 0.0 0.1 0.1 0.3 0.1
6 tt 0.3 13.6 11.2 0.0 1.1 0.3 1.4 0.0
7
tt 0.2 10.8 13.5 0.1 2.5 0.0 2.5 0.1
1 RA 0.2 7.2 17.2 0.2 2.3 0.2 2.4 0.0
2 tt 0.5 9.3 30.1 0.0 0.9 0.0 0.9 0.0
3 tt 0.8 8.9 8.1 0.0 0.9 0.2 1.2 0.0
4 tt 0.3 10.3 13.2 0.1 1.6 0.0 1.6 0.3
5 tt 0.6 6.1 27.9 0.0 2.5 0.0 2.5 0.9
6 tt 1.4 7.9 23.3 0.0 0.7 0.1 0.8 0.9
7
tt
0.4 8.3 32.8 0.2 9.7 0.2 9.8 0.4
1 LD 0.5 7.0 18.6 0.0 3.0 0.1 3.1 0.9
2 tt 0.1 2.7 11.9 0.0 0.9 0.0 0.9 0.1
3 tt 0.2 6.1 8.2 0.0 1.3 0.0 1.3 0.2
4 tt 0.3 12.2 8.5 0.2 1.9 0.0 1.9 0.4
5 it 1.2 10.3 38.1 0.0 2.3 0.4 2.6 0.2
6 tt 0.4 5.3 14.2 0.1 0.7 0.2 0.9 0.7
7
tt 0.0 17.5 9.0 0.1 4.2 0.0 4.2 0.0
1 LA 0.5 7.7 16.2 0.1 1.7 0.3 2.0 0.3
2 tt 0.9 8.3 20.8 0.0 1.3 0.0 1.3 0.1
3 tt 1.3 18.5 13.4 0.8 0.9 0.0 0.9 0.1
4 tt 0.2 8.1 7.9 0.0 0.4 0.7 1.1 0.4
5 tt 0.9 4.8 23.0 0.0 0.3 0.3 0.6 0.2
6 tt 1.5 8.6 23.6 0.0 2.0 0.0 2.0 0.0
7 it 0.2 10.8 8.1 0.1 3.1 0.1 3.2 0.4
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APPENDIX 8.6(B) COPD affected horses.
N° SITE NEUT LYM MAC EOS MAST BAS TOTBAS EP
1 RD 9.1 5.6 3.2 0.1 0.4 0.1 0.6 0.1
2 tt 28.4 1.9 2.2 0.0 0.4 0.0 0.4 0.0
3 fi 3.0 19.3 28.3 0.0 2.0 0.0 2.0 0.5
4 tt 39.7 7.2 2.7 0.0 0.2 0.3 0.5 0.0
5 tt 6.1 13.4 16.4 0.0 1.6 0.0 1.6 0.0
6 tt 32.3 1.3 0.6 0.1 0.0 0.0 0.0 0.0
1 RA 5.2 6.6 3.4 0.0 0.6 0.0 0.6 0.0
2 tt 41.9 2.6 3.6 0.0 0.5 0.0 0.5 0.6
3 tt 3.4 23.5 36.1 0.2 0.8 0.0 0.8 0.0
4 tt 40.6 4.3 1.6 0.1 0.3 0.1 0.5 0.6
5 tt 5.7 8.7 23.2 0.3 0.3 0.1 0.4 0.0
6 it 26.9 1.5 0.1 0.1 0.0 0.0 0.0 0.0
1 LD 18.4 19.9 8.6 0.0 1.5 0.3 1.8 0.0
2 tt 32.8 1.5 2.9 0.0 0.6 0.0 0.6 0.0
3 tt 4.0 4.4 51.8 0.0 2.5 0.0 2.5 0.2
4 " 30.3 2.3 1.0 0.3 0.4 0.0 0.4 0.0
5 tt 1.7 9.4 21.0 0.1 0.8 0.1 0.9 0.0
6 tt 52.0 3.7 2.3 0.0 0.2 0.0 0.2 0.0
1 LA 24.0 14.3 13.5 0.2 2.8 0.0 2.8 0.7
2 tt 81.6 5.7 5.7 0.0 0.7 1.2 1.9 0.3
3 tt 3.0 13.8 44.6 0.0 1.1 0.0 0.7 0.0
4 tt 36.2 1.2 0.7 0.0 0.7 0.0 0.7 0.0
5 it 18.0 24.4 44.6 0.9 3.0 0.9 3.9 0.0
6 tt 21.3 0.6 0.4 0.0 0.1 0.0 0.1 0.0
APPENDIX 8.7 Total PELF cell counts (xlO^/ul) for the diaphragmatic lobe of the right
(RD) and left (LD) lungs, the accessory lobe of the right lung (RA) and the apical lobe of the
left lung (LA) of control (n=7) and COPD affected (n-6) horses.
CONTROL COPD
RD RA LD LA RD RA LD LA
1 21.7 26.5 27.1 29.8 13.5 11.1 18.1 11.3
2 18.9 30.4 18.2 13.6 10.3 21.5 13.4 21.2
3 15.1 26.4 18.3 24.9 29.2 29.8 28.7 26.1
4 16.7 12.7 13.9 28.4 20.7 14.7 17.0 20.3
5 36.8 36.2 19.1 12.5 13.7 16.6 19.9 20.2
6 14.2 17.6 22.2 30.3 14.7 11.4 11.6 12.2
7 32.5 21.9 23.9 15.9 - - - -
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APPENDIX 8.8 Absolute PELF cell counts (xl(P/ul) for the diaphragmatic lobe of the right
(RD) and left (LD) lungs, the accessory lobe of the right lung (RA) and the apical lobe of the
left lung (LA) of (A) control (CONT) (n=7) and (B) COPD affected (n=6) horses.
(A) Control horses.
N° SITE NEUT LYM MAC EOS MAST BAS TOTBAS EP
1 RD 0.2 4.3 14.9 0.2 2.1 0.0 2.1 0.1
2 tt 0.2 4.8 12.7 0.0 1.0 0.0 1.0 0.2
3 »t 0.3 7.6 5.4 0.0 1.5 0.3 1.8 0.0
4 tt 0.3 6.7 7.3 0.0 1.8 0.3 2.1 0.3
5 tt 1.5 7.6 27.3 0.0 0.1 0.1 0.3 0.1
6 tt 0.1 7.3 6.0 0.0 0.6 0.2 0.8 0.0
7 tt 0.2 12.9 16.2 0.1 3.0 0.0 3.0 0.1
1 RA 0.2 7.0 16.8 0.2 2.2 0.2 2.4 0.0
2 tt 0.4 6.9 22.4 0.0 0.7 0.0 0.7 0.0
3 tt 1.1 12.4 11.3 0.0 1.3 0.3 1.7 0.0
4 tt 0.1 5.1 6.5 0.0 0.8 0.0 0.8 0.2
5 tt 0.6 5.8 26.5 0.0 2.4 0.0 2.4 0.8
6 tt 0.7 4.1 12.0 0.0 0.4 0.1 0.4 0.5
7 tt 0.2 3.5 13.9 0.1 4.1 0.1 4.2 0.2
1 LD 0.5 6.3 16.7 0.0 2.7 0.1 2.8 0.8
2 tt 0.1 3.1 13.8 0.0 1.1 0.0 1.1 0.1
3 tt 0.2 7.0 9.5 0.0 1.5 0.0 1.5 0.2
4 tt 0.2 7.3 5.1 0.1 1.1 0.0 1.1 0.2
5
tt 0.4 3.8 13.9 0.0 0.8 0.1 1.0 0.1
6 it 0.4 5.4 14.6 0.1 0.7 0.2 1.0 0.7
7 tt 0.0 13.5 7.0 0.1 3.3 0.0 3.3 0.0
1 LA 0.6 8.6 18.1 0.1 1.9 0.3 2.2 0.3
2 tt 0.4 3.6 9.0 0.0 0.5 0.0 0.5 0.0
3 tt 0.9 13.1 9.5 0.6 0.7 0.0 0.7 0.1
4 tt 0.3 13.2 12.7 0.0 0.6 1.1 1.7 0.6
5 tt 0.4 2.0 9.8 0.0 0.1 0.1 0.3 0.1
6 tt 1.3 7.3 20.0 0.0 1.7 0.0 1.7 0.3
7 tt 0.1 7.6 5.7 0.0 2.2 0.0 2.2 0.3
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APPENDIX 8.8(B) COPD affected horses.
N° SITE NEUT LYM MAC EOS MAST BAS TOTBAS EP
1 RD 6.6 4.1 2.3 0.1 0.3 0.1 0.4 0.0
2 II 8.9 0.6 0.7 0.0 0.1 0.0 0.1 0.0
3 " 1.7 10.6 15.6 0.0 1.1 0.0 1.1 0.3
4 ti 16.4 3.0 1.1 0.0 0.1 0.1 0.2 0.0
5 2.2 4.9 6.0 0.0 0.6 0.0 0.6 0.0
6 ti 13.9 0.5 0.3 0.0 0.0 0.0 0.0 0.0
1 RA 3.7 4.6 2.4 0.0 0.4 0.0 0.4 0.0
2 it 18.3 1.1 1.6 0.0 0.2 0.0 0.2 0.3
3 ti 1.6 10.9 16.8 0.1 0.4 0.0 0.4 0.0
4 ti 12.5 1.3 0.5 0.0 0.1 0.0 0.1 0.2
5 ti 2.5 3.8 10.1 0.1 0.1 0.0 0.2 0.0
6 it 10.7 0.6 0.0 0.0 0.0 0.0 0.0 0.0
1 LD 6.8 7.4 3.2 0.0 0.5 0.1 0.7 0.0
2 it 11.6 0.5 1.0 0.0 0.2 0.0 0.2 0.0
3 it 1.8 2.0 23.6 0.0 1.1 0.0 1.1 0.1
4 15.0 1.1 0.5 0.2 0.2 0.0 0.2 0.0
5 1.0 5.6 12.7 0.1 0.5 0.1 0.5 0.0
6 10.4 0.7 0.5 0.0 0.0 0.0 0.0 0.0
1 LA 4.9 2.9 2.8 0.0 0.6 0.0 0.6 0.1
2 it 18.1 1.3 1.3 0.0 0.1 0.3 0.4 0.1
3 ii 1.2 5.7 18.5 0.0 0.3 0.0 0.3 0.0
4 " 19.1 0.6 0.3 0.0 0.3 0.0 0.3 0.0
5 " 4.0 5.4 9.8 0.2 0.7 0.2 0.9 0.0
6 11.6 0.3 0.2 0.0 0.0 0.0 0.0 0.0
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APPENDIX 8.9 Albumen concentrations of plasma (mg/ml) and of BALF (ug/ml),
recovered from the diaphragmatic lobe of the right (RD) and left (LD) lungs, the accessory
lobe of the right lung (RA) and the apical lobe of the left lung (LA), of control (CONT) (n=7)
and COPD affected (n=6) horses.
; HORSE GROUP PLASMA RD RA LD LA
1 CONT 21.4 87.4 74.7 56.7 84.0
2 tt 25.2 104.7 101.9 56.2 80.3
3 tt 25.7 65.0 88.1 89.4 84.2
4
tt 20.4 58.2 75.0 121.6 29.0
5
tt 22.0 81.1 62.0 84.0 97.0
6 tt 22.8 42.9 99.7 63.2 67.6
7 tt 24.5 67.5 97.0 83.4 59.7
1 COPD 24.4 118.0 146.0 70.0 110.0
2 M 25.9 86.5 81.5 44.5 43.5
3 " 28.1 37.0 109.5 34.0 89.5
4 tt 25.0 120.0 68.0 122.8 122.8
5 " 18.1 87.0 45.0 63.0 8.9
6 19.6 57.2 68.4 37.0 96.6
APPENDIX 8.10 Urea concentrations of plasma (mg/dl) and of BALF (mg/dl), recovered
from the diaphragmatic lobe of the right (RD) and left (LD) lungs, the accessory lobe of the
right lung (RA) and the apical lobe of the left lung (LA), of control (CONT) (n=7) and COPD
affected (n=6) horses.
HORSE GROUP PLASMA RD RA LD LA
1 CONT 30.1 0.125 0.108 0.089 0.106
2 tt 22.1 0.105 0.120 0.172 0.162
3 tt 23.6 0.086 0.058 0.071 0.109
4 tt 27.3 0.147 0.204 0.274 0.024
5 tt 31.8 0.121 0.246 0.333 0.330
6 tt 20.7 0.073 0.176 0.056 0.075
7 tt 18.2 0.042 0.170 0.080 0.063
1 COPD 26.3 0.175 0.225 0.203 0.581
2 tt 32.8 0.349 0.236 0.159 0.248
3 tt 28.4 0.068 0.238 0.297 0.218
4 tt 24.4 0.283 0.216 0.242 0.228
5
" 22.0 0.289 0.126 0.127 0.049
6 tt 32.4 0.220 0.284 0.307 0.292
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APPENDIX 9.1 Description of horses used in the evaluation of local endobronchial antigen
challenges in the horse.
HORSE GROUP TYPE SEX AGE (y) WEIGHT (kg)
1 CONTROL CROSS MN 15 593
2 TB MN 6 542
3 CROSS MN 10 515
4 TB MN 13 652
5 TB MN 6 525
6 CROSS F 20 500
7 TB MN 8 531
8 COPD CROSS F 20 371
9 CROSS F 20 488
10 CROSS MN 13 501
11 CROSS F 20 497
12 CROSS F 17 546
13 TB M 30 504
14 CROSS MN 14 450
CROSS=crossbred, F=female, M=male, MN= gelding, TB=Thoroughbred.
APPENDIX 9.2 BALF cell ratios for (A) control (n=7) and (B) COPD affected (n=7) horses
before (NIL) and at 5h after endobronchial challenges with PBS, 60ug MF and 600ug MF.
(A) Control horses.
HORSE NEUT LYM MAC EOS MAST BAS TOTBAS EP
1 NIL 3.3 19.0 74.3 1.0 2.0 0.3 2.3 0.0
2 tt 1.0 6.0 76.7 11.3 4.0 1.0 5.0 0.0
3 tt 0.3 22.0 72.7 0.0 2.7 1.3 4.0 1.0
4 tt 1.0 53.0 38.7 0.0 3.3 0.7 4.0 3.3
5 tt 0.7 35.7 60.3 0.3 2.0 0.0 2.0 1.0
6 tt 4.7 42.0 50.7 0.3 2.0 0.3 2.3 0.0
7 it 2.0 5.3 86.7 0.0 3.0 1.3 4.3 1.7
8 tt 1.7 39.7 52.7 0.0 3.0 1.7 4.7 1.3
1 PBS 0.3 37.7 51.3 4.7 5.7 0.7 6.3 0.3
2 tt 11.0 18.0 41.7 28.0 1.0 0.0 1.0 0.3
3 tt 5.0 44.7 44.0 0.0 4.0 1.0 5.0 1.3
4
tt
3.7 35.3 61.0 0.0 0.0 0.0 0.0 0.0
5 tt 12.7 44.0 43.3 0.0 0.0 0.0 0.0 0.0
6 tt 11.0 29.3 56.3 0.0 2.0 1.0 3.0 0.3
7 tt 28.0 20.0 49.0 0.3 2.7 0.0 2.7 0.0
1 60ug MF
tt
4.3 37.7 50.7 4.3 2.3 0.7 3.0 0.0
2 10.7 45.7 40.3 0.0 3.3 0.0 3.3 0.0
3 tt 1.7 51.3 41.0 0.0 0.0 0.7 5.7 0.3
4 tt 5.0 25.0 68.0 0.0 0.0 0.0 1.0 1.0
5 tt 10.0 49.0 39.0 0.0 1.3 0.0 1.3 0.7
6 tf 15.0 26.7 55.3 0.0 2.7 0.3 3.0 0.0
7 tt 27.0 13.0 57.7 0.0 1.0 0.3 1.3 1.0
1 600ug MF 5.3 37.3 51.0 3.7 2.0 0.7 2.7 0.0
2 tt 25.0 17.7 45.7 0.0 7.0 2.3 9.3 2.3
3 it 54.7 21.7 21.7 0.0 2.0 0.0 2.0 0.0
4 tt 40.7 38.0 61.0 0.0 1.0 0.0 1.0 0.3
5 tt 7.7 49.7 41.7 0.0 1.0 0.0 1.0 0.0
6 tt 75.0 5.0 16.7 0.0 0.3 0.0 0.3 3.0
7 tt 33.0 18.0 46.3 0.0 2.0 0.3 2.3 0.3
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APPENDIX 9.2 (B) COPD affected horses.
HORSE NEUT LYM MAC EOS MAST BAS TOTBAS EP
1 NIL 3.3 19.0 74.3 1.0 2.0 0.3 2.3 0.0
2 tt 1.7 63.7 25.0 0.0 6.0 0.7 6.7 3.0
3 it 3.0 32.0 59.0 0.3 4.7 1.0 5.7 0.0
4 tt 0.0 63.7 33.0 1.0 2.0 0.0 2.0 0.3
5 tt 3.0 11.3 82.0 1.3 0.7 0.0 1.0 1.3
6 tt 4.0 39.3 49.0 2.0 3.0 0.7 3.7 2.0
7 tt 4.3 43.7 44.0 3.7 4.0 0.3 4.3 0.0
1 PBS 8.0 35.0 51.0 1.0 4.0 0.3 4.3 0.7
2 tt 5.3 51.3 38.0 0.0 3.0 1.0 4.0 1.3
3 ft 9.7 39.0 48.0 0.0 3.0 0.3 3.3 0.0
4 tt 2.0 28.0 57.7 2.0 9.3 1.0 10.3 0.0
5 tt 52.0 3.0 43.0 2.0 0.0 0.3 0.0 0.0
6 tt 48.0 8.0 37.0 0.0 0.7 0.0 0.7 6.3
7 tt 3.3 35.7 52.0 0.3 4.0 0.7 4.7 4.0
1 60ug MF
tt
9.7 33.3 50.0 1.0 4.3 0.7 5.0 0.3
2 17.3 36.0 40.0 0.0 5.0 1.0 6.0 0.7
3 tt 16.0 48.7 23.0 6.0 4.0 0.3 4.3 2.0
4 tt 0.7 45.0 45.3 0.7 6.3 2.0 8.3 0.0
5 tt 68.0 2.0 28.7 0.0 0.0 0.0 0.0 1.3
6 tt 43.0 3.0 43.0 0.0 1.0 0.0 1.0 11.0
7 tt 6.0 41.0 46.0 1.0 4.0 0.7 1.7 1.3
1 600ug MF 30.0 24.0 38.3 2.3 5.0 0.3 5.3 0.0
2 tt 38.3 35.0 18.0 0.0 5.0 2.0 7.0 1.7
3 tt 19.0 33.0 38.0 4.0 4.0 0.0 4.0 2.0
4 tt 2.0 0.0 87.0 1.0 5.3 0.7 6.0 4.0
5 tt 65.7 7.7 26.0 0.3 0.3 0.0 0.3 0.0
6 tt 51.3 14.7 28.0 0.0 1.3 0.3 1.7 4.3
7 tt 36.0 15.0 43.7 0.0 1.3 0.3 1.7 3.7
APPENDIX 9.3 Total BALF cell counts (/ul) for control (CONT) (n=7) and COPD affected
horses (n=7) before (BASE) and at 5h after endobronchial challenges with PBS, 60ug MF and
600ug MF.
CONTROL COPD
HORSE BASE PBS 60ugMF 600ugMF BASE PBS 60ugMF 600ugMF
1 455 630 280 345 95 95 190 410
2 400 155 240 215 135 100 100 195
3 135 270 680 645 515 375 760 515
4 250 245 95 175 555 365 440 40
5 435 265 460 575 425 70 175 695
6 100 330 330 435 155 60 40 210
7 625 1005 770 395 170 185 325 635
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APPENDIX 9.4 BALF cell ratios for (A) control and (n=5) (B) COPD affected horses (n=5)
before challenge (PRE) and for control sites (CONT) and challenge sites (CHAL) at 5h after
endobronchial hay extract challenge.
(A) Control horses.
HORSE NEUT LYM MAC EOS MAST BASO TOTBAS EP
1 PRE 0.0 30.7 63.3 0.3 5.3 0.3 0.3 5.7
2 " 0.3 32.3 59.7 0.0 5.3 0.0 2.3 5.3
3 " 0.7 24.3 70.3 0.0 3.3 0.3 1.0 3.7
4 M 2.0 34.7 53.7 0.3 6.7 2.3 0.3 9.0
5 tt 3.3 40.7 48.3 0.0 5.3 2.0 0.3 7.3
1 CONT 0.3 20.0 73.0 0.0 6.7 0.0 0.0 6.7
2 if 7.7 25.0 58.3 0.3 4.7 0.3 3.7 5.0
3 tt 1.7 13.0 80.7 0.0 3.3 0.0 1.0 3.3
4 tt 13.7 44.3 28.0 0.3 9.0 2.0 3.0 11.0
5 " 9.3 45.7 36.0 0.0 6.7 2.3 0.0 9.0
1 CHAL 14.7 37.3 44.0 0.0 4.0 0.0 0.0 4.0
2 " 30.7 10.3 56.0 0.3 1.7 0.0 0.7 1.7
3 tt 8.7 31.7 58.3 0.0 1.3 0.0 1.0 1.3
4 it 21.0 40.0 25.7 0.3 11.3 0.3 1.3 11.7
5 tt 19.7 51.7 19.3 0.3 8.7 0.3 0.0 9.0
(B) COPD affected horses.
HORSE NEUT LYM MAC EOS MAST BASO TOTBAS EP
1 PRE 2.3 48.3 48.7 0.0 2.3 0.3 0.0 2.7
2 " 1.7 44.3 48.3 0.0 3.7 1.0 1.0 4.7
3 tt 3.3 28.7 62.7 0.3 4.3 0.3 0.3 4.7
4
" 4.0 56.0 37.7 0.0 2.0 0.3 0.0 2.3
5 " 1.3 45.0 48.4 0.0 4.3 0.0 1.0 4.3
1 CONT 4.0 52.7 41.0 0.7 1.3 0.3 0.0 1.7
2 tt 8.3 44.7 37.0 0.0 7.0 0.7 2.3 7.7
3 tt 17.3 41.3 38.0 0.0 2.3 1.0 0.0 3.3
4 " 15.0 70.3 9.3 0.0 4.7 0.3 0.7 5.0
5 tt 4.0 41.0 53.0 2.0 0.0 0.0 0.0 0.0
1 CHAL 70.3 16.3 8.7 0.7 1.0 3.7 0.3 4.7
2 tt 19.0 31.0 44.3 0.0 4.3 1.0 0.3 5.3
3 " 30.7 42.3 24.0 0.3 2.3 0.0 0.3 2.7
4 tt 63.0 27.0 3.7 1.0 4.3 0.3 0.7 4.7
5 9.0 59.3 29.3 0.0 1.3 0.7 0.3 2.0
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APPENDIX 9.5 Total BALF cell counts (/ul) for control (n=5) and COPD affected horses
(n=5) before challenge (PRE) and for control sites (CONT) and challenge sites (CHAL) at 5h
after endobronchial mouldy hay extract challenge.
CONTROL COPD
HORSE PRE CONT CHAL PRE CONT CHAL
1 95 300 90 230 187 400
2 115 400 300 420 230 215
3 130 210 240 100 315 320
4 265 140 310 85 275 100
5 275 95 175 215 100 100
APPENDIX 10.1 Description of horses used for oil seed rape challenge study.
HORSE GROUP TYPE SEX AGE (y) WEIGHT (kg)
1 CONTROL CROSS MN 15 593
2 M SHETLAND F 7 212
3 »t TB MN 19 643
4 tt CROSS F 16 561
5 tt CROSS F 10 515
6 tt TB MN 13 652
7 tt TB MN 25 609
8 COPD CROSS F 20 371
9 tt CROSS F 20 488
10 tt CROSS MN 13 501
11 tt CROSS MN 25 422
12 tt CROSS F 17 546
13 tt CROSS MN 14 450
F=female, MN= gelding, Cross=crossbred, TB=Thoroughbred.
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The aim of this concluding addendum is to provide an overview of the possible
aetiopathogenesis of equine COPD, in light of the findings of the present study.
AETIOLOGY OF EQUINE COPD
This study and previous studies (reviewed in Chapter 1) indicate that inhaled moulds,
including Micropolyspora faeni (MF) and Aspergillus fu.miga.tus (AF), are aetiological agents
of equine COPD in Northern Britain. Geographical variations in the aetiology of this disease
may, however, exist.
The potential role of other airborne agents, including forage mites and endotoxins, which
have been demonstrated in stables containing hay and straw (Woods,P. et al, pers comm.) and
which have been shown to cause pulmonary disease in other species (reviewed in Chapter 1),
warrants further study.
PATHOGENESIS OF EQUINE COPD
The present study and previously published studies (reviewed in Chapter 1) provide
considerable evidence to suggest that equine COPD is a pulmonary hypersensitivity, rather
than a pulmonary toxicity.
Inhaled antigens may interact with the pulmonary immune system to induce a
hypersensitivity response in a number of possible ways;
1. Inhaled antigen may interact with pulmonary dendritic cells, which function as antigen
presenting cells, and be presented, in association with Class II major histocompatability
antigens, to antigen specific CD4+ T helper/inducer cells. Subsequent lymphokine production
by the activated T cells may then attract and activate other inflammatory cells (reviewed in
Chapter 4) and induce the pulmonary inflammatory response of equine COPD. The natural
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challenge (NC) induced pulmonary recruitment of CD4+ T cells, which was demonstrated in
COPD affected horses in the present study (Chapter 4), may be fundamental to the
development of such an inflammatory response.
2. Inhaled antigen may interact with antigen specific IgG or IgA antibody, present in
pulmonary epithelial lining fluid (PELF) or in the pulmonary parenchyma, to form immune
complexes. These complexes may induce a type III hypersensitivity response via activation of
the complement, coagulation and kinin systems or by stimulating release of inflammatory
mediators from activated mast cells, neutrophils, macrophages or platelets.
Generation of the complement fragments C3a and C5a, which are chemoattractants for equine
neutrophils (Camp and Leid 1982) and human CD4+ T helper cells (El Naggar et al 1981),
may account for the pulmonary recruitment of neutrophils and CD4+ T cells observed in
equine COPD. Alternatively the pulmonary neutrophilia characteristic of equine COPD may
be induced by interleukin-8, a recently described potent human neutrophil chemoactivator
which is produced predominantly by alveolar macrophages, possibly in response to immune
complexes (Lynch et al 1992).
Immune complex or anaphylatoxin mediated mast cell/basophil degranulation (Abdel-Salam
1989; Peters 1990) may account for the NC induced late phase increase in PELF histamine
which was demonstrated in COPD affected horses in the present study (Chapter 5).
Consistent with a role for type III hypersensitivity in the pathogenesis of equine COPD are
the increased levels of MF and AF specific IgG and IgA in bronchoalveolar lavage fluid
(BALF) from asymptomatic and symptomatic COPD affected horses (Halliwell et al In
Press), the increased ratios of B cells in BALF from asymptomatic COPD affected horses
(Chapter 4, present study), the presence of C3 and IgG deposits in the alveolar septae of a
COPD affected horse (Winder and Von Fellenberg 1986) and the finding that intradermal
mould antigen testing of horses induced a late phase intradermal response which was
histologically consistent with an Arthus type response (Halliwell et al 1979; McPherson et al
1979).
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3. Inhaled antigen may complex with homocytotropic IgE antibody present on pulmonary
mast cells/basophils, inducing an early and/or late phase type I hypersensitivity response. A
late phase, allergen mediated type I hypersensitivity response could account for the increased
PELF histamine concentrations observed in COPD affected horses at 5h after NC in the
present study (Chapter 5).
Histamine releasing factors and histamine releasing inhibitory factors may play an important
role in the pathogenesis of equine COPD by controlling immunological and non
immunological mast cell/basophil degranulation (discussed in Chapter 5).
The finding that BALF from asymptomatic and symptomatic COPD affected horses has
increased levels of MF and AF specific IgE (Halliwell et al In Press) is consistent with
involvement of an early or late phase type I hypersensitivity response in the pathogenesis of
COPD, although IgE may also induce pulmonary inflammation via interaction with Fcg
receptors on macrophages, lymphocytes and eosinophils (Rossi et al 1991).
While the present study did not yield evidence to support involvement of an early phase, type
I hypersensitivity response in the pathogenesis of equine COPD, its involvement cannot be
ruled out. Indeed, the dependence of human late phase bronchial and cutaneous responses on a
preceding early phase response (Cochrane, quoted by Pepys 1978) suggests that such a
response is indeed likely to have a role in the pathogenesis of equine COPD. Thus, while
histamine was not increased in plasma or pulmonary fluids from COPD affected horses at
0.5h after NC (Chapter 5), it may have increased transiently prior to this time.
The role of early type I hypersensitivity responses in the pathogenesis of equine COPD
warrants further investigation. This may be achieved by quantifying histamine in plasma and
in pulmonary fluids collected sooner after NC than in the present study, i.e. at 5-15min after
NC. Alternatively, ultrastructural examination of mast cells/basophils in BALF or bronchial
biopsies, collected from COPD affected horses at 5-15min after NC, for evidence of
degranulation, may prove useful. Mast cells, in bronchial biopsies from humans with atopic
asthma (Beasley et al 1989), and in BALF from human asthmatics during the early phase
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response to allergen challenge (Metzger et al 1986) showed ultrastructural evidence of
degranulation.
If mast cell/basophil degranulation does, indeed, occur in the early phase of COPD, mediators
released from these cells may be responsible for recruiting CD4+ T helper cells to the lungs of
COPD affected horses, as demonstrated in the present study (Chapter 4) (Center et al 1983;
Berman et al 1984).
4. Inhaled MF and AF may activate the complement system directly, via the alternate pathway
(Marx and Flaherty 1976), inducing a type III hypersensitivity response independent of
specific precipitating antibody. As previously discussed, complement fragments may induce
mast cell/basophil degranulation (Abdel-Salam 1989) and initiate the pulmonary recruitment
of CD4+ T helper cells (El Naggar et al 1981) and neutrophils (Camp and Leid 1982), which
was demonstrated in this study.
However, as complement activation by the alternate pathway would be expected to occur
equally in all individuals exposed to appropriate concentrations of AF and MF antigens, this
mechanism does not account for the development of pulmonary disease in COPD affected
horses but not in control horses following NC. It is thus unlikely that alternate complement
activation by AF and MF has an important role in the pathogenesis of equine COPD.
Complement fragments produced by this mechanism may, however, potentiate the effects of
complement fragments generated, in horses with specific precipitins, via the direct pathway,
as is thought to occur in human hypersensitivity pneumonitis (Edwards 1976).
5. Inhaled antigen may induce an inflammatory response by interacting directly with
pulmonary epithelial cells. Epithelial cells from other species can convert arachidonic acid to
metabolites of the 5-lipoxygenase pathway in vitro and yield metabolites which are potent
neutrophil chemotaxins (Bigby et al 1985)
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As the previous discussion has highlighted several possible mechanisms by which
complement fragments may have an important role in the pathogenesis of equine COPD, the
role of complement in this disease warrants further investigation.
Complement activation is thought to have an important role in the pathogenesis of
Goodpasture's syndrome, adult respiratory distress syndrome and hypersensitivity
penumonitis in man and of experimental lung diseases in laboratory animals, while its role in
the pathogenesis of human chronic bronchitis, bronchial asthma, sarcoidosis and 'heroin lung'
is less well defined (Johnson and Ward 1974; Yoshizawa et al 1982; Langlois and Gawryl
1988; Morgan 1990).
The role of complement in equine COPD may be investigated by quantifying individual
complement fragments in plasma and/or pulmonary fluids from COPD affected horses before
and after NC. However, immunoassay of equine complement is currently hampered by the
lack of specific monoclonal antibodies to individual complement fragments. Furthermore,
quantification of complement fragments in pulmonary fluids from human asthmatics has
proved problematic and has yielded conflicting results (reviewed by Barnes et al 1991).
Perhaps a more useful strategy would be to determine the protective effect of specific
inhibitors of the complement pathway, such as N-acetyl aspartyl glutanic acid (NAAGA), on
the response of COPD affected horses to NC. In this respect, preliminary studies have
suggested that NAAGA may ameliorate human allergic rhinitis, implicating complement in
the pathogenesis of this condition (Ghaem 1987).
Despite the neutrophil being, by far, the most predominant cell to infiltrate the airways of
COPD affected horses, the role of the neutrophil in the pathogeneis of this condition has
received scant attention.
While it is unlikely that neutrophils release significant quantities of mediators in the lungs of
COPD affected horses (discussed in Chapter 1), the neutrophil has a well established role in
several pulmonary diseases in man including adult respiratory distress syndrome, idiopathic
pulmonary fibrosis, emphysema and hypersensitivity pneumonitis (reviewed by Sibille and
Reynolds 1990), and the role of this cell in equine COPD warrants further investigation.
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The role of the neutrophil in the pathogenesis of equine COPD may be elucidated by
quantifying neutrophil derived mediators, in plasma and/or pulmonary fluids before and after
NC, biochemically (Bieth et al 1974) or, when suitable monoclonal antibodies become
available, immunologically. Alternatively, ultrastructural analyses of neutrophil granule
morphology and numbers (Yamada et al 1982) and cytofluorographic assay of neutrophil
granule contents (Abrams et al 1983) may be used to determine whether neutrophils have
degranulated.
From the preceding discussion and from the review presented in Chapter 1, it will be evident
that there is considerable potential interaction between the many different immune effector
mechanisms which may be involved in the pathogenesis of equine COPD. This interaction
limits the value of classification of different types of hypersensitivity effector responses.
Additionally, it is unlikely that the inflammatory response characteristic of equine COPD is
induced by a single mediator or a single effector cell type, and more likely that it represents
the culmination of a complex interaction of many different cells and mediators. Furthermore,
the present study has demonstrated that COPD is a dynamic inflammatory response, with
different cell types and inflammatory mediators playing different roles at different stages in
the disease. Unfortunately, most of the techniques currently used to dissect the inflammatory
response of equine COPD provide data which reflect the inflammatory response at single time
points. This limitation is likely to explain, in part, the different results of other studies.
Fortunately, as equine COPD is a naturally occurring, reversible inflammatory response,
which may be induced and reversed in affected horses, simply and reproducibly by
environmental alteration, it is a useful disease model to investigate pulmonary
hypersensitivity responses.
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